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ABSTRACT 
This study investigated the occurrence of 52 xenobiotic micropollutants – pharmaceuticals, 
metabolites, transformation products, and organophosphorus compounds (OPs) – in hospital 
and municipal wastewater. It aimed to characterise the xenobiotic fingerprint in raw wastewater 
from different sources and the impact of different advanced treatment technologies on 
concentration levels and distribution patterns of xenobiotic micropollutants. Thus, temporal 
concentration profiles of the influent and effluent of a nanofiltration membrane biofilm reactor 
(NF-MBR) situated at the influent of a municipal wastewater treatment plant (population 
equivalent: 300,000) as well as of a particle-supported biofilm reactor (PS-BFR) installed at the 
main effluent of a municipal hospital (186 beds, about 200 medical staff) were studied. 
Furthermore, the occurrence of xenobiotics in biosolids was addressed. For this, a multi-residue 
extraction method was developed and subsequently used to determine the micropollutants in 
sewage sludge from the NF-MBR and in sludge and carrier material from the PS-BFR. Ultimately, 
an aquatic environmental assessment for the investigated micropollutants was carried out based 
on the results of the presented study. 
It shows that a wide range of xenobiotics is present in both municipal and hospital wastewater. 
In summary, it can be said that there are basic differences between wastewater streams 
originating from the hospital and from mixed municipal sources regarding concentrations for 
iodinated contrast media, while other pharmaceuticals are more evenly distributed. For OPs, 
similar overall concentrations in the two wastewater types derived from a very different set of 
single substances. Regarding the contribution of hospitals to the overall xenobiotic load of 
municipal wastewater, it was found that even a small hospital can contribute greatly to the 
overall annual load: 21.5% of the annual load of diatrizoic acid reaching the municipal 
wastewater treatment plant is estimated to originate from the investigated hospital.  
While the NF-MBR revealed a much greater potential for micropollutant removal than the PS-
BFR, even this system showed unsatisfactory results (< 75% removal) for 45% of the 
investigated substances. The NF-MBR was especially efficient with regard to biodegradation, 
while the removal of non-biodegradable substances (e.g. carbamazepine) was insufficient, which 
suggests that the filtration capacity of the loose NF membrane yielded retention results that 
were no better than those previously described for wider membrane types.  
The seasoned PS-BFR (start-up time prior to the study: 199 days) successfully adapted to the 
dynamic matrix which hospital wastewater represents, and demonstrated basic potential for 
biodegradation by stable removal rates of over 75% for primidone, ibuprofen and morphine, but 
failed in terms of increased overall xenobiotic degradation. However, high concentrations 
(ranging up to over 2,000 ng/g d.w.) of clarithromycin found in the biosolids (sludge and biofilm 
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of the carrier material) might indicate that the system has a high sorption potential for ionic 
compounds.  
The aquatic environmental assessment showed that wastewater, both raw and treated, 
represents a risk when it reaches receiving waters. High risk levels are being caused by 
substances from not just a single therapeutic group but several (psycho-active compounds, 
antibiotics, non-steroidal anti-inflammatory drugs). However, in all wastewater types 
investigated, the highest risk was found to be the psycho-active compound oxazepam.  
Taking all of the above mentioned into account, it is impossible to say with certainty that 
pharmaceuticals and other xenobiotics in (waste)water are not a threat to the aquatic 
environment. To compensate for the lack of knowledge, precautionary principles must be 
applied, and these xenobiotics should be kept from reaching the aquatic environment. 
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1. THE CHALLENGE OF XENOBIOTIC MICROPOLLUTANTS IN URBAN 
WATER CYCLES – INTRODUCTION AND SCOPE OF THE STUDY 
 
All the water that will ever be is, right now. 
– National Geographic, October 1993 – 
 
 
We forget that the water cycle and the life cycle are one. 
– Jacques-Yves Cousteau (1910-1997) –  
 
 
WATER, THE SOURCE OF LIFE, IS LIMITED. The earth’s water resources are not endless but finite. 
Water is merely recycled and redistributed within a global water cycle which is influenced by 
climatic conditions and nowadays, to an alarming degree, by human activity (UNESCO, 2009). 
Access to safe water is a major subject with regard to disease control and it is recognized as one, 
maybe the one fundamental base for human well-being, economic growth and political stability 
(Prüss-Üstün et al., 2008). Yet, water is becoming a costly treasure.  
 
WATER CRISIS. Globally, the pressure on fresh water resources is rising, already reaching the 
level of acute crisis in many regions (UNESCO, 2009). Reasons include the increasing demands of 
growing populations, rapid urbanisation and rising water consumption for agricultural and 
industrial production. This is compounded by shrinking water resources brought about by 
changes in climatic conditions leading to temperature rise and declining rainfall. This causes 
prolonged drought periods, during which surface water reservoirs are no longer able to match 
water demand (Hagare, 2012; EPA, 1998). Excessive groundwater abstraction results in water 
table drawdown, which opens the door to additional environmental problems such as land 
subsidence and saltwater intrusion (Takizawa, 2008; Rodriguez et al., 2009). Certain 
geographical situations, such as the dependence of large urban settlements on a single river (for 
example, London is provided with drinking water mainly by the river Thames), small landmass 
or missing natural aquifers can exacerbate the water scarcity further (Cho, 2011). In Germany, 
the Berlin area is expected to experience decline in the replenishment of natural groundwater 
which currently provides 30% of Berlin’s drinking water. At the same time the flow rate of 
regional surface waters, which as a result are becoming more important for the drinking water 
supply, are expected to drop by 40% (Dünnbier, 2012).  
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WATER REUSE STRATEGIES. With surface and groundwater sources increasingly failing to provide 
a long-term, continuous supply, water reuse in an artificially shortened water cycle is rapidly 
becoming more essential for practical water resources management (Wintgens et al., 2005; Le-
Minh et al., 2010). While water recycling for non-potable purposes (e.g. irrigation of agricultural 
fields, parks and golf courses, process water in industrial contexts or water for toilet flushing in 
households) is largely established today (EPA, 1998), so-called indirect potable water reuse is 
becoming increasingly important (Rodriguez et al., 2009). In this process purified wastewater is 
intentionally used to supplement drinking water supplies by e.g. groundwater recharge or 
infusion into lakes and water reservoirs. A technique which is to date less common, but 
considered crucial to meet the challenges of water management, is direct potable reuse, where 
highly purified wastewater is directly used as raw water for drinking water production without 
a temporal and spatial buffer (Crook, 2010). 
 
NO SUCH THING AS PURE, NATURAL WATER. Natural water always contains substances in 
suspended or particular form. Some of them are favourable, such as minerals that give spring 
water a certain distinct taste (EPA, 1999). However, natural waters are often a habitat for 
microbial organisms, many of them harmful to human health. The WHO estimates roughly 10% 
of the global disease burden would be preventable by improving water supply, sanitation, 
hygiene and the management of water resources (Prüss-Üstün et al., 2008). Safe drinking water 
is always the result of a production process, its complexity depending on the quality of the feed 
water and the available financial resources.  
 
XENOBIOTIC ORGANIC MICROPOLLUTANTS. Microbial impact on water is traditionally the major 
concern regarding drinking water quality, while nutrients are of most concern in wastewater 
because of their potential to induce eutrophication in receiving waters. However, in the last 
decades so-called xenobiotic substances, meaning chemicals not naturally occurring in the 
environment, increasingly came into focus. Firstly, pesticides were recognised as possible 
threats to water quality (e.g. Greve, 1972; Dawson and Riley, 1977; El-Dib and Aly, 1977; McNeil 
et al., 1977). Due to better analytical instrumentation allowing the detection of polar substances 
in the ng/L range, a group of “emerging” organic micropollutants was noticed in the 1990s, 
among them pharmaceuticals (Ternes, 2007; Busetti et al., 2009; Fatta-Kassinos et al., 2011a).  
 
PHARMACEUTICALS. Soon thereafter pharmaceuticals were recognized as environmentally 
relevant chemicals (Ternes, 1998), since they are by design biologically effective in human and 
animal organisms at low doses and to some degree persistent, which makes their presence in the 
environment a matter of concern (Comeau et al., 2008). In recent years, there have been 
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frequent reports of pharmaceuticals being identified in environmental samples of wastewater, 
surface water and drinking water (e.g. Heberer, 2002a; Heberer, 2002b; Kolpin et al., 2002; Kim 
et al., 2007; Huerta-Fontela et al., 2011; Kleywegt et al., 2011; Wang et al., 2011). Today, the 
concentrations of some pharmaceuticals in surface water equal the concentrations of common 
pesticides (Gentili, 2007). Moreover, it is not only the parent drugs which can be detected in the 
environment but their metabolites, too. Many of the metabolites are biologically active and their 
ecotoxicological properties unknown (Kolpin et al., 2002; Miao et al., 2005; Bataineh et al., 2006; 
Leclercq et al., 2009; Fatta-Kassinos et al., 2011b). Furthermore, environmental transformation 
products of pharmaceuticals are as yet often completely unidentified and have only very 
recently become subject to research studies. Thus, to date, their environmental pathways are 
mostly unclear. This basically makes them an entirely unknown hazard to aquatic ecosystems 
and human health (e.g. Kosjek et al., 2007; Kormos et al., 2009; Kosjek et al., 2009). 
 
INDUSTRIAL CHEMICALS. Another group of xenobiotic substances causing increasing concern are 
industrial chemicals like flame retardants and plasticisers that are used as high production 
volume (HPV) substances in a wide range of everyday products and applications (EPA, 2012a). 
Since even moderately persistent substances among them are constantly found in high 
environmental concentrations they are regarded as “pseudo-persistent” compounds (Daughton, 
2002a). 
 
UNKNOWN LONG-TERM EFFECTS. Little is known about the long-term effects of the environmental 
presence of xenobiotic micropollutants (Gentili, 2007; Hernando et al., 2007; Busetti et al., 
2009), but plain evidence of possible risks was given in 2004, when a study of Oaks et al. (Oaks 
et al., 2004) proved that the mass extinction of vultures in Pakistan was caused by the massive 
intake of the painkiller diclofenac which was used to treat the cows that provided the vultures’ 
nutrition base. Furthermore, some xenobiotic micropollutants are considered endocrine 
disrupting compounds. For these, possible connections between their occurrence in the 
environment and severe health effects like deteriorating reproductive health in humans and 
development of cancer are discussed (Gunten et al., 2006; Mückter, 2006). In increasingly 
tightening urban water cycles, xenobiotics can accumulate rapidly. Thus, in accordance with 
precautionary principles, the entry of pharmaceuticals and other micropollutants into the 
aquatic environment has to be prevented (Ternes, 2007; Rechenberg and Dieter, 2009). 
 
REDUCING MICROPOLLUTANTS. One way to reduce micropollutants in water is to prevent their 
production and use. Efforts have been made to reduce the input of micropollutants into the 
environment, e.g. regulations for the phase-out of known harmful HVP-substances such as 
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brominated flame retardants. In an as yet unique attempt to reduce the environmental pressure 
caused by pharmaceuticals, Sweden developed an environmental classification system for 
pharmaceuticals (LIF, 2007; LIF, 2012). Still, in many cases, especially regarding 
pharmaceuticals, end-of-pipe solutions in the form of the treatment of wastewater are the only 
currently viable way to reduce the occurrence of xenobiotics in the environment. 
 
TREATMENT METHODS. However, conventional wastewater treatment plants (WWTPs) were 
identified as major point sources of xenobiotic substances and gateways for their entry into the 
aquatic environment, since they are not designed to remove (polar) persistent micropollutants 
(Joss et al., 2006; Ternes, 2007). For this purpose, advanced treatment techniques in form of 
additional steps beyond conventional treatment or as alternative treatment designs are 
necessary. Various concepts like advanced oxidation, filtration systems and enhanced biological 
treatment have been investigated recently, but the need for further research is apparent (Huber 
et al., 2005; Lin et al., 2010; Tambosi et al., 2010; Behera et al., 2011). In addition, decentralised 
treatment of local hot spots such as wastewater from hospitals, which are considered a possible 
primary source of certain pharmaceutical contamination, is currently being discussed (e.g. Souza 
et al., 2009; Chang et al., 2010; Beier et al., 2011; Escher et al., 2011; Verlicchi et al., 2012a; 
Perrodin et al., 2013).  
 
THE STUDY PRESENTED. This study investigated the occurrence of 52 xenobiotic micropollutants – 
pharmaceuticals, metabolites, transformation products and HPV organophosphorus compounds 
– in raw hospital and municipal wastewater. It aimed to characterise a) the xenobiotic 
fingerprint in wastewater from different sources and b) the impact of different advanced 
treatment technologies on concentration levels and distribution patterns of xenobiotic 
micropollutants. For this, temporal concentration profiles of raw municipal wastewater were 
studied, including both weekdays and the weekend, and the removal of the studied 
micropollutants during wastewater treatment by a nanofiltration membrane biofilm reactor 
(NF-MBR) situated at the influent of a municipal WWTP (population equivalent: 300,000) was 
investigated (Chapter 3). These results were compared to the elimination performance of pure 
NF-treatment without biological treatment. In the same way as the municipal wastewater 
stream, untreated wastewater from a municipal hospital was studied and the influence of a 
particle-supported biofilm reactor (PS-BFR) on the distribution patterns of xenobiotic 
micropollutants was investigated (Chapter 4). In the third part of the presented work, the 
occurrence of xenobiotics in biosolids was addressed (Chapter 5). For this, a multi-residue 
extraction method was developed and subsequently used for the determination of the 
micropollutants in sewage sludge from the NF-MBR and in sludge and carrier material from the 
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PS-BFR. The results of the individual studies presented in Chapters 3 to 5 were subsequently 
contrasted and related to each other with regard to xenobiotic distribution patterns, xenobiotic 
loads of different wastewater streams and the capacity for xenobiotic removal found for the 
studied wastewater treatment methods (Chapter 6). Finally, an aquatic environmental 
assessment for the investigated micropollutants was carried out based on the results of the 
presented study.  
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2. FUNDAMENTALS 
 
Access to a secure, safe and sufficient source of fresh water is a fundamental requirement for the 
survival, well-being and socio-economic development of all humanity. Yet, we continue to act as if 
fresh water were a perpetually abundant resource. It is not. 
– Kofi Annan (1938- ), Awake! magazine, June 22, 2001 – 
 
 
2.1 CHARACTERISTICS OF SELECTED XENOBIOTIC ORGANIC MICROPOLLUTANTS FROM 
DIFFERENT CLASSES  
2.1.1 PHARMACEUTICALS – METABOLISM, CONSUMPTION AND OCCURRENCE IN THE AQUATIC 
ENVIRONMENT  
DESIGN OF PHARMACEUTICALS. Pharmaceuticals are designed to have a pharmacological, i.e. 
biological, effect at low concentrations (Halling-Sørensen et al., 1998; Hörsing et al., 2011). At 
the same time, they are meant to withstand biological processes to reach their target organ in 
human or animal organisms. Thus, they are to some degree persistent by design. These 
characteristics are the main sources of concern regarding pharmaceutical occurrence in the 
environment (Kümmerer, 2001).  
 
METABOLISM AND BIOTRANSFORMATION. After intake, pharmaceuticals are completely or partly 
metabolised before excretion. Metabolism takes place mainly in the liver and also, to a lesser 
extent, in the gastrointestinal tract, kidneys, lungs or skin. It can be described as a two-phase-
process: the first phase (phase I reaction) typically consists of oxidation, reduction or hydrolysis 
of the compound, before, in the phase II reaction, the metabolite is conjugated in a way that 
enhances polarity and therefore excretion (Figure 2-1). While phase I metabolites are often 
bioactive, phase II usually leads to the deactivation of the metabolites (detoxication) (Mutschler 
et al., 2008). However, these principles do not apply in all cases: some compounds only undergo 
the phase I reaction and are excreted directly afterwards, others show a phase II reaction 
without a prior phase I (Ternes, 1998; Alder et al., 2006).  
As well as metabolism in the target organism, pharmaceuticals can also be biotransformed in the 
environment after excretion (Alexy and Kümmerer, 2006; Heberer and Ternes, 2006). 
Microorganisms use organic compounds directly as an energy source for life sustainment and 
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growth. Furthermore, organic compounds are co-metabolised without being used as a carbon 
source by the metabolising microorganism (Nyholm et al., 1996).  
 
 
Figure 2-1: Principle human metabolism of pharmaceuticals (adapted from Mutschler et al., 2008). 
 
UNIDENTIFIED PROPERTIES. Despite intensive research during the last decades, the kinetics and 
mechanisms of drug metabolism are still in many cases not known precisely. This is partly 
because of the large number of substances used in modern human and veterinary medicine. 
According to Kümmerer, 2004, at the end of the twentieth century about 50,000 drugs were 
registered in Germany for human use, of which 2,700 accounted for 90% of the overall 
consumption, the latter containing approximately 900 different pharmaceutically active 
compounds. At the same time in the UK, about 3,000 active compounds were registered 
(Ayscough et al., 2000). 
In addition, the identification of metabolites is difficult, time-consuming and costly; it requires 
high-end analysis equipment and very often the in-house synthesis of metabolites which are not 
commercially available (Kosjek et al., 2007). Furthermore, the metabolic processes of one 
pharmaceutical compound can result in a large number of metabolites; e.g. for carbamazepine 
33 metabolites were found in human and rat urine (Lertratanangkoon and Horning, 1982).  
The extent to which a drug is metabolised during passage through the target organism varies 
between substances, as does the percentage excreted in either urine or faeces (Table 2-1). 
However, Alder et al., 2006 estimates that overall approximately 70% of pharmaceutical 
compounds are excreted via urine and 30% are faeces-bound. In sewage and sewage treatment 
(or, in the case of veterinary drugs, in manure), metabolite conjugated with e.g. glucuronic acid 
Chapter 2 
 
page | 8  
or sulphate can be cleaved by enzymes and/or bacteria resulting in a re-introduction of the 
active parent compound in the wastewater during treatment and subsequently elevated 
amounts in the receiving water bodies (Heberer and Ternes, 2006). Consequently, several 
studies reported negative removal rates for various pharmaceuticals in wastewater treatment 
plants (e.g. Lishman et al., 2006; Barron et al., 2008; Chang et al., 2008c).  
In addition to the metabolism that drugs undergo in the target organism, an “environmental” 
biotransformation of drug residues and metabolites by microorganisms occurs in sewers, 
WWTPs, receiving water bodies and soils which are treated with sewage sludge or irrigated with 
treated water. For example, Kormos et al., 2009 described five, seven and eleven transformation 
products in soils for the contrast media iomeprol, iopamidol and iohexol respectively. 
Table 2-1: Excretion forms of selected pharmaceuticals. 
Substance 
Excreted unchanged  
in human urine/faeces 
[%] 
Excreted as glucuronide*** 
[%] 
Clarithromycin 20–30 / 4–111  
Roxithromycin 8 / 551  
Sulfamethoxazole 10 / -1  
N4-acetylsulfamethoxazole 
(metabolite) 
(50 / -)*1  
Sulfadimidine 10 / -1  
Trimethoprim 50 / -1  
Carbamazepine 0.5; 1-2**2 approx. 302 
Bezafibrate 50**2 22 
Diclofenac 15**2 < 12 
Ibuprofen 1-8**2 152 
Iopamidol 100**3  
Iomeprol 100**3  
Iopromide 100**3  
diatrizoic acid 100**3  
1 Göbel et al., 2005b; 2 Alder et al., 2006; 3 Pérez and Barceló, 2007 *percentage of the administered sulfamethoxazole 
dose; **manner of excretion not further specified; *** phase II metabolite without previous phase I reaction 
 
ENVIRONMENTAL FATE. Until recent years, the release of pharmaceuticals into the environment 
attracted little attention (Halling-Sørensen et al., 1998). Only when improved analytical methods 
with considerably lower detection limits became available did these micropollutants start to be 
(re-)discovered in environmental samples as “emerging compounds”, a somewhat misleading 
term because many of the drugs had been in use for decades (Möller et al., 2011).  
Possible pathways of pharmaceuticals into the environment are shown in Figure 2-2. As early as 
during production, potential input pathways are opened by disposal of solid waste or process 
waters. After intake, excreted human drugs enter the sewage system and reach wastewater 
treatment plants, where they are removed (i.e. biotransformed) to very different degrees before 
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being released into the aquatic environment. The disposal of unused pharmaceuticals via the 
toilet is another entrance to this pathway. In Germany, a study showed that 23% of prescribed 
liquid drugs were discarded; the amount of pharmaceuticals flushed into the sewers equals 
approximately 364 t per year (Lubick, 2010). Subsequently, wastewater treatment plants have 
been identified as the most important gateway for drugs into the aquatic system (Barceló, 2004; 
Kümmerer, 2004; Alder et al., 2006). In the assessment of the environmental fate of 
pharmaceuticals, sorption to sewage sludge, soils and sediments has to be considered. While 
drugs disposed of with solid waste are destroyed by oxidation during waste incineration, waste 
disposal in landfills can lead to the occurrence of pharmaceuticals in the aquifer through landfill 
leakage or by passage with drainage water (Alder et al., 2006). Sewer leakages can open various 
pathways for pharmaceuticals into groundwater. Veterinary pharmaceuticals are introduced to 
the environment via manure applied to agricultural land as fertiliser, from where they might be 
transferred to surface water via run off or infiltrate into groundwater. The same exposure 
pathway is possible for drugs associated with sewage sludge after application to agricultural soil 
(Kümmerer, 2004).  
 
 
 
 
Figure 2-2: Principal exposure routes of human and veterinary pharmaceuticals into the environment 
(adapted from Barceló, 2004; Alder et al., 2006; Heberer and Ternes, 2006). 
  
Sewage Domestic waste Manure
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2.1.1.1  ANTIBIOTICS 
SIGNIFICANCE AND APPLICATION. A therapeutic group of special interest is antibiotics. They are 
possibly the most important pharmaceutical substances (Alexy and Kümmerer, 2006) for they 
revolutionised modern medicine by enabling the treatment of a wide range of fatal diseases 
efficiently for the first time in human history. Furthermore, they enabled the development of 
sophisticated surgical applications like joint replacements and heart surgery by controlling 
accompanying infections. Antibiotics are used not only in human medicine, where they are the 
third most prescribed pharmaceutical class (Schwabe and Paffrath, 2007; see also Table 2-2), 
but in livestock, poultry production and aqua cultures in quantities equalling those of human 
medicine applications. In many cases it is difficult to obtain reliable and accurate consumption 
data. The Union of Concerned Scientists (Union of Concerned Scientists, 2001) estimates that of 
the approx. 16,200 t of antibiotics produced in the USA in 2000, 70% were used in healthy 
livestock. In 1996, approximately 50% of the antibiotics used in the European Union (about 
10.200 t) were applied in veterinary medicine and as animal growth promoters (FEDESA, 1997). 
To limit extensive non-medical use, in the EU antibiotics were banned as growth promoters in 
2006 (WHO, 2011a). In veterinary use, antibiotics represent 70% of all consumed 
pharmaceuticals (Barceló, 2004).  
 
PROPERTIES. Antibiotics embody a very diverse range of chemical classes with very different 
physico-chemical and biochemical properties (Le-Minh et al., 2010). According to the statistics 
of German Statutory Health Insurance, in 2009 the leading antibiotic classes in use in Germany 
were beta-lactam antibacterials at 44% (data based on reimbursable pharmaceuticals bought in 
a pharmacy and available on prescription as well as reimbursable over-the-counter drugs in the 
case of defined exceptions), followed by tetracyclines (20.7%), macrolides (16.8%), quinolones 
(9.9%) and sulfonamides and trimethoprim (4.9%) (ESAC, 2009). 
Despite being the most abundant group, beta-lactam antibacterials are not detected in the 
environment, since they are eliminated by biodegradation during conventional wastewater 
treatment (Le-Minh et al., 2010). Therefore they are not further discussed in this study, which 
will focus on macrolides, sulfonamides, trimethoprim and tiamulin. The term “antibiotics” 
hereafter refers to these named antibiotic classes.  
 
MACROLIDES. Macrolides (physico-chemical properties shown in Table 2-3) are mainly applied in 
the treatment of upper and lower respiratory tract infections (Göbel et al., 2005b) to combat 
Gram-positive bacteria, the Gram-negative legionella bacterium, mycoplasma pneumonia, 
campylobacter and chlamydia species (Schwabe and Paffrath, 2007) by inhibiting ribosomal 
protein synthesis (Bryskier et al., 1993). The name of the compound group derives from the 
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macrocyclic lactone structure of the parent drug erythromycin, which was discovered in a strain 
of Streptomyces erythreus in 1952 (Mückter, 2006). In the late decades of the twentieth century, 
several derivates such as clarithromycin and roxithromycin became available and are used today 
in considerable amounts (Table 2-1). They are applied only in human medicine, whereas 
erythromycin is used in both human and veterinary applications.  
After intake, macrolides are not largely metabolised (Table 2-1), but are mostly excreted in 
faeces in form of the original drug (Göbel et al., 2005b).  
Table 2-2: Estimated oral consumption of selected prescribed drugs in Germany for 2005.  
Compound DDD oral1 
DDD in Mio. prescribed for 
oral treatment 
in Germany, 20052 
Estimated prescribed oral 
consumption in Germany in 20053 
 
[g] 
 
[t/year] 
Antibiotics  
Clarithromycin 0.50 21.5 10.8 
Roxithromycin 0.30 19.6 5.88 
sulfamethoxazole 2.00 22.4 44.8 
Psychoactive drugs 
Trimethoprim 0.40 23.6 9.44 
carbamazepine 1.00 63.5 63.5 
Primidone 1.25 5.0 6.25 
Codeine 0.10 25.4 2.54 
dihydrocodeine 0.15 7.6 1.14 
Methadone 0.03 1.2 0.03 
Morphine 0.10 15.7 1.57 
Oxycodone 0.08 14.4 1.08 
Diazepam 0.01 38.3 0.383 
Nordiazepam 0.02 n.r. n.r. 
Oxazepam 0.05 19.6 0.98 
Temazepam 0.02 9.3 0.186 
Doxepin 0.10 55.9 5.59 
Lipid-regulators 
Bezafibrate 0.60 24.7 14.8 
Non-steroidal anti-inflammatory drugs 
Diclofenac 0.10 472 47.2 
Ibuprofen 1.20 221 265 
Naproxen 0.50 9.1 4.55 
Iodinated x-ray contrast media 
Iopamidol n.r. n.r. 43.0 5 (2001) 
Iomeprol n.r. n.r. 83.4 5 (2001) 
Iopromide n.r. n.r. 1304/64.1 5 (2001) 
diatrizoic acid n.r. n.r. 60.7 5 (2001) 
1 (WHO, 2012); 2 Schwabe and Paffrath, 2007; 3 calculated by multiplying defined daily doses for oral application 
(WHO, 2012) with the prescribed number of defined daily doses in 2005 (Schwabe and Paffrath, 2007); 4 Alder et al., 
2006; 5 sales in Germany in 2001 according to BLAC, 2003; n.r. = not reported in the searched databases  
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SULFONAMIDES. These are a group of synthetic antibiotics which have been used in medical 
treatment since the 1930s. They are mainly used for the treatment of urinary tract infections, 
pneumonia and some other infections (Schwabe and Paffrath, 2007). Although thousands of 
sulfonamides were developed and tested, less than 200 reached the market and today only a few 
are widely used in human or veterinary medicine. Sulfonamides act against Gram-positive and -
negative bacteria through growth blockage by competitive inhibition of bacterial folate 
biosynthesis (Mückter, 2006).  
In human medicine, sulfamethoxazole is the most extensively used sulfonamide – in Germany 
the only one at all (Schwabe and Paffrath, 2007) – while in veterinary medicine a range of 
sulfonamides, e.g. sulfamethoxine, sulfisoxazole, sulfamerazin and sulfadimidine are used.  
After treatment, sulfonamides are excreted via urine, partly metabolised, partly as the original 
drug (Table 2-1). Major metabolites are the biologically inactive N4-acetylated forms of the drug, 
e.g. N4-acetylsulfamethoxazole, which accounts for about 50% of the administered dose of the 
parent compound sulfamethoxazole (Table 2-1) (Göbel et al., 2005b). The retransformation of 
N4-acetylsulfamethoxazole back to the active parent drug during wastewater treatment was 
observed by Göbel et al., 2005b; Berger et al., 1986 found the same for N4-acetylsulfadimidine 
which was biotransformed to the parent compound sulfadimidine during the storage of manure. 
This intertransformation between the original drugs and their respective metabolites may 
account for reported negative removal rates in conventional wastewater treatment (Göbel et al., 
2007) (see above).  
As Table 2-4 depicts, sulfonamides have two functional groups of which the amine attached to 
the aromatic group is deprotonated at pH levels under 1.8 – 2.3 (depending on the compound, 
see pKa,1 in Table 2-4) while the amide attached to the sulphur is deprotonated at pHs above 
4.8 – 7.5 (pKa,2). Consequently, in general sulfonamides are positively charged under acidic 
conditions and negatively charged under alkaline conditions (Haller et al., 2002).  
 
TRIMETHOPRIM. To enhance their therapeutic potential and lessen the risk of resistance 
development, sulfonamides are often used in combination with trimethoprim. Trimethoprim is a 
polyalkoxybenzyldiaminopyrimidine derived from pyrimethamine, an anti-malaria drug which 
hinders the bacterial folate biosynthesis by inhibiting the bacterial enzyme dihydrofolate 
reductase (DHFR) (Mückter, 2006). Additionally, it has the same half-life in the treated body as 
the sulfonamides and is likewise excreted renally (Schwabe and Paffrath, 2007). Since it is much 
more expensive as a mono-drug, trimethoprim is rarely administered in isolation, although it is 
recommended in medical guidelines as treatment of choice for certain indications, as it is equally 
potent and better tolerated than the combination (Schwabe and Paffrath, 2007).  
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The metabolic rate of trimethoprim is similar to that of sulfonamides: approximately half of the 
administered drug is excreted in metabolised form (Table 2-1). 
Like sulfonamides, trimethoprim is charged differently at different pHs; the two pKa values of 
trimethoprim (pKa,1 3.3, pKa,2 6.8) are assigned to the basic N3 and N1 sites respectively in the 
pyrimidine ring (Table 2-5) (Quiang and Adams, 2004).  
 
TIAMULIN. Tiamulin (Table 2-5) is a diterpene antimicrobial with a pleuromutilin chemical 
structure, which mainly targets Gram-positive bacteria and mycloplasma. It is used in veterinary 
medicine for both treatment and prophylaxis of dysentery, pneumonia and mycoplasmal 
infections in pigs and poultry (EMEA, 2008).  
 
 
 
 
 
 
Table 2-3: Physico-chemical properties of macrolides. Ws: water solubility (if not otherwise indicated at 
25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-m3/mole]; Ws = water solubility 
[mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or databases consulted. 
Substance Clarithromycin Roxithromycin 
Abbreviation CLA ROX 
Chemical 
structure  
 
 
CAS-No. 81103-11-9 80214-83-1 
MW  747.95  837.05 
Log KOW 2.42a; 3.16b  2.750b 
pKa 8.99a,b 9.2c 
HLC  1.73x10-29d  --- 
Ws  0.342b 0.0189d 
a Sangster, 2012; b NLM, 2005; c Bryskier et al., 1993; d SRC Research Corporation; e Maria and Reginald, 1993; f Gros et 
al., 2006a; g Quiang and Adams, 2004   
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Table 2-4: Physico-chemical properties of sulfonamides. Ws: water solubility (if not otherwise indicated at 
25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-m3/mole]; Ws = water solubility 
[mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or databases consulted. 
Substance Sulfadimethoxine 
Sulfadimidine; sulfamethazine; 
sulfadimethylpyrimidine 
Abbreviation SMI SDI  
Chemical 
structure  
  
CAS-No. 122-11-2 57-68-1 
MW  310.33 278.33 
Log KOW 1.63a  0.28a; 0.89b 
pKa,1 1.87e 2.28e 
pKa,2 5.86e; 5.98a 7.42e; 7.59a,b 
HLC 1.30x10-14d 3.05x10-13d 
Ws  343b 1500b 
   
Substance Sulfisoxazole; sulfafurazole Sulfamerazine; sulfamerathyldiazine 
Abbreviation SSX SMA 
Chemical 
structure  
  
CAS-No. 127-69-5 127-79-7 
MW 267.30 264.31 
Log KOW 1.01a 0.14a,b 
pKa,1 --- 2.17e 
pKa,2 4.8a 6.77e; 6.83a 
HLC 1.06x10-12d 1.75x10-10d 
Ws  300b 202b 
 
Substance sulfamethoxazole N4-acetylsulfamethoxazole 
Abbreviation SMX N-Ac-SMX 
Chemical 
structure  
  
CAS-No. 723-46-6 21312-10-7 
MW  253.28 295.32 
Log KOW 0.89f; 0.89a 1.2d 
pKa,1 1.83e 5.0d 
pKa,2 5.57e; 6.0f; 5.81a  
HLC 6.42x10-13d 3.1x10-15d 
Ws  610 (37 °C)b 1220d 
a Sangster, 2012; b NLM, 2005; c Bryskier et al., 1993; d SRC Research Corporation; e Maria and Reginald, 1993; f Gros et 
al., 2006a; g Quiang and Adams, 2004 
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Table 2-5: Physico-chemical properties of trimethoprim and tiamulin. Ws: water solubility (if not 
otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-
m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or 
databases consulted. 
Substance Tiamulin Trimethoprim 
Abbreviation TAM TMP 
Chemical 
structure  
 
 
CAS-No. 55297-95-5 738-70-5 
MW 493.74 290.32 
Log KOW 4.750b 0.91f,b 
pKa,1 --- 3.23g 
pKa,2 --- 6.76g; 7.12f,b 
HLC 4.21x10-16d 2.39x10-14b 
Ws 0.696d 400b 
a Sangster, 2012; b NLM, 2005; c Bryskier et al., 1993; d SRC Research Corporation; e Maria and Reginald, 1993; f Gros et 
al., 2006a; g Quiang and Adams, 2004  
 
ENVIRONMENTAL OCCURRENCE – STATE OF RESEARCH. Antibiotics have been found in domestic and 
hospital wastewater (Ashton et al., 2004; Carballa et al., 2004; Göbel et al., 2004; Batt and Aga, 
2005; Yang et al., 2005; Gros et al., 2006a; Göbel et al., 2007; Kim et al., 2007; McClure and Wong, 
2007; Chang et al., 2008b; Gros et al., 2008; Radjenović et al., 2009a) and in agricultural 
wastewater (Malintan and Mohd, 2006). Reported amounts vary according to local patterns of 
pharmaceuticals use. In general, reported concentrations in wastewater range from the middle 
and upper ng/L to the low µg/L range, similarly showing different patterns in different 
countries. In effluents from pharmaceutical production sites and hospitals, some antibiotics 
were found in concentrations potentially high enough to cause adverse effects on wastewater 
bacteria (Al-Ahmad et al., 1999; Kümmerer et al., 2000; Alexy and Kümmerer, 2006). They are 
greatly diluted by mixing with municipal wastewater before reaching the WWTP. Since 
antibiotics can diffuse into biofilms such as those present in the pipes of a sewer system, 
unknown amounts of the pharmaceuticals are held back there, temporarily or permanently, 
resulting in a sink with the possibility of later re-release of the substances into the water (Alexy 
and Kümmerer, 2006). Additionally, increased contact times of bacteria and antibiotics in 
biofilms in sewer systems, especially the effluents of production sites or hospitals, are discussed 
as source of spread of MDR (multiple drug-resistant) bacteria (see below). 
The studies undertaken reported highly diverse removal rates of antibiotics in conventional 
wastewater treatment, ranging from none to complete biotransformation for the same 
substance, but in general antibiotics seem to be only partly removed during wastewater 
treatment (Le-Minh et al., 2010). It is indicated that operating conditions such as solids retention 
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time (SRT) and hydraulic retention time (HRT) influence the biodegradation processes of 
micropollutants (Clara et al., 2005; Oppenheimer et al., 2007; Yu et al., 2009); thus variations in 
elimination could be explained by different operational modes. In contrast to sulfonamides, 
observed negative removal rates of macrolides are primarily attributed to the release of the 
unmetabolised parent drug from faeces during wastewater treatment rather than 
intertransformation of metabolites (Göbel et al., 2007).  
Some studies investigated the occurrence of antibiotics in sewage sludge (Göbel et al., 2005a; 
Göbel et al., 2005b; Yang et al., 2005; Lindberg et al., 2006; Lillenberg et al., 2009; Radjenović et 
al., 2009b; Li et al., 2013). As shown above, the sorption of antibiotics to sewage sludge is highly 
dependent on pH, stereochemistry and the chemical nature of the micropollutant and the 
sorbent as well. Subsequently, results differ between studies, but, generally speaking, the 
sorption processes of the antibiotic groups presented in this study have been found to be of only 
minor consequence for the removal of antibiotics during wastewater treatment (Göbel et al., 
2005b; Le-Minh et al., 2010).  
 
Due to their incomplete removal, antibiotics are frequently detected in surface water (cf. e.g. 
Kolpin et al., 2002; Ashton et al., 2004; Yang et al., 2004; Kim et al., 2007; Kim and Carlson, 2007; 
Chang et al., 2008b; Díaz-Cruz et al., 2008; Gros et al., 2008; Tamtam et al., 2008; Kleywegt et al., 
2011), in river sediment (Kim and Carlson, 2007) and groundwater (Hirsch et al., 1999; Kolpin 
et al., 2002; Díaz-Cruz et al., 2008). Kleywegt et al., 2011 detected antibiotics in finished drinking 
water in the low ng/L-range. Díaz-Cruz et al., 2008 reported finding sulfadimethoxine in bottled 
mineral water.  
In aquatic environments, sulfonamides have been described as photosensitive and their 
photodegradation has been observed in natural waters (Boreen et al., 2004).  
  
ADVERSE EFFECTS. One particular concern regarding antibiotics is a possible adverse effect on 
non-target organisms in the environment (Alexy and Kümmerer, 2006). Only a few studies have 
investigated this issue so far. In an ecotoxicity study based on bioassays performed on various 
organisms to determine acute and chronic toxicity as well as the genotoxic potential of 
sulfamethoxazole and clarithromycin (among others) proved that sulfamethoxazole was 
mutagenic, while clarithromycin was found to be the most harmful for the aquatic environment 
(Isidori et al., 2005b). Toxicity details for all investigated antibiotics are shown in Table 2-6.  
 
BACTERIAL RESISTANCE. Besides the ecotoxicological effect on non-target organisms (LD50 values 
see Table 2-6), the wide-spread presence of antibiotics in the environment may increase the 
development of bacterial resistance to specific compounds (Alexy and Kümmerer, 2006). In 
recent years, antibiotic resistance in bacteria has become a serious health problem. It is 
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estimated that in the European Union, Norway and Iceland around 25,000 people died in 2007 
of infections connected with antibiotic resistance (ECDC, 2009; WHO, 2011a; WHO, 2011b). 
According to the European Centre for Disease Prevention and Control (ECDC), two thirds of 
these deaths resulted from infections due to Gram-negative bacteria. In addition, infections 
caused by antibiotic-resistant bacteria led to approximately 2.5 million extra hospital days 
(ECDC, 2009), making antibiotic resistance both a medical and economic burden.  
Resistance to antimicrobial drugs is part of the natural adaptation process due to mutation not 
only in bacteria but in fungi, viruses and parasites as well, causing similar problems for the 
control of antimicrobial resistance in all these microorganisms (WHO, 2001). It was only four 
years after the mass-production of penicillin began that the first resistant microbes were found 
(the first bacterium adapting successfully was Staphylococcus aureus) (WHO, 2011a). Although 
resistance occurs naturally as a result of the application of antibiotics, it is particularly increased 
by inappropriate use, which includes overprescribing e.g. for treatment of minor or non-
bacterial infections, misuse because of false diagnosis or lack of information about alternatives, 
and also underuse due to lack of access or financial ability, or inadequate compliance with the 
prescription to complete treatment correctly (WHO, 2011a). Development of resistance may also 
occur by uptake of genetic material encoding resistance (e.g. in hospital effluents) (Alexy and 
Kümmerer, 2006) or by information exchange via DNA between bacteria, which is especially 
easy to accomplish in biofilms or microbial flocs (e.g. in sewers and WWTPs) where large 
numbers of microorganisms are in close proximity to one another (Karatan and Watnick, 2009; 
Nadell et al., 2009; CBE, 2013c). Antibiotic resistance is also important in terms of food safety 
(WHO, 2011b), since resistant bacteria and resistant genes carried by food-producing animals 
can spread to humans through the food chain as foodborne diseases caused by antibiotic-
resistant bacteria like salmonella (WHO, 2011a), through direct contact with the animals, or via 
environmental pathways such as contaminated water (WHO, 2011b).  
Bacterial resistance shows highly differentiated national patterns, often due to varying 
treatment regulations. For example, while in most EU countries antibiotics are only used as 
prescribed drugs, they are sold as OTC drugs in some eastern European countries, leading to 
greatly increased use and mirrored by high resistance rates of up to 50%, while for the EU, 
Norway and Iceland, antibiotic resistance of up to 25% is reported (WHO, 2011a). Additionally, 
national actions of surveillance and control are at very different levels. In Denmark, a significant 
decrease in resistance in some bacteria was observed after the prohibition of using antibiotics as 
a growth promoter (WHO, 2011a).  
To date, the issue of resistance spread in wastewater is controversial (cf. Kümmerer and 
Henninger, 2003; Michael et al., 2013). Laboratory-scale studies have found that the presence of 
antibiotics in wastewater – even in microbiologically effective concentrations – had no influence 
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on the bacterial population in WWTP, which suggests that resistant bacteria are already present 
in wastewater reaching the WWTP (Al-Ahmad et al., 2009). Municipal wastewater treatment has 
been reported to be accompanied by significant increases in antimicrobial resistance (Figueira 
et al., 2011a), while other studies have found significant reduction of antibiotic resistance genes 
and antibiotic-resistant bacteria – of over 2 log-units – to have been achieved by conventional 
wastewater treatment. Disinfection steps such as chlorination and UV treatment fail to 
significantly reduce antibiotic resistant bacteria (Munir et al., 2011) or even seem to increase the 
incidence (Gao et al., 2012c). Studies suggest that resistance introduced to a stream via WWTP 
effluents rapidly decreases downstream (Akiyama and Savin, 2010). Nonetheless, antibiotic-
resistant bacteria were recently found in drinking water samples (Figueira et al., 2011b). Taking 
the complexity of microorganism communities in sewage into account, further studies need to 
be conducted on this issue (Alexy and Kümmerer, 2006).  
Table 2-6: Chemical toxicity data of antibiotics for aquatic life (EPA, 2012b). LC50: median lethal 
concentration; t: exposure duration; LOEC: lowest observable effect concentration; species given in index 
numbers: 1: Thamnocephalus platyurus (Fairy Shrimp); 2: Oryzias latipes (Japanese Medaka); 3: Anguilla 
Anguilla (Common Eel); 4: Morone saxatilis (Striped Bass); 5: Brachionus calyciflorus (Rotifer); 6: Hydra 
attenuata (Hydra); 7: Pseudokirchneriella subcapitata (Green Algae); 8: Lemna gibba (Inflated Duckweed); 
9: Daphnia magna (Water Flea); 10: Xenopus laevis (African Clawed Frog). 
Substance  
(CAS-No.) 
LC50 LOEC 
 
lowest LC50 
(µg/L) for the 
most sensitive 
indicator species 
(indicator 
species) 
t 
no. of aquatic 
studies 
identified 
lowest LOEC 
(µg/L) 
for the most 
sensitive indicator 
species (indicator 
species) 
t 
no. of aquatic 
studies 
identified 
Clarithromycin 
(81103-11-9) 
33,640 (1) 24 h 2 40 (7) 72 h 1 
Roxithromycin 
(80214-83-1) 
--- --- 0 40 (7) 72 h 1 
Sulfadimethoxine 
(122-11-2) 
> 100,000 (2) 24 h 4 300 (8) 196 h 6 
Sulfadimidine  
(57-68-1) 
> 75,000 (3) 24 h 4 
1,000 (8); 3,125 
(9) 
21 days;  
21 days 
4 
Sulfisoxazole 
(127-69-5) 
--- --- 0 --- --- 0 
Sulfamerazine 
(127-79-7) 
> 100,000 (4) 1–96 h 5 --- --- 0 
Sulfamethoxazole 
(723-46-6) 
26,270 (5) 24 h 5 
800 (7); 
> 100,000 (10);  
10,000 (6) 
72 h;  
96 h;  
96 h 
11 
N4-acetyl- 
sulfamethoxazole 
(21312-10-7) 
--- --- 0 --- --- 0 
Tiamulin  
(55297-95-5) 
--- --- 0 --- ---- 0 
Trimethoprim 
(738-70-5) 
> 100,000  
(2, 6) 
48 h; 
96 h 
3 20,000 (9) 21 days 6 
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2.1.1.2  IODINATED X-RAY CONTRAST MEDIA  
PROPERTIES AND USE. Iodinated x-ray contrast media (ICMs) are usually derivates of 2,4,6-
triiodinated benzoic acid. They are commonly divided into ionic (e.g. diatrizoic acid) and non-
ionic (e.g. iopamidol, iomeprol, iopromide) compounds. The latter are used, for example, in 
angiography and urography and represent 90% of the applied ICMs (Putschew and Jekel, 2006). 
Ionic ICMs contain carboxylic moieties in their side-chains, while non-ionic ICM are amide 
derivates with hydroxyl groups.  
Since iodine atoms absorb X-rays, ICMs are used to enhance the contrast between different 
blood vessels and/or organs which would otherwise be not visible under x-ray examination 
(Pérez and Barceló, 2007). Treatment doses can reach up to 200 g ICM per application, equalling 
approximately 100 g iodine (Pérez and Barceló, 2007). In terms of mass, ICMs are the most 
frequently applied pharmaceuticals in hospitals (Putschew and Jekel, 2006). The global 
consumption of ICMs is approximately 3,500 t per year (Sprehe et al., 2000). The consumption of 
selected ICMs in Germany is shown in Table 2-2, where iopromide is seen to be the most heavily 
used (130 t per year).  
 
EXCRETION AND ENVIRONMENTAL FATE. ICM are designed for metabolic stability: they are inert 
and do not interact with the treated organism. Therefore, they are excreted completely and 
unaltered via the patient’s urine within 24 h after application (Speck and Hübner-Steiner, 1999). 
The highest concentration in urine is found within one hour after treatment, reaching up to 
70 g/L (Sprehe et al., 2000). Since in consequence of their pharmaceutical purpose ICM are 
highly persistent and polar (log KOW diatrizoic acid: -1.05; iopamidol: -2.42; iopromide: -2.05; for 
more physico-chemical data see Table 2-7), they remain in the water phase and reach the 
sewage system unchanged. ICM are poorly eliminated by conventional wastewater treatment 
systems (Hirsch et al., 2000; Carballa et al., 2004; Pérez and Barceló, 2007; Ternes et al., 2007). 
Thus, they are discharged into the receiving waters in quantities up to µg/L levels, where they 
undergo practically no sorption by sediment or sludge and can be transported, dissolved, over 
long distances (Löffler et al., 2005; Haiß and Kümmerer, 2006; Seitz et al., 2006). Seitz et al., 
2006 found a WWTP to be a point source for ICM concentrations in the river Danube, releasing 
ICM in fluctuating amounts into the river, with detected concentrations being higher on 
weekdays than on weekends due to the working hours of hospitals and x-ray units. It can be 
assumed that ICM occur in all surface waters which are influenced by WWTP effluents 
(Putschew and Jekel, 2006). Additionally, groundwater can be affected, especially in areas where 
bank filtration is used for the production of drinking water. Ternes and Hirsch, 2000 found that 
ICM in surface water influenced ground water in the greater Frankfurt area (Southwest 
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Germany) and detected ICM in groundwater of agricultural fields receiving wastewater 
irrigation near Braunschweig (Germany) (Ternes et al., 2007).  
 
BIOTRANSFORMATION AND DEGRADATION IN THE ENVIRONMENT. While no profound biodegradation 
of ICM is observed in WWTPs, several laboratory studies point to biotransformation processes. 
Joss et al., 2006 observed the biodegradation of several ICM in batch experiments with activated 
sludge, revealing no biodegradation for diatrizoic acid, but in the case of iopromide 85% was 
transformed into 2 metabolites within 54 h in activated sludge. The metabolites were not 
identified, but partial deiodination is suspected because of rising amounts of inorganic iodine in 
the sludge batches. Haiß and Kümmerer, 2006 studied the biodegradation of diatrizoic acid 
during simulated biological sewage treatment (modified OECD 303 A test), observing 
biodegradation occurring only under special conditions and with long lag times. These and other 
laboratory studies simulating WWTP treatment found biodegration to be dependent on a) test 
period length, b) test substance concentration and c) sludge composition (Steger-Hartmann et 
al., 1999; Steger-Hartmann et al., 2002; Haiß and Kümmerer, 2006; Joss et al., 2006; Pérez and 
Barceló, 2007). In laboratory tests with river water, the degradation of iopromide was found to 
be concentration-dependent with the shortest half-life measured being about 3.1 days. 
Degradation of iopromide showed no lag time, while diatrizoic acid showed exponential decline 
(with a half-life of approximately 4.5 days) only after an acclimation time of 21 days, forming 
two water-soluble metabolites (Kalsch, 1999).  
Another study reported moderate persistence of iopromide in laboratory tests with river water 
sediment systems and its transformation into at least four metabolites after a lag period of two 
weeks (Löffler et al., 2005).  
Besides metabolism by microorganisms, photodegradation is another possible breakdown 
mechanism for ICM in the environment. For example, Doll and Frimmel, 2003 established 
photodegradation for iomeprol. In general, sorption to particles can also result in the elimination 
of micropollutants from water, but due to the polar nature of ICM an accumulation in sediments 
and sludges can be excluded as a major elimination process (Steger-Hartmann et al., 1999; 
Löffler et al., 2005; Putschew and Jekel, 2006). 
 
TRANSFORMATION PRODUCTS. Until now, few studies have identified transformation products of 
ICM (Table 2-8). Schulz et al., 2008 and Kormos et al., 2009 used a hybrid triple quadrupole 
linear ion trap mass spectrometer (Qq-LIT-MS) in combination with nuclear magnetic resonance 
(NMR) analysis to identify the chemical structures of biotransformation products which the ICM 
iohexol, iomeprol and iopamidol form in water and soil. A number of these transformation 
products were detected in surface-, ground- and drinking water, with the highest concentrations 
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shown for biodegradation products of iomeprol (up to 1,450 ± 110 ng/L in wastewater-
influenced groundwater and 289 ± 41 ng/L in drinking water) (Kormos et al., 2009). Steger-
Hartmann et al., 2002 reported the transformation of iopromide into one major metabolite, 
postulating it being 5-amino-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-methylisophthalamide.  
In most cases, identified metabolites are the result of laboratory studies, and their occurrence 
under real environmental conditions and in environmental concentrations still has to be 
investigated (Pérez and Barceló, 2007). 
Table 2-7: Physico-chemical properties of iodinated x-ray contrast media. Ws: water solubility (if not 
otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-
m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or 
databases consulted. 
Substance Diatrizoic acid  
(Diatrizoate; Amidotrizoic acid) 
Iomeprol 
Abbreviation DTZ IOP 
Chemical 
structure  
 
 
 
 
 
 
CAS-No. 117-96-4 78649-41-9 
MW  613.91  777.09 
Log KOW -1.05a --- 
pKa   
HLC 2.81x10-18b 
 
---- 
Ws  8.89b 
 
---- 
Substance Iopamidol Iopromide 
Abbreviation IPM IMI 
Chemical 
structure  
 
 
 
 
 
 
CAS-No. 60166-93-0 73334-07-3 
MW 777.08 791.11 
Log KOW -2.42a,c -2.05a,c 
pKa --- --- 
HLC 1.14x10-25b 1.00x10-28b 
Ws  1.40x105c 23.8c 
a Sangster, 2012; b SRC Research Corporation; c NLM, 2005  
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Table 2-8: Chemical structures of transformation products of iopromide (Schulz et al., 2008).  
Substance Iopromide TP 805 A Iopromide TP 805 B 
Abbreviation IMI-TP 805 A  IMI-TP 805 B 
Chemical 
structure  
 
 
 
 
  
   
Substance Iopromide TP 819 Iopromide TP 729 A 
Abbreviation IMI-TP 819 IMI-TP 729 A 
Chemical 
structure  
 
 
 
 
  
   
Substance Iopromide TP 817 A Iopromide TP 787 A 
Abbreviation IMI-TP 817 A IMI-TP 787 A 
Chemical 
structure  
 
 
 
 
  
   
Substance Iopromide TP 731 A Iopromide TP 731 B 
Abbreviation IMI-TP 731 A IMI-TP 731 B 
Chemical 
structure  
 
 
 
 
  
   
Substance Iopromide TP 759 Iopromide TP 701 B 
Abbreviation IMI-TP 759 IMI-TP 701 B 
Chemical 
structure  
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Table 2-8: continued. 
Substance Iopromide TP 701 A Iopromide TP 643 
Abbreviation IMI-TP 701 A IMI-TP 643 
Chemical 
structure  
 
 
 
 
  
   
 
 
TOXICITY. Besides the still fundamental lack of knowledge about the environmental fate of ICM 
and their potential adverse health impact, ICM came into focus when studies showed that they 
contribute profoundly to AOX (adsorbable organic halogen) concentrations in hospital effluents 
and the municipal sewage system (Putschew and Jekel, 2006). In hospital effluents, up to 90% of 
the AOX concentration originate from ICM (Pérez and Barceló, 2007).  
As micropollutants, ICM are of concern mainly because of their high polarity, resulting in long 
range transport and high mobility combined with extreme persistence and high consumption 
quantities, which makes them the “worst case” contaminants in terms of their environmental 
exposure (Ternes and Hirsch, 2000). Toxicity data of ICM are scarce. Short-term toxicity tests 
with bacteria (Vibrio fischeri, Pseudomonas putida), algae (Scenedesmus subspicatus), crustaceans 
(Daphnia magna), and fish (Danio rerio, Leuciscus idus) have shown no toxic effects at maximum 
concentrations of ICM of 10 g/L (Steger-Hartmann et al., 1999; see also Table 2-9). In a chronic 
toxicity test (> 20 days) with Daphnia magna, no effect was observed at concentrations of 1 g/L 
(Steger-Hartmann et al., 1999). Haiß and Kümmerer, 2006 tested the effects of both diatrizoic 
acid and its transformation products on microorganisms in sewage sludge, finding no adverse 
effects. So seemingly, ICM are no immediate threat when released into the environment. 
Nonetheless, their high environmental concentrations, persistent nature and the lack of 
information about long-term sublethal effects indicate the need for further investigations 
(Ternes and Hirsch, 2000). 
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Table 2-9: Chemical toxicity data of ICM for aquatic life (EPA, 2012b). LC50: median lethal concentration; t: 
exposure duration; LOEC: lowest observable effect concentration; species given in index numbers: 1: 
Leuciscus idus (Ide, Silver Or Golden Orfe); 2: Danio rerio (Zebra Danio). 
Substance  
(CAS-No.) 
LC50 LOEC 
 
lowest LC50 
(µg/L) for the 
most sensitive 
indicator species 
(indicator 
species) 
t 
no. of aquatic 
studies 
identified 
lowest LOEC 
(µg/L) 
for the most 
sensitive indicator 
species (indicator 
species) 
t 
no. of aquatic 
studies 
identified 
Diatrizoic acid 
(117-96-4) 
--- --- 0 ---- ---- 0 
Iomeprol  
(78649-41-9) 
--- --- 0 --- --- 0 
Iopamidol 
(60166-93-09) 
--- --- 0 --- --- 0 
Iopromide 
(73334-07-3) 
> 10,000,000 
(1;2) 
96 h; 
48 h 
2 --- --- 0 
  
 
2.1.1.3  LIPID REGULATORS 
PROPERTIES AND USE. Lipid regulators (also called hypolipidemic agents, antihyperlipidemic 
agents or lipid-lowering drugs) are designed to counteract high levels of lipidproteins in blood 
(hyperlipidaemia) which, when untreated, increase the risk of cardiovascular diseases (Schwabe 
and Paffrath, 2007). Different groups of lipid regulators (e.g. fibrates, statins, niacin) act in 
different ways on the blood-lipid system. In Germany in 2005, lipid regulators were the second 
best-selling group of prescription pharmaceuticals (Schwabe and Paffrath, 2007). Worldwide, 
cholesterol and triglyceride reducers are counted amongst the ten largest therapy classes and 
show an increase in sales of over 10% year-on-year (IMS, 2005).  
 
BEZAFIBRATE. Bezafibrate is a fibrate drug used to lower triglycerides and, to a lesser extent, 
cholesterol (Table 2-10). It was first marketed in 1971 by Boehringer Mannheim. As with other 
clofibrin acid derivates (clofibrate, fenofibrate), its use in Germany is decreasing due to new 
studies casting scientific doubt on their effectiveness and the introduction in recent years of new 
classes of lipid regulating drugs (Schwabe and Paffrath, 2007). In a long-term study with a 
duration of 6.2 years and with more than 3,000 participants, bezafibrate failed to prevent effects 
on cardinal end points such as heart attack and sudden cardiac death (BIP, 2000). 
 
EXCRETION AND ENVIRONMENTAL OCCURRENCE. Bezafibrate is readily degraded in WWTPs with 
reported removal rates of 80–95% (Ternes, 1998; Clara et al., 2005; Radjenović et al., 2009b). 
The elimination depends on the temperature and solid retention times of the operating WWTP 
(Clara et al., 2005). Temperature dependence could also explain the more effective removal of 
bezafibrate observed in summer samples compared to samples taken in winter (Castiglioni et al., 
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2005; Sacher et al., 2008). Subsequently, winter accumulation was observed in a Swedish river 
due to reduced natural transformation processes (Daneshvar et al., 2010). The same study found 
the mean mass flow of bezafibrate being highest in spring. During investigations of two WWTPs 
in Spain, Pedrouzo et al., 2011 detected no bezafibrate in any influent samples taken over 
several months but frequently found the drug in effluent samples in concentrations of up to 
0.5 µg/L. This can be explained by the cleavage of metabolites during wastewater treatment 
(Lindqvist et al., 2005). Other studies reported finding bezafibrate in both influent and effluent 
of WWTPs. Quintana and Reemtsma, 2004 reported bezafibrate with concentrations of 
2,775 ng/L and 565 ng/L in raw and treated municipal wastewater respectively, while in lake 
Tegel in Berlin (which receives treated wastewater and is also used for the production of 
drinking water through artificial groundwater recharge) 847 ng/L of the drug was detected. In a 
study including 24 drug residues, Ternes, 1998 found the highest concentrations of bezafibrate 
in wastewater-receiving river water.  
 
TOXICITY. In an ecotoxicological risk assessment considering human metabolism, Lienert et al., 
2007 found bezafibrate to pose a potential ecotoxicological risk. While studies described LC50 
values (96 h) of 70,710 µg/L for the indicator species Hydra attenuata (Hydra), LOEC was found 
to be 3.61 µg/L (24 h, indicator species used: Mytilus galloprovincialis (Mediterranean Mussel)) 
(EPA, 2012b). 
Table 2-10: Physico-chemical properties of the lipid regulator bezafibrate. Ws: water solubility (if not 
otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-
m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or 
databases consulted. 
Substance Bezafibrate 
Abbreviation BZF 
Chemical 
structure  
 
CAS-No. 41859-67-0 
MW 361.82 
log KOW 4.25a; 4.250b 
pKa --- 
HLC  --- 
Ws 0.355c 
a Gros et al., 2006a; b NLM, 2005; c SRC Research Corporation  
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2.1.1.4  NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 
USE AND PROPERTIES. Analgesics and antirheumatics are the leading pharmaceutical group in 
terms of their dispensed prescriptions in Germany (Schwabe and Paffrath, 2007) and their use 
in many other countries (Alder et al., 2006). Among them, non-steroidal anti-inflammatory 
drugs (NSAIDs) are a widely used group, resulting in consumption rates of over 250 t per year 
for ibuprofen alone (data for Germany, see Table 2-2; other sources give sale rates of more than 
344 t for Germany in 2001 (BLAC, 2003).  
The term “non-steroidal” distinguishes them from steroids (especially glucocorticoids) which 
have similar anti-inflammatory properties (Gentili, 2007). One distinctive characteristic of 
NSAIDs, which singles them out among analgesics, is their non-narcotic nature which is based on 
their pharmacologic mechanism: they act as non-selective or selective inhibitors of the 
isoenzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) which control the 
formation of prostaglandins and thromboxane. As locally acting messenger molecules, 
prostaglandins mediate inflammation by acting on the thermoregulatory centre of hypothalamus 
to produce fever (Schwabe and Paffrath, 2007).  
Chemically, all NSAIDs are acidic compounds (see pKa in Table 2-11) since the acidic group is 
essential for therapeutic effect.  
 
NON-SELECTIVE COX INHIBITORS. Diclofenac, ibuprofen and naproxen are non-selective COX 
inhibitors. They are mainly used in human medicine to treat pain (e.g. in post-operative 
treatment and treatment of cancer pain), fever, inflammatory disorders like rheumatoid arthritis 
and dysmenorrhea (BfArM, 2007a; BfArM, 2007b; U.S. National Library of Medicine, 2010; U.S. 
National Library of Medicine, 2012). The propionates (“profens”) ibuprofen and naproxen were 
patented in 1961 (U.S. National Library of Medicine, 2010) and 1968 (Thieme Chemistry, 2009), 
respectively, and the phenylacetic acid diclofenac was patented in 1966 (Thieme Chemistry, 
2009). Ibuprofen in particular is widely used today (see above and Table 2-2) and is part of the 
WHO’s List of Essential Medicines, which lists core drugs for a basic healthcare system (WHO, 
2011c). Only naproxen is also used to considerable extent in veterinary medicine (Löscher et al., 
1994). 
 
METABOLISM. After administration, NSAIDs are excreted as a mixture of parent drug and 
metabolites. Diclofenac is completely resorbed in the stomach before rapidly being hydroxylated 
and conjugated, resulting in a half-life of approximately 2 h. Over 99% of it is excreted in the 
form of inactive metabolites, with about 30% being excreted with faeces and 70% being 
excreted renally (BfArM, 2007a).  
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Ibuprofen is renally metabolised with a half-life of about 2 h (IIF, 2002). Weigel et al., 2004 
reported 15% of the substance being excreted in original form of the parent drug while nearly 
70% is excreted in metabolic form (26% as hydroxyibuprofen, 43% as carboxyibuprofen).  
After application, naproxen has a half-life of 16–36 h. Vree et al., 1993 reported it to be 
metabolised to naproxen acyl glucuronide (51%) and its isomerised conjugate isoglucuronide 
(6.5%), to O-desmethylnaproxen acyl glucuronide (14%) and its isoglucuronide (5.5%). The 
same authors found practically no excretion of the unchanged parent compound or of O-
desmethylnaproxen (< 1%). 
ENVIRONMENTAL FATE. Corresponding to their high consumption rates, their hydrophilicity and 
stability, NSAIDs are among the most frequently detected pharmaceuticals in wastewater and 
the environment (Gentili, 2007). Despite relatively high removal rates in conventional 
wastewater treatment with e.g. 50%, 83%, 85% (Radjenović et al., 2007) and 22%, 99%, 72% 
(Radjenović et al., 2009b) of diclofenac, ibuprofen and naproxen respectively, they are found 
globally in both the influent and effluent of WWTPs (Öllers et al., 2001; Carballa et al., 2004; 
Clara et al., 2004a; Botitsi et al., 2007; Santos et al., 2007; Smook et al., 2008). Reported 
concentrations vary between countries depending on application patterns and consumption 
rates, but reach up to the µg/l range, with higher influent amounts for ibuprofen than for 
diclofenac and naproxen. For example, Pedrouzo et al., 2007 reported the detection of all three 
NSAIDs in two Spanish WWTPs over several months, with ibuprofen frequently detected in 
influents (max. 5.99 µg/L) and effluents (0.69 µg/L), while naproxen was less regularly found 
(concentrations of up to 8.62 µg/L (influent) and 0.42 µg/L (effluent)). Diclofenac was 
repeatedly detected in influent and effluent in concentrations of up to 0.5 µg/L.  
Possibly due to more efficient removal during wastewater treatment in the warmer seasons, 
Sacher et al., 2008 described seasonal variations of concentrations of diclofenac and ibuprofen in 
the river Rhine with considerably lower concentrations in summer, while Daneshvar et al., 2010 
observed elevated amounts of NSAIDs (among other pharmaceuticals) in WWTP effluents and 
receiving waters in winter. Busetti et al., 2009 detected diclofenac and ibuprofen in secondary 
wastewater in Australia. Gómez et al., 2006 reported amounts of 1.5–151 µg/L for ibuprofen and 
0.06–1.9 µg/L for diclofenac in hospital effluent: Jose Gomez et al., 2007 found 0.30–5.48 µg/L of 
naproxen in hospital wastewater. 
Kosma et al., 2014 found NSAIDs in sludge samples from three WWTPs in Spain with 
concentrations of up to 74.9 ng/g, 117 ng/g and 5.9 ng/g of diclofenac, ibuprofen and naproxen 
respectively. Yu et al., 2009 investigated the removal of NSAIDs in sewage sludge, finding it 
depended on operational parameters of the wastewater treatment system as well as on the 
initial concentration of the substances. Lapen et al., 2008 investigated the behaviour of naproxen 
and ibuprofen in tile drainage and found them not readily washed off. 
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In two different studies, Radjenović found the elimination of diclofenac, ibuprofen and naproxen 
from the aqueous phase in conventional wastewater treatment to be 50.1%, 82.5% 81.5% 
(Radjenović et al., 2007), and 21.8%, 99.1%, 71.8% (Radjenović et al., 2009b) respectively. 
Ashton et al., 2004 investigated the fate of diclofenac and ibuprofen through wastewater 
treatment and in the receiving surface waters for 11 WWTPs in the UK, finding wide differences 
in efficiency between various WWTPs. Gros et al., 2006a detected all three NSAIDs in influents 
and effluents in Croatian urban WWTPs and in the Ebro river.  
Moldovan et al., 2009 investigated the influence of technological upgrades in WWTPs on the 
amount of ibuprofen (among others) in a river in Romania. Accordingly, NSAIDs are frequently 
detected in rivers and streams (Öllers et al., 2001; Antonić and Heath, 2007). In a mass balance 
approach based on a long-term study of the river Rhine, Sacher et al., 2008 calculated that up to 
10% of the prescribed volume of diclofenac end up in the river.  
Bataineh et al., 2006 studied the degradation of NSAIDs during sand bank filtration. Togola and 
Budzinski, 2008 detected all three NSAIDs not only in samples of WWTP effluent and surface 
water but in drinking water in France as well. 
Comeau et al., 2008 detected NSAIDs in wastewater-receiving freshwaters in Canada but not in 
the connected marine waters or watersheds.  
 
ECOTOXICITY. The environmental fate of NSAIDs has not yet been investigated in depth, but 
Isidori et al., 2005a reported photodegradation of naproxen. With phototransformation of the 
drug already reported in laboratory studies (Schmitt-Jansen et al., 2007), Kreuzinger et al., 2004 
suggested the same as a possible elimination form of diclofenac in pretreated wastewater. In the 
case of naproxen, a higher ecotoxicological effect for photoproducts was found compared to the 
parent drug regarding both acute and chronic toxicity, while no genotoxic or mutagenic effects 
were found in bioassays performed on algae, rotifers and microcrustaceans (Isidori et al., 
2005a). In biotests with the cladoceran Daphnia magna, the chlorophyte Desmodesmus 
subspicatus and the macrophyte Lemna minor, the aquatic ecotoxicity of diclofenac and 
ibuprofen was reported to be moderate (Cleuvers, 2003; see also Table 2-12). Nonetheless, 
investigating the phytotoxicity of diclofenac exposed to natural sunlight, Schmitt-Jansen et al., 
2007 revealed fast degradation of the drug with a half-life of 3.3–6.4 h during the first three days 
of exposure. This was accompanied by increasing toxicity to the unicellular chlorophyte 
Scenedesmus vacuolatus after 3.5 h of sunlight exposure and sixfold enhanced toxicity after 53 h 
caused by several phototransformation products.  
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Table 2-11: Physico-chemical properties of non-steroidal anti-inflammatory drugs. Ws: water solubility (if 
not otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-
m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or 
databases consulted. 
Substance Diclofenac Ibuprofen 
Abbreviation DCF IBP 
Chemical 
structure  
 
 
CAS-No. 15307-86-5 15687-27-1 
MW 296.15 g/mol 206.29 g/mol 
log KOW 4.51a; 4.40b; 4.51c 3.97a,c; 3.50b 
pKa 4.14a; 4.15b 4.91a,c; 4.91b 
HLC 4.73x10-12c 1.50x10-07c  
Ws  2.37c 21c 
   
Substance Naproxen  
Abbreviation NPX  
Chemical 
structure  
 
 
CAS-No. 22204-53-1  
MW  230.259   
log KOW 3.18a; 3.18b; 3.18c  
pKa 4.15a; 4.15b  
HLC 3.39x10-10c  
Ws  15.9c  
a Gros et al., 2006a; b Sangster, 2012; c NLM, 2005 
 
Table 2-12: Chemical toxicity data of NSAIDs for aquatic life (EPA, 2012b). LC50: median lethal 
concentration; t: exposure duration; LOEC: lowest observable effect concentration; species given in index 
numbers: 1: Oryzias latipes (Japanese Medaka); 2: Planorbis carinatus (Keeled Ramshorn Snail); 3: Hydra 
attenuata (Hydra); 4: Daphnia magna (Water Flea). 
Substance  
(CAS-No.) 
LC50 LOEC 
 
lowest LC50 
[µg/L] for the 
most sensitive 
indicator species 
(indicator 
species) 
t  
no. of 
aquatic 
studies 
identified 
lowest LOEC 
[µg/L] 
for the most 
sensitive indicator 
species (idicator 
species) 
t 
no. of 
aquatic 
studies 
identified 
Diclofenac 
(15307-86-5) 
8,000 (1)* 96 h 1 0.36 (4) ~ 6 days 45 
Ibuprofen  
(15687-27-1) 
32 (4) 24-96h 9 1 (1) 42 days 13 
Naproxen  
(22204-53-1) 
22,360 (3) 96 h 2 1,000 (3) 96 h 5 
* LC10; no LC50 values given in searched database   
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2.1.1.5 PSYCHOACTIVE DRUGS  
In Germany, psychoactive drugs were the fourth most prescribed pharmaceutical group in 2005 
(Schwabe and Paffrath, 2007); they are often used in quantities of several tonnes per year (Table 
2-2). Oxycodone (under its brand name Oxygesic) was among the 30 top-selling pharmaceuticals 
in Germany in 2005 (Schwabe and Paffrath, 2007). 
 
OPIOIDS. Today, strong opioids are mainly used in palliative care, especially to treat cancer pain 
(Schwabe and Paffrath, 2007). To relieve pain, opioids act directly on the central nervous system 
(and on the peripheral nervous system and the gastrointestinal tract) by binding to opioid 
receptors. Some opioids also act as powerful cough suppressants (Schwabe and Paffrath, 2007). 
Natural plant alkaloids like morphine and codeine count among opioids as well as the semi-
synthetic opioid analgesics dihydrocodeine and oxycodone (Table 2-13).  
 
MORPHINE. In clinical medicine, morphine is the benchmark of analgesics applied to relieve 
agonising pain, and it is the gold standard for cancer pain treatment in the World Health 
Organization’s three-level programme (WHO, 1996). Morphine metabolism mainly occurs in the 
liver. Approximately 87% of the administered dose is excreted via urine within 72 h after 
treatment. It is metabolised by phase-II-metabolism into two main products: about 60% is 
biotransformed into morphine-3-glucuronide, and 6–10% into morphine-6-glucuronide, the 
latter being half as potent as the parent drug in humans while the former has no analgesic effect 
(Kilpatrick and Smith, 2005; van Dorp et al., 2006).  
 
CODEINE. Codeine is the prototype of weak to midrange opioids (e.g. dihydrocodeine: see below). 
After treatment, 80% of it is metabolised to codeine-6-glucuronide by conjugation with 
glucuronic acid. Codeine-6-glucuronide is mostly responsible for the analgesic effect of codeine. 
Additionally, 15% of the parent drug is biotransformed to norcodeine while 5% is metabolised 
to morphine, which thereafter undergoes morphine metabolism (see above) (Vree et al., 2000).  
 
SEMI-SYNTHETIC OPIOIDS. Dihydrocodeine and oxycodone are semi-synthetic opioids with half-
lives of 4-6 h. Like the natural opioids, they are metabolised renally and excreted via urine. For 
oxycodone, the percentage of the unchanged drug excreted is given as 19% (Lalovic et al., 2006). 
Dihydrocodeine is counted among the less potent opioids and can, among other applications, be 
used as an alternative to codeine (Schwabe and Paffrath, 2007). Oxycodone (half-life 4–6 h) is 
used similar to morphine, i.e. used in treatment of severe and agonising pain, but it is more than 
twice as expensive as morphine generics (Schwabe and Paffrath, 2007).  
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Table 2-13: Physico-chemical properties of opioids (for details refer to text). Ws: water solubility (if not 
otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-
m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or 
databases consulted. 
Substance Codeine  Dihydrocodeine, also DHC, Drocode, Paracodeine, 
Parzone 
Abbreviation CDN DHC 
Chemical 
structure  
 
 
CAS-No. 76-57-3 125-28-0 
MW 299.36 301.38 
Log KOW 1.14a 1.490c 
pKa 8.1a --- 
HLC 7.58x10-14b 8.61x10-14b 
Ws 9,000 (20 °C)b  6,710b  
   
Substance Morphine Oxycodone 
Abbreviation MPN  OCN 
Chemical 
structure  
  
CAS-No. 57-27-2 76-42-6 
MW 285.34 315.364 
Log KOW 0.89c 0.660b 
pKa 8.21c --- 
HLC 1.33x10-16b 2.33x10-16b 
Ws 149c 4,160b  
a Sangster, 2012; b SRC Research Corporation; c NLM, 2005 
 
 
SYNTHETIC OPIOIDS: METHADONE. This is a synthetic opioid mostly known for its use in opiate 
replacement therapy (Methadone Maintenance Treatment, MMT). Furthermore, it is used in the 
treatment of severe chronic pain. It is lipophilic and very slowly metabolised (half-life 15–60 h, 
although some studies give half-lives up to 190 h), resulting in extended effect times compared 
to morphine-based drugs (Eap et al., 1999; Eap et al., 2002; Manfredonia, 2005; see also Table 2-
14).  
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Table 2-14: Physico-chemical properties of methadone. Ws: water solubility (if not otherwise indicated at 
25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-m3/mole]; Ws = water solubility 
[mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or databases consulted. 
Substance Methadone 
Abbreviation MTD 
Chemical structure  
 
CAS-No. 76-99-3 
MW 309.45 
Log KOW 3.93a 
pKa 8.94a 
HLC 4.97x10-10a 
Ws 48.5a 
a NLM, 2005  
 
 
BENZODIAZEPINES. Benzodiazepines consist of a core chemical structure of a benzene ring fused 
with a diazepine ring (Table 2-15). They increase the effect of the neurotransmitter 
gammaaminobutyric acid (GABA) and are used as tranquilisers for their sedative, sleep-inducing 
(hypnotic), anxiolytic (anti-anxiety), amnesic, anticonvulsant and muscle relaxant actions to 
treat e.g. insomnia, anxiety, agitation, muscle spasms and the effects of alcohol withdrawal. 
Additionally, they are used in premedication for medical or dental procedures (Olkkola and 
Ahonen, 2008).  
The first benzodiazepine, chlordiazepoxide, was marketed in 1960. Three years later, diazepam 
(brand name valium) followed. It became rapidly the standard choice of benzodiazepines and is 
to date still one of the leading drugs used in the treatment of anxiety. The WHO considers it a 
core medicine for minimum medical needs of a basic health system (WHO, 2005a). It has a long 
half-life (24–48 h). Therefore, and because of the even longer half-life of its active metabolite 
nordiazepam (50–80 h, Schwabe and Paffrath, 2007), an accumulation in the body is achieved. 
This results in long-lasting action which reduces the possibility of panic attacks should the drug 
intake be interrupted. On the other hand, the downsides of such long-acting benzodiazepines are 
increasing sedation and inhibition of psychomotor abilities, and the development of addiction. A 
second metabolite of diazepam is oxazepam, which results from the hydroxylation of 
desmethyldiazepam and is rapidly renally excreted in form of glucuronides. Most of the long-
acting benzodiazepines undergo the described metabolism, being biotransformed to 
nordiazepam and oxazepam (Schwabe and Paffrath, 2007).  
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Besides being an active metabolite of diazepam, oxazepam is used directly as a drug itself, 
entering the market as the third benzodiazepine in 1963. Since its biotransformation takes place 
without a further active metabolite being produced (direct glucuronidation in a phase-II-
reaction, see Chapter 2.1), and because of its relatively short half-life (7–15 h) it shows 
practically no cumulative effect and is more easily controllable. 
With a half-life of 8–20 h, temazepam is another intermediate-acting benzodiazepine which is 
often used for the treatment of insomnia. 
Table 2-15: Physico-chemical properties of benzodiazepines. Ws: water solubility (if not otherwise 
indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-m3/mole]; Ws = 
water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or databases 
consulted. 
Substance Diazepam Nordiazepam also known as nordazepam, 
desoxydemoxepam and desmethyldiazepam 
Abbreviation DZP NZP 
Chemical 
structure  
 
 
CAS-No. 439-14-5 1088-11-5 
MW 284.7 270.71 
Log KOW 2.82a 2.93a 
pKa 3.4a --- 
HLC 3.64x10-9a 1.78x10-10a 
Ws  50a 57a 
   
Substance Oxazepam Temazepam 
Abbreviation OZP TZP 
Chemical 
structure  
 
 
CAS-No. 604-75-1 846-50-4 
MW 286.71 300.70 
Log KOW 2.24a 2.19a 
pKa --- --- 
HLC 5.53x10-10a 1.13x10-8a 
Ws  179a 164a 
a NLM, 2005  
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TRICYCLIC ANTIDEPRESSANTS: DOXEPIN. Doxepin is a tricyclic antidepressant (Table 2-16) which is 
used to treat depression, anxiety disorders and insomnia, and is also used in dermatological 
cream-based preparations. It inhibits the re-uptake of serotonin and norepinephrine (Schwabe 
and Paffrath, 2007). Doxepin has a half-life of 17 h, its main metabolite desmethyldoxepin one of 
51 h, and it is excreted via urine (Thieme Chemistry, 2009).  
 
Table 2-16: Physico-chemical properties of doxepin. Ws: water solubility (if not otherwise indicated at 
25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-m3/mole]; Ws = water solubility 
[mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or databases consulted 
Substance Doxepin (cis-, trans-)  
Abbreviation DXP  
Chemical 
structure  
  
CAS-No. 1668-19-5  
MW 279.38  
Log KOW 4.29a  
pKa ---  
HLC 2.77x10-9b  
Ws 31.6a  
a NLM, 2005; b SRC Research Corporation 
 
 
ANTICONVULSANT DIBENZAZEPINE: CARBAMAZEPINE. Carbamazepine is an anticonvulsant 
dibenzazepine which is extensively used in the treatment of epilepsy, bipolar disorder and 
trigeminal neuralgia (Table 2-17). Its main application is as an antiepileptic drug. Although 
being one of the oldest antiepileptics used (it was first marketed in 1962), it is the first choice 
drug for focal seizures in several countries (SIGN, 2003; NICE, 2004; Arzneimittelkommision der 
deutschen Ärzteschaft, 2006). Other applications are attention-deficit hyperactivity disorder 
(ADHD), complex regional pain syndrome, neuromyotonia, borderline personality disorder, 
post-traumatic stress disorder, schizophrenia and others. Carbamazepine is structurally similar 
to tricyclic antidepressants and, like these, has mood-stabilising properties. Further, it is used 
for the treatment of alcohol withdrawal (Miao and Metcalfe, 2003).  
Daily doses of Carbamazepine range between 400 – 1200 mg/d (BfArM, 2003). The drug 
undergoes a complex hepatic metabolism via oxidation, hydration and conjunction with 
glucuronide resulting in a range of at least seven metabolites formed in the human organism 
(BfArM, 2003). Of these, some are pharmaceutically active, but the most abundant one, 10,11-
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Dihydro-10,11-dihydroxycarbamazepine is inactive (Miao and Metcalfe, 2003; see also Table 2-
17). The half-life of Carbamazepine is 18 – 65 h, with an average of 36 h. During long-term 
therapy, which is the main form of treatment due to the fact that it is used lifelong in its primary 
indications, the half-life is shortened by about 50% (10–20 h). According to BfArM, 2003, after 
oral treatment approximately 72% of the drug is excreted via urine (of which 2–3% is 
unmetabolised) and 28% via faeces (partly unmetabolised). Alder et al., 2006 estimates the 
overall excretion of the unmetabolised parent drug to be less than 3%. Bernus et al., 1995 
reported the percentage of unmetabolised carbamazepine in the urine of pregnant women as 
1%, while 10,11-Dihydro-10,11-dihydroxycarbamazepine accounts for 35%.  
 
ANTICONVULSANT BARBITURATE: PRIMIDONE. Primidone is an anticonvulsant of the barbiturate 
class (Table 2-17), which laid the foundations of epileptic therapy almost 100 years ago. It is 
used to treat a wide range of seizures, but is seldom administered in the treatment of psychiatric 
problems. Besides its application in human medicine, primidone is also used in veterinary 
medicine e.g. to prevent aggressive behaviour and cannibalism in young female pigs or to treat 
nervous disorders in various animals (e.g. dogs) (Thieme Chemistry, 2009; 5m Publishing). 
According to Schwabe and Paffrath, 2007 it is only recommended as the third choice treatment 
since it shows sedative effects that interfere with cognitive abilities even at plasma levels at 
which no other intolerances are displayed. Its still increasing use is explained by its broad 
spectrum of efficacy, easy application and low costs (Schwabe and Paffrath, 2007).  
Primidone acts mostly through its active metabolite, phenobarbital. The parent drug is 
metabolised renally; its half-life is 5–18 h, while Phenobarbital has a half-life of 75–120 h (Ochoa 
and Riche, 2012). 
 
ENVIRONMENTAL FATE. With the exception of Carbamazepine, the fate during wastewater 
treatment and the environmental behaviour of most psycho-active drugs has not yet been 
thoroughly investigated despite their extensive use. 
Carbamazepine has been documented as being ubiquitously present in influents and effluents of 
WWTPs in Europe, America, and Asia at concentrations of up to the lower µg/l range, finding 
only marginal removal rates for the parent substance during conventional wastewater treatment 
(Öllers et al., 2001; Clara et al., 2004b; Kreuzinger et al., 2004; Zuehlke et al., 2004; Gros et al., 
2006a; Vieno et al., 2006; Santos et al., 2007; Vieno et al., 2007; Zhang and Zhou, 2007; 
Radjenović et al., 2009b; Ying et al., 2009; Pedrouzo et al., 2011; Ryu et al., 2011). Miao et al., 
2005 additionally investigated the occurrence of carbamazepine metabolites in WWTP water, 
revealing that 10,11-Dihydro-10,11-dihydroxycarbamazepine exhibit up to three times higher 
concentrations than carbamazepine itself. Similar ratios of drug and metabolites were found by 
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Leclercq et al., 2009 when investigating the fate of carbamazepine and several of its metabolites 
in three different types of WWTP (CAS, trickling filter, and stabilisation ponds). Moreover, no 
removal of either parent drug or metabolites was found for CAS treatment, while the other 
treatment systems displayed varying removal rates, indicating that increased biodegradation or 
sorption as well as enhanced cleavage and re-transformation processes take place in these 
systems. 
Several studies failed to detect diazepam in influents and effluents of WWTPs in Germany and 
Spain (Ternes et al., 2001; Carballa et al., 2004; Hummel et al., 2006; Wick et al., 2009) while 
other benzodiazepines as well as several opioids and barbiturates were frequently detected in 
influents and effluents of German WWTPs (except oxycodone which was present only in 
influents) in concentrations of up to the low µg/L range (Hummel et al., 2006; Wick et al., 2009). 
These studies reveal that while more than 80% of the natural opium alkaloids morphine and 
codeine are removed during wastewater treatment, several psycho-active drugs such as 
primidone and oxazepam are not significantly removed.  
Gómez et al., 2006 detected carbamazepine and codeine in hospital wastewater in Spain in 
concentrations of 0.04 and 0.9 µg/L respectively.  
Wick et al., 2009 found sorption into activated sludge to be a negligible removal pathway, with 
removal rates of less than 3% for several psycho-active and lipid-regulating drugs, thus 
postulating that the removal of the beta blockers and psycho-active drugs examined could be 
described solely as biological transformation. Still, because of its log KOW of 2.47 (Table 2-17), 
carbamazepine shows a moderate sorption potential and subsequently was found in several 
studies in sewage sludge (Miao et al., 2005; Barron et al., 2008) and in tile drainage (Lapen et al., 
2008).  
Carbamazepine was frequently detected in surface water in several countries (Tixier et al., 2003; 
Zuehlke et al., 2004; Gros et al., 2006a; Vieno et al., 2006; Benotti and Brownawell, 2007; Zhang 
and Zhou, 2007; Conley et al., 2008; ter Laak et al., 2010). In a widespread study in Germany, 
carbamazepine was found to be among the most frequently detected pharmaceuticals in surface 
waters (BLAC, 2003) and was also detected in groundwater, with concentrations of up to 
0.9 µg/L. Loos et al., 2007 found CBZ in lake water and tap water in Italy. 
Hummel et al., 2006 reported the presence of 15 psycho-active drugs in surface waters in 
Germany in the low ng/L range. In the same study, carbamazepine, 10,11-dihydro-10,11-
dihydroxycarbamazepine and primidone were detected in tap water at concentrations of up to 
20 ng/L, 13 ng/L and 16 ng/L respectively. Valcárcel et al., 2011 found several psycho-active 
drugs in surface and tap water in the Madrid region in Spain.  
In a laboratory study using river sediment, Löffler et al., 2005 reported elevated levels of 
sorption of diazepam, oxazepam and carbamazepine into the sediment. 
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Table 2-17: Physico-chemical properties of anticonvulsant drugs and metabolites (for details refer to text). 
Ws: water solubility (if not otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's 
Law Constant [atm-m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not 
listed in the literature or databases consulted. 
Substance Carbamazepine 10,11-Dihydrocarbamazepine 
Abbreviation CBZ DH-CBZ 
Chemical 
structure  
 
 
CAS-No. 298-46-4 3564-73-6 
MW 236.27 238.29 
Log KOW 2.47a; 2.30b 2.46c 
pKa 7a --- 
HLC 1.08x10-10c 5.57x10-10c 
Ws 17.7c 16.8c 
   
Substance 10,11-Dihydro-10,11-
dihydroxycarbamazepine 
Primidone 
Abbreviation DHH PMD 
Chemical 
structure  
 
 
CAS-No. 35079-97-1  125-33-7 
MW 270.288 218.25 
Log KOW --- 0.91b,d 
pKa --- --- 
HLC --- 1.94x10-10c 
Ws --- 500 (22 °C)c 
a Gros et al., 2006a; b Sangster, 2012; c SRC Research Corporation; d NLM, 2005 
 
DEGRADATION. Data regarding the degradation of psycho-active drugs in the environment are 
scarce. Doll and Frimmel, 2003 reported the degradation of carbamazepine through simulated 
and natural sunlight into several unidentified degradation products. 
 
TOXICITY. In general, the environmental impact and possible adverse effects on non-target 
organisms of psycho-active drugs is unknown (see Table 2-18), which makes appropriate 
environmental risk assessments unfeasible. Based on its log KOW value (Table 2-17), BLAC, 2003 
postulates a moderate potential of accumulation in aquatic organisms for carbamazepine. The 
drug was shown to have a chronic toxic effect on crustaceae (Cerodaphnia dubia: NOEC (7 d): 
0,025 mg/L) and to a lesser extent on fish (Danio rerio: NOEC (10 d): 25 mg/L) (Ferrari et al., 
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2003). Oetken et al., 2005 found a concentration-dependent decrease in abundance of the non-
biting midge Chironomus riparius when exposed to carbamazepine-spiked sediment (lowest 
observed effect concentration (LOEC) 140 mg/kg). Gagné et al., 2006 established adverse effects 
of carbamazepine and morphine on the immune system of fresh water mussels (Elliptio 
complanata). Additionally, there are indications that carbamazepine may be toxic to 
reproduction in mammals (BLAC, 2003). Furthermore, its accumulative interaction with other 
pharmaceuticals is to be considered (BLAC, 2003).  
 
Table 2-18: Chemical toxicity data of psycho-active drugs for aquatic life (EPA, 2012b). LC50: median lethal 
concentration; t: exposure duration; LOEC: lowest observable effect concentration; species given in index 
numbers: 1: Chironomus tentans (Midge); 2: Hydra attenuata (Hydra); 3: Artemia parthenogenetica (Brine 
Shrimp); 4: Mytilus galloprovincialis (Mediterranean Mussel). 
Substance  
(CAS-No.) 
LC50 LOEC 
 
lowest LC50 
(µg/L) for the 
most sensitive 
indicator species 
(indicator 
species) 
t 
no. of 
aquatic 
studies 
identified 
lowest LOEC 
(µg/L) 
for the most 
sensitive indicator 
species (indicator 
species) 
t 
no. of 
aquatic 
studies 
identified 
Carbamazepine 
(298-46-4) 
9,900 (1); 29,400 
(2) 
240 h; 
96 h 
5 0.1 (4) 168 h 40 
10,11-Dihydro- 
carbamazepine 
(3564-73-6) 
--- --- 0 --- --- 0 
10,11-Dihydro-
10,11-dihydroxy-
carbamazepine 
(35079-97-1) 
--- ---- 0 --- --- 0 
Primidone  
(125-33-7) 
--- ---- 0 --- --- 0 
Doxepin  
(1668-19-5) 
--- ---- 0 --- --- 0 
Codeine  
(76-57-3) 
--- ---- 0 --- --- 0 
Dihydrocodeine 
(125-28-0) 
--- ---- 0 --- --- 0 
Methadone  
(76-99-3) 
--- ---- 0 --- --- 0 
Morphine  
(57-27-2) 
--- ---- 0 --- --- 0 
Oxycodone  
(76-42-6) 
--- ---- 0 --- --- 0 
Diazepam  
(439-14-5) 
12,200 (3) 48 h 22 --- --- 0 
Nordazepam 
(1088-11-5) 
--- ---- 0 --- --- 0 
Oxazepam  
(604-75-1) 
--- ---- 0 --- --- 0 
Temazepam 
(846-50-4) 
--- ---- 0 --- --- 0 
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2.1.2 ORGANOPHOSPHORUS COMPOUNDS  
ORGANOPHOSPHATE ESTERS. Among organophosphorus compounds, which are widely used as 
flame retardants, organophosphate esters (OPs) are the most utilized group (WHO, 1997). OPs 
do not naturally occur in the environment but only reach it as a result of human activity (WHO, 
1991a; WHO, 1991b; WHO, 1997; WHO, 1998a; WHO, 2000). The global consumption of flame-
retarding substances is directly connected to national and international regulations concerning 
fire precautions (WHO, 1997). 
Structurally OPs are derivates of phosphoric acid. They are produced industrially by a reaction 
of phosphorus oxychloride (POCl3) with a range of reactants, resulting in a variety of (tri)alkyl- 
and (tri)aryl-phosphates with diverse physico-chemical characteristics (Fisk et al., 2003; 
Marklund, 2005) as shown in Table 2-19. Organophosphate esters can also be halogenated 
combining the chemical properties of halogen and phosphorus components. Furthermore, the 
halogen reduces the mobility of the OP in the polymer matrix, leading to a longer lifetime of the 
OP in the end-product and therefore reducing blooming (see below) (Fisk et al., 2003). 
Halogenated flame retardants are practically exclusively brominated or chlorinated, since 
fluorinated compounds are ineffective and expensive while iodinated compounds are effective 
but unstable (Fisk et al., 2003). In this study five non-chlorinated OPs (TBEP, TnBP, TiBP, TEHP, 
TPP) and three chlorinated OPs (TCEP, TCPP, TDCPP) are investigated. 
 
APPLICATIONS. The variations in characteristics allow the use of OPs in different applications. 
Besides their use as flame retardants they are commonly utilised as plasticisers to decrease 
rigidity in polymers, and as solvents. As they are used in e.g. rigid and flexible polyurethane 
foams (PUF), polyvinyl chloride (PVC), thermoset resins, thermoplastic materials, textile 
finishes, polyesters and cellulosics (Marklund, 2005), they are incorporated into a wide range of 
everyday objects as computer housing, furnishings, upholstery and textiles. Additionally, they 
are used in paint, lubricants, hydraulic fluids and motor and transmission oils (WHO, 1997; 
Commonwealth of Australia, 2001; Umweltbundesamt, 2012). 
Although OPs have been produced since the 1930s and used increasingly throughout the 
twentieth century with the spread of plastics, their production increased drastically when 
substitutes for brominated flame retardants needed to be found after the latter had been 
identified as persistent organic pollutants (POPs), being persistent, bioaccumulative and toxic 
substances (PBTs). Consequently, the restriction of use or the complete phase-out of some 
brominated flame retardants was initiated by several national and international regulations, e.g. 
the Stockholm Convention on Persistent Organic Pollutants. The United States Environmental 
Protection Agency (EPA) named several OPs such as TPP and TDCPP as possible substitutes for 
brominated flame retardants in polyurethane foam (EPA, 2005). Hence, the consumption of OPs 
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is rising globally. In 2007, roughly 209,000 t were consumed worldwide; the overall 
consumption of OPs in Europe was 83,000 t (compared to 45,000 t of brominated flame 
retardants) (Clariant International Ltd). As high production volume (HPV) compounds, all OPs 
investigated in this study (except TiBP) were subject to registration within the EU REACH 
procedure before the first deadline of 1st December 2010 (registration of substances with 
production or import amounts of more than 1,000 t per year in the EU). According to 
Umweltbundesamt, 2012, the production of TCEP and TCPP exceeds 5,000 t per year in the EU, 
whilst SCHER, 2007 reported a total production of about 10,000 t per year in the EU for TDCPP. 
 
PROPERTIES OF SELECTED OPS. As mentioned above, OPs are used in a wide range of applications. 
In general, triaryl phosphates such as TPP are more effective flame retardants because of their 
greater thermal stability, while trialkyl phosphates are better plasticisers, improving the low-
temperature flexibility of plastics and synthetic rubber (Green, 1996). 
TBEP is commonly used as a plasticiser in PVC, synthetic rubber and plastics e.g. in hoses, seals 
and soles of footwear, as a levelling compound in floor polishes, waxes and paper coating, as a 
viscosity modifier in plastisols and as an antifoam agent (WHO, 2000; Marklund, 2005). 
Besides its use as flame retardant, TnBP is utilised as an extreme pressure additive in hydraulic 
fluids, lubricants and transmission and motor oils. Aircraft hydraulic fluids can consist of up to 
79% TnBP (Marklund, 2005).  
TnBP and TiBP are both used as solvents and antifoaming agents in concrete, textile auxiliaries 
and paper coating compounds. Additionally, TiBP is used in the production of synthetic resins 
and natural rubber. In cellulose-based plastics and resins it is used as a flame-retarding 
plasticiser; in pigment pastes it serves as a pasting agent. Being a very strong polar solvent, it is 
also utilised as a wetting agent in the production of textiles (LANXESS AG). 
TEHP is used as a flame retardant in cellulose acetate and as a flame-retarding plasticiser in PVC 
and natural rubber for low temperature applications. Furthermore, it serves as a solvent for 
certain chemical reactions, e.g. in the production of hydrogen peroxide, and is utilised in pigment 
pastes and as an additive in mineral oils (WHO, 2000; LANXESS AG, 2009). 
TPP is often used as a flame retardant in automobiles (e.g. vinyl upholstery) and electrical 
compounds (e.g. computer housings). It is a non-flammable plasticiser in cellulose-acetate based 
films as well as in lacquers and varnishes. TPP is used to impregnate roofing paper, and similar 
to TBP it is used in lubricants and hydraulic fluids (up to 5%) (WHO, 1991a; Marklund, 2005; 
LANXESS AG, 2008). 
Chlorinated OPs are widely used as flame retardants in flexible and rigid polyurethane foam 
(PUF), rubber, polyester resins and textile coatings (WHO, 1998a). While rigid PUF is mostly 
utilised for thermal insulation, flexible PUF is primarily used to add comfort in upholstered 
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furniture, mattresses and car interiors (EFRA). The level of additive in the product is usually 5-
15% (EFRA).  
TCEP is used in PVC, PUF, plastics, carpet backing, fabric back-coating formulations, cellulose 
ester compounds and coatings (WHO, 1998a; Fisk et al., 2003). Furthermore, it is largely used in 
the production of liquid unsaturated polyester resins (WHO, 1998a). TCPP is mainly used in 
rigid polyurethane foams such as in furniture and furniture upholstery, building insulation and 
in refrigerator casings. Small amounts of TCPP are used for textile back-coating and various 
coatings (WHO, 1998a; LANXESS AG, 2011). Recently, it has also been a substitute for TCEP 
(Umweltbundesamt, 2012). According to WHO, 1998a, TDCPP is used in both rigid and flexible 
PUF, in plastics and resins as well as in acrylic latexes. Mattresses in prisons and hospitals are 
commonly flame retarded by TDCPP (KemI, 1996).  
TCEP, TCPP and TDCPP were also found in shock- and sound-absorbing materials, wood 
preservation coatings and foam fillers (Marklund, 2005). 
  
PRODUCT LIFE CYCLE AND ENVIRONMENTAL OCCURRENCE. OPs are mostly used as additives, i.e. they 
are not chemically bound to the polymer backbone but remain as discrete molecules within the 
polymer matrix. This results in possible diffusion of the OPs out of these materials over the 
whole span of the products’ life cycle (also referred to as blooming) (Commonwealth of 
Australia, 2001; Marklund, 2005). The degree to which blooming occurs depends on the 
chemical properties of the particular OP and the polymer it is incorporated in (e.g. KOW, vapour 
pressure, surrounding temperature, size and shape of the polymer and OP molecules, stability of 
the polymer backbone against solvents)(Commonwealth of Australia, 2001). Though detailed 
studies are lacking, it is suspected that OPs which are moved by diffusion processes to the 
surface layers of a product can be rubbed or washed off or become airborne either through 
volatilisation or particle-bound, thus sustaining the diffusion gradient and leading to a constant 
drain of OPs from the end product. Subsequently, OPs are found in indoor dust (Carlsson et al., 
1997; Otake et al., 2001; Hartmann et al., 2004; Staaf and Östman, 2005; Stapleton et al., 2008, 
Ali et al., 2012) as well as in environmental compartments such as surface water (e.g. Andresen 
et al., 2004), groundwater (Fries and Puttmann, 2003) and wastewater (Bester, 2005). In a study 
of 95 organic wastewater contaminants in rivers in the U.S., TCEP was found to be one of the 
pollutants with the highest concentrations (Kolpin et al., 2002). Several studies showed long-
range transport of OPs to remote areas such as polar regions (e.g. Laniewski et al., 1998; Möller 
et al., 2012) and volcanic lakes (Bacaloni et al., 2008). After disposal, leaching from landfills is 
another way OPs can get into the environment (Yasuhara et al., 1999). When burning, e.g. during 
waste incineration, halogenated OPs form highly toxic dioxins and furans, which are only 
eliminated in state-of-the-art incinerators with multiple combustion zones (DiGangi et al., 2010).  
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TOXICITY. Although studies regarding the toxicity of phosphorus-containing flame retardants 
were published as early as in the 1970s (e.g. Liepins and Pearce, 1976), reliable data about the 
toxicity of OPs and their environmental fate are in most cases still lacking, scarce or incongruent, 
despite the efforts of REACH and other regulations. However, according to the Globally 
Harmonized System of Classification and Labelling of Chemicals (GHS (United Nations, 2011)), 
TiBP, TCEP and TPP are classified as being harmful (H412), toxic (H411) and very toxic (H410) 
to aquatic life, with long lasting effects, respectively. Three substances (TnBP, TCEP, TDCPP) are 
suspected of causing cancer (H351). TCEP may, in addition, impair fertility (H360F). TnBP, TCEP 
and TCPP are harmful if swallowed (H302). TnBP and TEHP cause skin irritation (H315); the 
latter also provokes serious eye irritation (H319), while TiBP may cause an allergic skin reaction 
(H317). 
In a study surveying commercial substances not currently part of contaminant measurement 
programs, TDCPP was described as being likely to be persistent and bioaccumulative (Howard 
and Muir, 2011). A recent study from Canada reports the presence of TCEP in predatory 
freshwater fish from Canadian lakes (McGoldrick et al., 2014). In general, the physico-chemical 
properties of OPs which determine their fate in the (aquatic) environment are very heterogenic, 
e.g. reported log KOW values range between 0.5 and 9.49 (Table 2-19), indicating very diverse 
potentials for sorption into particles and/or possible bioaccumulation.  
Of the substances in this study, TPP and TDCPP are reported to be the most toxic ones to aquatic 
organisms, with 96 h LC50 concentrations of 0.36 and 1.1 mg/L respectively for rainbow trout 
(WHO, 1991a; WHO, 1998a), while the toxicity of TBP is given as 4.2 – 12 mg/L for rainbow 
trout. For TCPP, the 96 h LC50 concentration in fathead minnow is reported with 51 mg/L; for 
TCEP in goldfish it is 90 mg/L (WHO, 1998a). Further details of acute toxicity of OPs are given in 
Table 2-20. Studies showed that OPs also have an adverse effect on algae and plants. TPP was 
found to completely inhibit algae growth at concentrations above 1 mg/L (WHO, 1991a). TBP 
increases plants’ drying rates and damages their leaf surfaces, thus inhibiting respiration (WHO, 
1991b). Furthermore, organophosphate flame retardants seem to alter sex hormone balances in 
zebrafish (Danio rerio) through several mechanisms, including alterations of steroidogenesis 
and oestrogen metabolism (Liu et al., 2012). 
For TDCPP (log KOW 3.65), the EU’s Simple Treat Model predicts that 25% of the substance 
present in water bodies would be associated with sludge, 5% may be released into the air while 
70% would remain dissolved (Commonwealth of Australia, 2001). Regarding the HVP character 
of the OPs, it can be assumed that not only the water compartment is affected by high amounts 
of TDCPP but air, sludge and soils as well. Similar is to be expected for other OPs (WHO, 1991b; 
WHO, 1998a; WHO, 2000; Marklund, 2005). In particular, chlorinated flame retardants are the 
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subject of recent scientific discussion and concern (cf. DiGangi et al., 2010). OPs utilised as flame 
retardants and plasticisers are of similar chemical structure from organophosphorus 
insecticides, the latter having an impact on the nervous system by inhibiting the action of 
acetylcholinesterase (AChE) and other enzymes in nerve cells of not only target organisms but 
non-target organisms, including humans, as well (e.g. Hayden et al., 2010, Terry, JR, 2012). Thus, 
many organophosphates are powerful nerve agents, and organophosphate poisoning is a 
common means of suicide in both developing and developed countries (e.g. Yurumez et al., 2007; 
Eddleston et al., 2008; Hrabetz et al., 2013). Sublethal exposure to organophosphates triggers 
transcriptional changes in genes associated with Parkinson's disease (Slotkin and Seidler, 2011); 
it is suspected of producing lasting neurotoxicity affecting cognitive functions, increasing the 
risk of dementia and Alzheimer’s disease (Santibáñez et al., 2007; Hayden et al., 2010), and 
causing or encouraging impairments generally recognised as psychologically based disorders, 
such as Gulf War Syndrome (Terry, JR, 2012) or depression (Beseler et al., 2008). Furthermore, 
low-level exposure to organophosphates shows the potential to modify the male hormone 
profile, pointing to their endocrine-disrupting potential (Aguilar-Garduño et al., 2013). 
 
Table 2-19: Physico-chemical properties of organophosphorus compounds. Ws: water solubility (if not 
otherwise indicated at 25 °C); MW = molecular weight [g/mol]; HLC = Henry's Law Constant [atm-
m3/mole]; Ws = water solubility [mg/L] at 25 °C if not otherwise indicated; ---, not listed in the literature or 
databases consulted. 
  
Substance tris(2-butoxyethyl) phosphate tributyl phosphate 
Abbreviation TBEP TnBP 
Chemical 
structure  
 
 
CAS-No. 78-51-3 126-73-8 
MW 398.54 266.3141 
log KOW 3.75a 4a; 4.00b  
pKa  ---  --- 
Ws 1,100c 280a 
HLC 1.20x10-11a 1.41x10-6a 
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a NLM, 2005; b Sangster, 2012; c SRC Research Corporation; d WHO, 2000; e WHO, 1998a  
Table 2-19: continued. 
Substance tri-iso-butyl phosphate  tris(2-ethylhexyl) phosphate 
Abbreviation TiBP TEHP 
Chemical 
structure  
  
CAS-No. 126-71-6 78-42-2 
MW 266.3141 434.64 
log KOW 3.600a 9.490a; 4.22d 
pKa  --- --- 
Ws 16.2a 0.6c 
HLC 3.19x10-6c 7.86x10-8a 
 
Substance triphenyl phosphate tris(chloropropyl) phosphate 
Abbreviation TPP TCPP 
Chemical 
structure  
 
 
CAS-No. 115-86-6 13674-84-5 
MW 326.28 327.57  
log KOW 4.59a; 4.59b 2.59a 
pKa  ---  --- 
Ws 1.9c 1,600e 
HLC 3.31x10-6a 5.96x10-8a 
   
Substance tris(2-chloroethyl) phosphate tris(1,3-dichloro-2-propyl) phosphate  
Abbreviation TCEP TDCPP 
Chemical 
structure  
 
 
CAS-No. 115-96-8 13674-87-8 
MW 285.49 430.91 
log KOW 0.5b; 1.44a 3.65a 
pKa ---  --- 
Ws 7,000a; 8,000e 7a 
HLC 3.29x10-6a 2.61x10-9 (25 °C)a 
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Table 2-20: Acute toxicity of organophosphorus compounds. BCF: Bioconcentration factor (BFC = 
concentration on organism/concentration in surrounding environment); a rainbow trout; b zebra fish; c 
goldfish; d fathead minnow; ---: not described in used the literature. 
OP NOEC [mg/L] 96h LC50 [mg/L] LD50 rat (orally) [mg/kg] BCF Reference 
TBEP 10a  24a 3,000 --- 1 
TnBP --- 4.2–12a  1,390 11–49a  2 
TiBP --- --- --- --- --- 
TEHP --- > 100b  37,000 250b  1 
TPP --- 0.36a  3,800 324–1,368a  3 
TCEP --- 90c 1,150 --- 4 
TCPP 9.8 d 51 1,017 --- 4 
TDCPP 0.56a 1.1 2,380 47–107a 4 
a WHO, 2000; b WHO, 1991b; c WHO, 1991a; d WHO, 1998a. 
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2.2 RECENT AND ADVANCED TECHNOLOGIES FOR WASTEWATER TREATMENT 
2.2.1 CONVENTIONAL ACTIVATED SLUDGE SYSTEMS (CAS) 
These days, wastewater treatment usually consists of a multi-step process (Figure 2-3).  
 
TREATMENT STEPS OF CAS. During preliminary treatment, wastewater is firstly passed through 
screens to remove large solids that otherwise could block the downstream mechanics or cause 
undue mechanical wear (EPA, 2004). Furthermore, grit removal usually precedes primary 
treatment. Grit consists of sand, gravel, cinder or other solid material with higher specific gravity 
than organic biodegradable solids (EPA, 2004). In primary (physical) treatment, the wastewater 
is held in a primary clarifier where larger suspended (organic) material settles at the tank 
bottom while oily and greasy substances float to the surface (Water UK, 2006). These are 
removed mechanically and the water passed on to the secondary (biological) treatment where in 
a controlled, optimised environment (aerated bioreactors) water-borne microorganisms are 
mixed with the wastewater (“mixed liquor” or “activated sludge”) (Radjenović et al., 2008). The 
main components of the biomass are saphrotrophic bacteria and protozoa. Using the 
biodegradable material in the water, these microorganisms metabolise dissolved and suspended 
matter and bind suspended material in the biological flocs they form by assemblage of single 
cells and micro-colonies (Nicolella et al., 2000a).  
This process of aerobic microbial biodegradation, as in every biological wastewater treatment, 
mirrors the natural process performed by the microbial community in natural water bodies, but 
in an optimised manner (Radjenović et al., 2008). To keep the growing biomass under control, 
excess mixed liquor (“secondary sludge”) is drawn from the system and treated further by e.g. 
thickening, dewatering, anaerobic stabilisation, chemical conditioning or thermal reduction, 
before being disposed of (Radjenović et al., 2008). A portion of the excess sludge (“return 
activated sludge”) is recirculated to the beginning of the secondary treatment to be mixed with 
fresh wastewater.  
In a third stage of treatment (tertiary treatment) the effluent quality is improved further e.g. for 
discharge into sensitive water bodies or bathing waters (Water UK, 2006). Nowadays the 
removal of nutrients is widespread. Both households (through urine, faeces, washing agents, 
etc.) and agriculture (through fertilisers) contribute nutrients to wastewater. In the past, large 
quantities of nitrogen and phosphate in incompletely treated wastewater discharged into the 
environment caused excessive eutrophication problems in all receiving aquatic systems 
(Radjenović et al., 2008). Today, their removal is usually incorporated into the biological 
treatment in WWTP as a tertiary treatment. Nitrogen is removed by biological nitrification and 
denitrification. Nitrification is the oxic process of converting ammonia to nitrite (NO2) and 
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further nitrate (NO3). By changing aerobic conditions to anaerobic, NO3 is then transformed to 
nitrogen gas (N2) (denitrification) which is released into the atmosphere and therefore removed 
from the water (EPA, 2008a). The rate-limiting factor in this process is the slow growth rate of 
nitrifying bacteria, which demands a certain sludge age, i.e. a long solid retention time (SRT) 
with the biomass being withdrawn from the system more slowly than the bacterial growth rate 
(Barnes and Bliss, 1983).  
Phosphorous in wastewater is usually found as phosphate. It is usually eliminated either 
biologically or by chemical precipitation (Radjenović et al., 2008). During enhanced biological 
phosphorus removal (EBPR) the growth of polyphosphate accumulating organisms (PAOs) is 
selectively encouraged by alternating between aerobic and anaerobic conditions, which limits 
the growth of strictly aerobic organisms. The subsequent removal of the phosphate-enriched 
biomass reduces the phosphorus load of the wastewater. For chemical precipitation, lime or 
salts of iron (e.g. ferric chloride) or aluminium are used (EPA, 2000; Radjenović et al., 2008). 
Before the treated wastewater is released into the environment, it is passed through secondary 
clarifiers and/or natural ponds (EPA, 2002) to remove remaining bacterial floc (Crown 
Copyright, 2012). Where especially high effluent quality is demanded, additional ‘polishing’ 
processes like UV oxidation or filtration are also included in this treatment step (see following 
chapters) (Water UK, 2006; Crown Copyright, 2012). 
The sludge emerging from the wastewater treatment is dewatered and digested to reduce 
organic matter and pathogenic microorganisms. Depending on the composition and volume of 
the sludge, digestion is carried out either aerobically or anaerobically, or a combination of both, 
with anaerobic treatment being the most common (Radjenović et al., 2008). 
 
LIMITATIONS. A number of drawbacks are connected with CAS. The immense demand for space 
(“footprint”) was identified by Fatone, 2010 as the main factor driving costs in conventional 
wastewater treatment. Still, there are other limitations to CAS. Firstly, it is restricted with regard 
to achievable effluent water quality (Radjenović et al., 2008) which can cause problems with 
demands for higher effluent quality for e.g. indirect potable water reuse. Today, reclaimed water 
is used in many countries to augment drinking water supplies (Wintgens et al., 2002). The 
removal efficiency of CAS is entirely based on the separation of treated water and sludge by 
sedimentation, so that the smallest possible amount of microbacteria is co-discharged into the 
receiving waters. Poorly settling sludge (“bulking sludge”) leads to reduced discharge quality. 
Furthermore, it can temporarily disable the whole treatment plant. Consequently, good 
sedimentation behaviour in the sludge is the most important aspect of CAS plant maintenance. 
This is achieved by operating the CAS in a way that favours the formation of well settling flocs, 
which is in turn directly connected to the characteristics of the microbial flocs. Since CAS are 
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operated at low SRTs (usually in the range of several days), substantial microbial communities 
have to be not only floc-forming but fast-growing, too. In many cases specialised 
microorganisms are needed for the biodegradation of special compounds like some “emerging 
compounds”. Since many of them are slow-growers, they cannot develop at low SRTs and the 
removal of certain trace pollutants is subsequently unfeasible in CAS. However, even without the 
concern of emerging compounds, the production of large volumes of sludge during CAS is one of 
the main drawbacks of this technique. With rising regimentations of the agricultural use of 
excess sludge, the handling, treatment and deposition of the material is becoming more and 
more expensive, reaching up to 60% of the total costs of wastewater treatment (Spellman, 1996; 
Radjenović et al., 2008). It follows, that to run efficiently, CAS requires constant attention and 
close monitoring of many parameters (Radjenović et al., 2008) with the multitude of single 
processes included making it a delicate system, prone to instability.  
Since necessary upgrades are often made to CAS treatment plants for the sake of higher effluent 
quality, conventional wastewater treatment is now becoming more expensive (Radjenović et al., 
2008). 
 
 
 
Figure 2-3: Generalised diagram of conventional activated sludge treatment (CAS). For more details refer 
to text.  
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2.2.2 BIOFILM REACTORS (BFR) 
In biofilm reactors (BFRs), the microorganisms involved in the biological water treatment are 
immobilised on the surface of an inert support material, which could be a fixed structure such as 
a trickling filter or freely movable, submerged particles that function as carriers (Nicolella et al., 
2000a).  
 
INTRODUCTION TO BIOFILMS. By immobilizing the microorganisms, a disconnection between HRT 
and SRT is achieved since the separation of water and activated sludge no longer depends on the 
sludge’s settlement properties. Additionally, high biomass concentrations are easily maintained 
(van Loosdrecht and Heijnen, 1993). A drastic increase of biofilm surface area is achieved by 
growing biofilms on small particles, and at the same time microorganisms are much less prone 
to being washed out of the system (Nicolella et al., 2000b). For these reasons, a considerably 
higher sludge age is achievable, which ultimately allows for a different composition of the 
microbial community, with e.g. slow growing microorganisms that are disadvantaged in 
suspended-growth systems of activated sludge treatment (Hall, 1987; van Loosdrecht and 
Heijnen, 1993; Nicolella et al., 2000b). Fully developed biofilms (see below) often maintain a 
complex biocenosis, where aerobic microorganisms inhabit the biofilm layers close to the 
biofilm-water interface, while anaerobic organisms colonise the oxygen-limited and oxygen–free 
regions further away from the interface. Additionally, slow growers are generally overgrown by 
fast growers and thereby protected from mechanical influences (Nicolella et al., 2000a).  
 
 
DEFINITION OF BIOFILMS. While biofilms had already been detected in the 17th century (CBE, 
2013a), the term “biofilm” was only introduced in the 20th century. For decades the term was 
characterised differently by different authors and in different contexts and a final definition is 
still elusive (Karatan and Watnick, 2009). Nowadays, biofilms are generally described as 
complex, coherent structures of cells and cellular products (extracellular polymeric substances, 
EPS) (Characklis and Marshall, 1990; Nicolella et al., 2000a) which appear as large, dense 
granules or grow on solid surfaces, either static (static biofilms) or suspended carrier material 
(particle-supported biofilms) (van Loosdrecht and Heijnen, 1993; Nicolella et al., 2000b). More 
specifically, biofilms are defined as surface-associated multicellular communities (Branda et al., 
2005) or as thin coatings consisting of living material (Karatan and Watnick, 2009). Pointing out 
the complexity of the biofilm micro ecosystem, Watnick depicts the biofilm as a “city of 
microbes” (Watnick and Kolter, 2000).  
 
COMPOSITION OF BIOFILM MATRICES. Biofilms can be built up by just a single bacterial species, but 
naturally occurring biofilms generally consist of an enormous mixture of different species of 
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bacteria, fungi, algae, yeasts, protozoa and other microorganisms (CBE, 2013a). Furthermore, 
biofilms incorporate inorganic particulate material like debris and the products of corrosion 
(CBE, 2013a). Sutherland (Sutherland, 2001) described the composition of biofilm matrices as 
shown in Table 2-21, revealing that biofilms are highly hydrated structures with the actual 
microbial cells only accounting for at most 15% of the matrix. Even with the exact composition 
depending greatly both on the microorganism community building the biofilm and on the 
environmental conditions, overall water is the main compound. It is bound within the microbial 
cells and is also present extracellularly, thus enabling diffusion in the biofilm (Sutherland, 2001).  
 
EPS. The backbone of the gels which surround the cells in the biofilm is extracellular polymeric 
substances (EPS). These are biopolymers, namely exopolysaccharides, of microbial origin that 
are produced by archaeal, bacterial and eukaryotic microbes (Flemming et al., 2007). Further 
components of the biofilm matrix are cell materials (proteins, polysaccharides, DNA and RNA, 
peptidoglycan, lipids, phospholipids etc.), absorbed nutrients (e.g. ions like Ca2+), membrane 
vesicles, metabolites, cell lysis products and particles of surrounding material (Sutherland, 
2001; Karatan and Watnick, 2009). 
The EPS matrix can be depicted as a “house of biofilm cells” which defines the architecture and 
structure of the biofilm in terms of mechanical stability, porosity, density, water content, charge, 
hydrophobicity and sorption properties, and ultimately characterises the immediate conditions 
for the microorganisms in the biofilm (Flemming et al., 2007). Thus, by nature, biofilms are 
extremely heterogeneous micro ecosystems, displaying chemical heterogeneity with gradients of 
substrate, nutrients and gases and different ecological microniches (see below) (Nadell et al., 
2009).  
The functional roles of EPS are numerous. Regarding biofilm-environment interactions, the 
biofilm matrix enables the sequestering of particulate and dissolved substances from the bulk 
liquid and thus provides nutrients for the biofilm community. Additionally, EPS ease the 
adherence of new microorganisms (Apilánez et al., 1998).  
The EPS structure of multilayered biofilms is sponge-like (Karatan and Watnick, 2009) with 
interstitial gas-filled voids and channels between discrete aggregates of microbial cells. They 
enable liquid flow, molecular and possibly even cell transport deep into and through the biofilm 
matrix by convective mass transport (Beer et al., 1996; Sutherland, 2001; Karatan and Watnick, 
2009). In the overall biofilm system, transport of substrates involves convection from the bulk 
liquid to the close vicinity of the cell clusters, diffusion through the mass transfer boundary layer 
and further diffusion from cell to cell. Since diffusion processes are generally slower than 
convective transport, cell-to-cell-diffusion is the energy limiting factor of biofilm growth (Beer et 
al., 1996; Nicolella et al., 2000b). Channels and voids in the matrix provide pathways for 
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convective transport in the biofilm areas at depths that would not be reached by diffusion in a 
channel-less biofilm (Stoodley et al., 1994). Furthermore, the biofilm provides a viscous or 
gelatinous shield against physical forces, it enables microorganisms to stay located instead of 
being washed out of a favourable micro environment, it influences predator-prey-interactions 
and it protects microorganisms against the effect of antimicrobials such as antibiotics in the 
surrounding liquid (Characklis, 1973; Watnick and Kolter, 2000; Stewart and Costerton, 2001; 
Sutherland, 2001; Flemming et al., 2007). Studies have shown that microbial biofilms can be up 
to 1,000 times more resilient to antibiotics than planktonic (free-floating) bacteria (CBE, 2013a).  
By keeping cells fixed in close proximity to each other, and by providing a transport medium, the 
biofilm matrix represents a unique ecological niche with all forms of inter- and intra-species 
competition, cooperation and coexistence (Sutherland, 2001; Nadell et al., 2009). It enables cell-
cell communication by accumulation of signal molecules to coordinate gene expression within 
the biofilm (quorum sensing or “signalling”) (Sauer et al., 2002; Karatan and Watnick, 2009; 
Kievit, 2009; Nadell et al., 2009; CBE, 2013c) as well as ‘warfare’ against competing 
neighbourhoods, for example by releasing bacteriocins, microcins or antibiotics (Sutherland, 
2001).  
 
BIOFILM DEVELOPMENT. Biofilms develop naturally on almost every surface which comes into 
lasting contact with an aqueous liquid, whether fresh or salty (Apilánez et al., 1998). The 
prerequisite initial step to biofilm development is the sorption of organic compounds on the 
submersed support surface (Figure 2-4). This surface is usually charged by adsorption of ions or 
by the ionisation of surface groups (Annachhatre and Bhamidimarri, 1992). The charged surface 
attracts oppositely charged ions from the feed liquid which are at the same time hindered by the 
thermal motion of the counter ions. Due to counterbalancing, this ultimately leads to the 
development of a diffuse electric double layer in close proximity to the charged surface where 
ions are accumulated in higher concentrations than in the surrounding liquid. By the subsequent 
sorption of dissolved organic material (glycoproteins, proteins etc.) the liquid-surface interface 
thus becomes a favourable nutrient-rich environment for microorganisms (Characklis, 1973; 
Annachhatre and Bhamidimarri, 1992).  
Subsequently, planktonic bacteria attach to the surface in first reversible (transient attachment), 
then irreversible manner (permanent attachment) and change to a genetically diverse sessile 
phenotype (Karatan and Watnick, 2009; CBE, 2013a), as shown in Figure 2-4. The production of 
EPS enables a permanent hold on the surface and keeps developing microcolonies in close 
proximity. After initial adherence, the biofilm grows through cellular reproduction, production 
of EPS and adherence of new microbes.  
  
Chapter 2 
 
page | 52  
Table 2-21: Composition of typical biofilm matrices (Sutherland, 2001) 
Component % of matrix 
Water Up to 97% 
Microbial cells  2–15% (many species) 
Polysaccharides (homo- and heteropolysaccharides) 1–2% (neutral and polyanionic) 
Proteins (extracellular and resulting from lysis) < 1–2% (many, including enzymes)  
DNA and RNA < 1–2% (from lysed cells) 
Ions ? (bound and free) 
 
Due to the consumption of substrates, nutrients and oxygen or electron donors by the 
microorganisms during biofilm growth, concentration gradients in the biofilm develop which 
cause these chemicals to diffuse into the biofilm, while metabolism by-products diffuse out of 
the biofilm (Annachhatre and Bhamidimarri, 1992). A typical example of chemical and 
ultimately physiological heterogeneity in biofilms is the depletion of oxygen with increasing 
distance from the biofilm-liquid-interface (Nadell et al., 2009), allowing microbes in the outer 
zone to use aerobic metabolism while anaerobic microorganisms occupy the oxygen-depleted 
zones (Xu et al., 1998). The spatial heterogeneities result in a stratification of the biofilm ( 
Figure 2-5) due to the development of microniches along gradients of nutrients, substrate or 
waste products (Nadell et al., 2009). These waste products can lead to a toxication of biofilm 
zones or they can be used by other types of microbes.  
During the growth phase of the biofilm, total coverage of the available surface occurs (Apilánez 
et al., 1998).  
 
 
Figure 2-4: Schematic of the biofilm life-cycle (CBE, 2013a)  
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MORPHOLOGY AND TOPOLOGY. The morphology and surface topology of the biofilm is, in addition 
to the influence of shear forces, strongly determined by the nature of the feed liquid. It is 
suggested as a general rule that in nutrient-limited environments, biofilms are dense, sometimes 
even only of mono-layered structure, and feature a smooth surface, while in nutrient-rich 
surroundings, biofilms grow as thick multi-layers (Characklis, 1973; Nadell et al., 2009). 
However, studies have revealed that different microorganisms react in different ways to 
nutrient changes. While for some microbes an acceleration of biofilm growth was observed 
when nutrient supply increased, for other species growth is boosted by nutrient deprivation 
(Karatan and Watnick, 2009). The limitation of available nutrients is also discussed as a possible 
reason for the development of voids and channels in biofilms when only a thin layer of active 
cells on top of the biofilm is provided with nutrients like oxygen, which is rapidly depleted in the 
depth of the EPS matrix (Figure 2-6). Under these conditions, irregularities in the surface of the 
biofilm might become greatly amplified, with cells growing well at the top of irregularities due to 
sufficient access to nutrients from the bulk liquid, and cells growing poorly in the irregulation’s 
troughs, resulting in fast-growing towers and growth-reduced bay-like areas which develop into 
channels when overgrown (Nadell et al., 2009). In contrast to the theory that cells on top of the 
towers grow faster because of better access to nutrients, some authors discuss surface 
depressions as spots of highly turbulent liquid flow that, depending on the flow rate, can be 
better provided with nutrients than smooth zones experiencing laminar flow (Beer et al., 1996).  
 
BIOFILM SLOUGHING. The detachment of cells from the biofilm (“biofilm sloughing”) is a natural 
phenomenon occurring either by the dispersal of single cells of planktonic, motile phenotype 
(so-called “swarmers”) or by the detachment of whole clumps of biofilm (Annachhatre and 
Bhamidimarri, 1992; Sauer et al., 2002; CBE, 2013b). Studies imply that the release from the 
biofilm is not only a result of a weakening biofilm matrix, either due to cell lysis under 
unfavourable environmental conditions or due to pure force of flow shear, but it can be actively 
driven by the microbes through quorum-sensing induced enzymatic breakdown of the 
surrounding biofilm structure (Annachhatre and Bhamidimarri, 1992; Watnick and Kolter, 2000; 
Karatan and Watnick, 2009; Nadell et al., 2009). Thus, microorganisms are provided with an exit 
strategy from surface association (Watnick and Kolter, 2000; Karatan and Watnick, 2009) and 
subsequently can propagate to new areas downstream of the original community (CBE, 2013b). 
Depending on the environmental conditions, mature biofilms can reach a steady state where 
biofilm growth is balanced by detachment (Sauer et al., 2002).  
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Figure 2-5: Stratification of biofilm (schematic diagram, Characklis and Marshall, 1990; Anton et al., 2002; 
Nadell et al., 2009) 
STATE OF RESEARCH. To date, biofilms are far from being fully understood and their multiple roles 
have only partly been discovered. Even the function and precise construction principles of EPS 
are not fully comprehended (Flemming et al., 2007), let alone the extremely complex ecosystems 
that biofilms represent. The intensive research that has been carried out in recent years and is 
still underway constantly reveals more details, and new findings are frequently reported (CBE, 
2013a).  
 
BIOFILMS IN WASTEWATER TREATMENT. Biofilms are used in various applications for wastewater 
treatment (Figure 2-7). The biofilm is either fixed on a large, static support structure (fixed bed 
reactors or rotating biological contactors (RBC), also named rotating biological reactors) or it is 
attached to suspended particles (carriers). Typical carriers reported in literature are sand, 
activated carbon, pulverised rock, glass beads, diatomite earth material as well as plastic and 
ceramic materials (Koch et al., 1991; Apilánez et al., 1998; Garcia-Calderon et al., 1998; 
Welander et al., 1998; Nicolella et al., 2000a; Zhou et al., 2006). A significantly higher biofilm 
surface is achievable by attachment to small particles than with fixed-bed applications (Nicolella 
et al., 2000b). Carriers made of different material differ regarding their physical and chemical 
properties, which results in different start-up times and, according to some studies, even 
variations in the microbial community that will be developed (Apilánez et al., 1998; Anton et al., 
2002). Several studies stated that porous carriers like foamed polyurethane or polystyrene are 
preferable since they provide a greater (inner) surface than mineral materials, and biofilms 
developing in these carriers are protected from shear stress (Loukidou and Zouboulis, 2001; 
Anton et al., 2002). On the other hand, shear forces are specifically used for the control of biofilm  
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Figure 2-6: Influence of nutrient availability on the biofilm topology. In nutrient-rich environments (left 
column), smooth biofilms grow due to a high diffusion rate reaching deep into the biofilm, allowing for a 
thick layer of actively growing cells, while in nutrient-poor environments (right column) only a thin layer 
of cells is growing fast. Irregularities in the biofilm surface lead to the development of towers with actively 
growing cells on top and growth-inhabited cells in the troughs, resulting in a rough biofilm surface and 
channels (Computational simulations; nutrient: oxygen; Nadell et al., 2009).   
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thickness on the carriers. In wastewater treatment, thin, smooth biofilms are preferable to 
ensure high mass transfer rates into the biofilm. In addition, thick biofilms are prone to being 
randomly detached, resulting in a patchy, irregular and less effective biofilm and high biomass 
loads in the effluent (Nicolella et al., 2000a). Thick biofilm layers change the hydrodynamic 
properties of the carriers, seriously decreasing their particle density. This results in carriers 
being swept out of the system, leading to the need for an additional separation step (Nicolella et 
al., 2000a).  
The application of fixed or particle-supported BFRs as the reactor of choice depends very much 
on the substrate load of the feed water and the flow rate (Figure 2-8).  
 
 
Figure 2-7: Biofilm principles and techniques for water treatment (Nicolella et al., 2000a; ATV-DVK-
Arbeitsgruppe IG-5.6) 
 
PARTICLE-BASED BFRS. As already mentioned, particle-based BFRs offer numerous advantages 
when compared to suspended-growth systems (Table 2-22). Thus, the settling velocity and the 
reactor concentration of particle-based biofilm reactors are described as being ten times higher. 
With greater biofilm surface area, higher biomass concentration and subsequently a higher mass 
transfer area, particle-supported BFRs provide higher conversion capacities. High SRTs lead to 
less excess sludge. Furthermore, biofilm reactors have a considerably smaller spatial footprint. 
Drawbacks include long start-up phases, the previously described difficulty of controlling the 
biofilm thickness and the overgrowth of carriers, as well as costs for liquid distribution in 
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fluidised bed reactors, since mechanical stirring is not feasible due to the possibility of damaging 
carriers and biofilm (see Table 2-22, Nicolella et al., 2000a).  
 
FIXED-BED BFRS. Biofilms have been used in fixed-bed applications for wastewater treatment for 
more than a century (Tchobanoglous and Burton, 1991; Mathure and Patwardhan, 2005). In 
contrast, particle-based biofilm reactors did not come into use until the 1970s (Nicolella et al., 
2000a). In 1976, a Biofilm Fluidized Bed (BFB) configuration was patented in the USA (Jeris et 
al., 1976). At about the same time, the first commercial-scale application of the BFB process was 
installed in the form of a denitrification system for municipal wastewater, quickly followed by 
industrial applications as well, where it was soon applied to different treatment processes like 
nitrification, denitrification, anaerobic treatment and carbonaceous oxidation (Nicolella et al., 
2000a). In BFB reactors, the particles are kept fluidised by the up-flowing influent. Later 
developments of the same basic principle (Figure 2-9) are the Expanded Granular Sludge 
Blanket (EGSB) and the Biofilm Upflow Sludge Blanket (USB). In contrast, the more recently 
developed Biofilm Airlift Suspension (BAS) and Internal Circulation (IC) reactors use gas for 
mixing particles with liquid. In the case of BAS reactors, air is pumped into the system, while IC 
reactors use the gas that is produced in the system itself (Nicolella et al., 2000a). 
 
 
Figure 2-8: Diagram of concentration-flow rate phases for the application of floc and biofilm reactors. A: 
microbes grow in suspension due to long retention times; B: high flow rates only allow the retention of 
static biofilms unless the reactor is of an extremely flat and extended shape; C: conditions are suitable for 
the application of particle-supported biofilm reactors; D: conditions are suitable for the application of 
microbial flocs as long as liquid-solid separation and biomass recycling are used (e.g. activated sludge 
treatment); Note that regions C and D are partly overlapping. E: under conditions of high load and low 
flow, upflow sludge blanket reactors can be utilised (Nicolella et al., 2000a).  
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Table 2-22: Characteristics of particle-supported biofilm reactors (adapted from Nicolella et al., 2000a) 
Advantages Disadvantages 
High terminal settling velocity of solids (50 m h-1; for 
flocculated sludge: 5 m h-1), leading to possible 
elimination of external clarification/separation stages 
 
Biofilm formation on carriers poses problems leading to 
long start-up times  
High reactor concentration (30 kg m-3; for flocculated 
sludge systems: 3 kg m-3) 
 
Control of biofilm thickness is difficult (depending on 
reactor type) 
High biofilm surface area (3000 m2 m-3; in trickling 
filters: 300 m2 m-3) 
 
Overgrowth of biofilms can lead to elutriation of 
particles 
High biomass concentration and mass transfer area 
result in high conversion capacities (for oxygen, 20 kg m-
3 day-1; in activated sludge and trickling filter processes: 
3 kg m-3 day-1) 
 
Liquid distributors for fluidised systems are costly for 
large-scale reactors and pose problems with respect to 
clogging and uniform fluidisation 
Compact reactor with small area requirements 
High biomass age (several weeks); and minimisation of 
excess sludge production 
 
 
COMMERCIAL IMPLEMENTATIONS AND THE STATE OF AFFAIRS OF BFRS. Over the last two decades, 
biofilm reactors have been put to use for aerobic and anaerobic water treatment, nitrification 
and denitrification or a combination of both, as well as for more specialised applications like the 
removal of persistent compounds such as dichloromethane, chlorophenols, phenols and 
naphthalensulfonic acid. Commercial full-scale systems, treating both industrial and municipal 
wastewater, have been developed and installed in, e.g., the USA, France and the Netherlands 
since the middle of the 1990s (Nicolella et al., 2000a).  
To summarise, it can be said that biofilm technology is nowadays regarded as a fully developed 
wastewater treatment technology with the majority of parameters (biofilm formation, mass 
transfer, hydrodynamics etc.) well investigated and understood (Nicolella et al., 2000b). 
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Figure 2-9: Main types of biofilm reactors operating with suspended carriers (Welander et al., 1998; 
Nicolella et al., 2000b) 
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2.2.3 NANOFILTRATION (NF) 
Membrane filtration processes have become increasingly important in water and wastewater 
technology over the last decades (Radjenović et al., 2008). Their first introduction in water 
treatment processes was for treating secondary or tertiary effluent as a polishing step to achieve 
higher quality in excess waters (Wintgens et al., 2005).  
 
MEMBRANE SEPARATION. Membranes, in the simplest terms, are two-dimensional materials which 
separate the constituents of fluids according to their relative size or their electrical charge in a 
purely physical process, leaving all compounds chemically unchanged (Semião and Schäfer, 
2010). During membrane separation, feed water passes over the membrane surface dividing it 
into two very different streams by solid-liquid separation based on semipermeability. The 
rejected portion is called concentrate or retentate, the cleared water is named permeate (Kunst 
and Košutić, 2008).  
  
MATERIALS AND PROPERTIES. In general, membranes are made of plastic or ceramic materials, 
while metallic membranes are rare. The most common materials are celluloses, polyamides, 
polysulphone, charged polysulphone and other polymeric materials (e.g. polyacrylonitrile (PAN), 
polyvinylidene difluoride (PVDF), polyethylsulphone (PES), polyethylene (PE) or polypropylene 
(PP) (Radjenović et al., 2008). While all of these materials possess a favourable chemical and 
physical resistance (Radjenović et al., 2008), they have the drawback of being hydrophobic, 
which is known to promote membrane fouling (Choi et al., 2002). Therefore, commercially 
available membrane surfaces are modified to reach a more hydrophilic finish (Radjenović et al., 
2008). Besides the method of fabrication, this finish is the distinguishing element between 
different membranes (Radjenović et al., 2008). 
Sophisticated separation membranes have an asymmetric structure, being anisotropic in vertical 
cross section, with a thin dense “skin” (selective layer) as the surface on top of a supporting, 
much thicker, porous layer (Kunst and Košutić, 2008). 
Filtration membranes are based on either planar or cylindrical geometry. Three different 
configurations are commonly used: hollow fibre (HF), spiral-wound and flat sheet (FS); to a 
lesser extent, tubular membranes and pleated filter cartridges are employed (Radjenović et al., 
2008). FS are mostly used as “plate-and-frame” configurations in modular forms with a number 
of FS mounted to a supporting construction (Radjenović et al., 2008). Equally, hollow fibre and 
spiral-wound fibres are usually connected by manifolds and bundled into units for easy 
maintenance and changing (EPA, 2008b).  
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MEMBRANE TYPES. The most common pressure-driven membrane separation processes are 
microfiltration (MF, separation 100-1,000 nm), ultrafiltration (UF, separation 5-100 nm), 
nanofiltration (NF, 1-5 nm; Radjenović et al., 2008), also given with 0.5-2 nm (Kunst and Košutić, 
2008) and reverse osmosis (RO, 0.1 – 1 nm; Radjenović et al., 2008), also given with 0.2-1 nm 
(Kunst and Košutić, 2008),). All of these produce permeate and concentrate (retentate). Since NF 
and RO share similar pore size ranges, their rejection properties mostly differ in relation to ions. 
NF membranes typically reject di- and multivalent ions almost completely, whilst the rejection of 
univalent ions is less than 70%. The retention by RO is less variant and mostly driven by the size 
of the hydrated ion. Since in the case of organic molecules the rejection behaviour of NF and RO 
is very similar, they are often discussed together as NF/RO membranes (Kunst and Košutić, 
2008).  
 
RETENTION MECHANISMS. Several basic retention mechanisms determine the retention of organic 
solutes by filtration membranes. The most important ones identified are: size exclusion, charge 
repulsion and physico-chemical interactions such as sorption on the membrane surface (Kunst 
and Košutić, 2008; Radjenović et al., 2008; Wu et al., 2010). 
 
SIZE EXCLUSION. Size exclusion, defined as the retention of solutes by sieving through steric 
hindrance, is the essential mechanism in the retention of organic solutes by NF/RO membranes 
(Kunst and Košutić, 2008). To determine the size of molecules, a number of parameters are used 
(molecular weight, molecular diameter, effective molecular size taking into account the 
molecular shape etc.) and while it was proved to not be completely accurate and predictive 
regarding the retention performance (Kunst and Košutić, 2008), the most common parameter 
used to describe the retention behaviour based on size exclusion in commercially available 
membranes is molecular weight cut-off (MWCO), the manufacturer’s rating of the membrane’s 
ability to reject an uncharged molecule based on its weight. Membrane pore size is another 
helpful parameter to estimate retention behaviour based on size exclusion, see e.g. Kimura et al., 
2004 who found a better correlation of the rejection of antibiotics with pore size than with the 
MWCO. 
 
CHARGE REPULSION. Charge repulsion (or charge exclusion) is based on the electric charge of the 
filtration membrane created by the manufacturer by integrating sulfonic, carboxylic or 
ammonium groups into its surface. Depending on pH, the groups dissociate resulting in a 
charged membrane. Typically, commercial membranes are negatively charged under neutral 
conditions (Kunst and Košutić, 2008; Semião and Schäfer, 2010). This results in the retention of 
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charged molecules at the membrane, an effect which is especially important for molecules 
smaller than the membrane pore size (Semião and Schäfer, 2010).  
 
PHYSICOCHEMICAL INTERACTIONS. Physicochemical interactions between membrane material, 
solutes and water molecules, namely solute sorption on and in the membrane, are of importance 
for many substances. These mechanisms are mainly based on hydrophobic nonspecific 
interactions or on hydrogen bonding between solute and membrane, on the solute molecular 
polarity described by its dipole moment and on the equilibrium of ionised and non-ionised 
species of a solute in the water, expressed by the solute dissociation constant value, pKa (Kunst 
and Košutić, 2008).  
 
STATE OF RESEARCH. It is acknowledged that all mechanisms mentioned above, as well as a large 
number of additional parameters, are involved and interact in membrane separation. 
Subsequently, Semião and Schäfer, 2010 stated that the prediction of retention of a certain 
compound is difficult and more investigations of the still not fully understood mechanisms are 
required. Among other topics, the rejection of xenobiotic micropollutants by membranes is of 
special interest and has recently been comprehensively studied. Bellona et al., 2004 developed a 
rejection diagram for micropollutants during membrane treatment (Figure 2-10).  
 
 
Figure 2-10: Rejection of organic micropollutants by membrane treatment (Bellona et al., 2004).  
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NF/RO FILTRATION. Mulder, 1996 defines NF/RO membranes as being intermediate between 
porous and nonporous type barriers. Depending on the description of NF as either homogeneous 
or porous, the theoretical description and modelling of the performance of membranes was 
carried out by various researchers with diverse approaches, e.g. solution-diffusion models, 
surface force–pore flow models (Smith et al., 1969; Chang and Kim, 2005) and hydrodynamic 
approaches (Cho and Fane, 2002). For the transport of charged particles through charged 
membranes (especially narrow pore NF), space-charge models (e.g. Wang et al., 1995; Bowen et 
al., 1997; Combe et al., 1997; Wang et al., 1997) have been applied, while van der Bruggen and 
Vandecasteele, 2002 promoted a porous membrane model to describe the passage of uncharged 
organics through NF membranes. Bowen and Welfoot, 2002 developed a two-parameter model 
based on pore radius and membrane charge for electrolyte rejection. Still, in order to develop 
models which provide a successful prediction of NF/RO membrane filtration behaviour, further 
research is necessary to gain a comprehensive understanding of the factors driving the mass 
transfer of solutes and regulating the retention mechanisms of said solutes (Bellona et al., 2004; 
Kunst and Košutić, 2008).  
 
MEMBRANE PROCESSES. Nonetheless, some basic membrane processes can be described by the 
following governing equations (Radjenović et al., 2008):  
 
The mass balance of solutes is generally given as:  
 
                 
  
  
with Qf being the flow rate of the feed, cf being the solute concentration in the feed, Qp the flow 
rate of the permeate, cp the solute concentration in the permeate, Qc the flow rate of the 
concentrate and cc the solute concentration in the concentrate.  
 
The membrane rejection of solutes (R) is calculated as:  
 
   
     
  
 
 
with cf representing the concentration of solute in the feed and cp the concentration in the 
permeate, respectively.  
 
Chapter 2 
 
page | 64  
The yield (Y, also called recovery or water recovery) is the fraction of feed flow converted to 
permeate:  
 
   
  
  
 
 
with Qp representing the permeate flow and Qf the feed flow. 
 
The permeate flux (J) is determined as the volume of water passing through a unit area of the 
membrane per unit of time, commonly given in [Lm–2 day–1]. J is often normalised to a standard 
temperature. The driving force of J is the transmembrane pressure (TMP or ΔP). The 
membrane permeability (K) as a description of the membrane performance is calculated as 
the permeate flux per unit of TMP and mostly given in [Lm-2 h-1 bar-1]. 
 
The limiting factor of membrane use is so-called membrane fouling which results in the 
increase of TMP or the decrease of permeate flux through the membrane. Though a lot of 
research was aimed at this multi-factorial phenomenon, it is only partly understood at this time 
(Radjenović et al., 2008) and its complexity presents a challenge to mathematical descriptions 
and models (Kunst and Košutić, 2008). 
 
Among the main causes for membrane fouling are: a) the sorption of macromolecular/colloidal 
matter, b) the growth of microorganisms (“biofilms”) on the membrane surface, c) the 
precipitation on the membrane. All these factors become progressively more severe with 
membrane aging.  
 
Fouling is usually described by the resistance (R): 
 
   
  
  
 
 
with η being the permeate viscosity [kg m-1 s-2].  
 
This total filtration resistance can be divided into three parts (Chang and Lee, 1998; Chang et 
al., 1999; Jiang et al., 2003; Chang and Kim, 2005):  
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with Rm being the membrane resistance, Rc being the cake resistance and Rf being the fouling 
resistance. 
 
MEMBRANE FOULING. The complex interactions of membrane fouling are far from being fully 
understood but it is generally agreed that it is caused by suspended particles present in the feed 
that form a cake layer in the membrane surface (cake layer resistance) as well as by soluble 
organic and colloid materials (organic fouling and colloidal fouling) that are responsible for e.g. 
blocking of membrane pores (Radjenović et al., 2008; Simon et al., 2011). Extracellular 
polymeric substances (EPS), produced by microorganisms, play a vital role in membrane fouling 
(Chang and Lee, 1998; Cho and Fane, 2002; Rosenberger et al., 2002). Besides being used as 
protective layers around bacteria cells and in the formation of flocs and microbial aggregates 
they are also present freely dissolved in the water and can block membranes in the form of a 
hydrated gel layer (Radjenović et al., 2008). Fouling changes the physico-chemical properties of 
the membrane surface considerably (e.g. morphology and charge), thus changing the separation 
mechanisms (size exclusion, electrostatic interactions) significantly. Whilst fouling is generally 
seen as a drawback reducing the performance of the fouled membrane, several studies showed 
increased retention of various compounds due to membrane fouling (Kunst and Košutić, 2008; 
Le-Minh et al., 2010; Semião and Schäfer, 2010). However, since fouling shortens the life-span of 
the membrane, therefore requiring shorter maintenance cycles and resulting in higher energy 
costs, it is undesirable in membrane usage.  
 
FOULING CONTROL AND MEMBRANE CLEANING. The fouling rate increases with the flux. To control 
and minimize fouling, the operational flux of membrane systems is normally kept below the 
critical flux which is determined as the highest flux under which a prolonged filtration with 
constant permeability is possible (Radjenović et al., 2008). Another controlling mechanism is the 
suppression of concentration polarisation (the tendency of solutes to accumulate within the 
boundary layer of the membrane surface) by providing a mechanical shear stress over the 
membrane surface by cross-flow velocity or aeration (Radjenović et al., 2008).  
Still, fouling is inevitable even with zero flow (Radjenović et al., 2008). To clean fouled 
membranes, various forms of cleaning are available. Physical cleaning uses back-flushing or 
relaxation of the membrane. It only takes minutes, but it does not remove all adsorbed material 
from the membrane. More effective is chemical membrane cleaning using e.g. sodium 
hypochlorite, sodium hydroxide or acidic solutions (Kunst and Košutić, 2008; Radjenović et al., 
2008). The filtration system down-time required is greater than for physical cleaning. However, 
neither form of cleaning removes fouling completely, and this ultimately determines the life-
span of the membrane.   
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COMMERCIAL IMPLEMENTATIONS AND THE STATE OF AFFAIRS. Today, membrane filtration is 
considered to be a fully developed water treatment technology. In recent years, a number of full-
size treatment plants have been equipped with membrane filtration technology, e.g. the Méry-
sur-Oise water purification plant in Paris, France (potable usage of river water and secondary 
effluent; maximum daily production: 340,000 m3; treatment with MF followed by NF) or 
NEWater facilities in Singapore (water reclamation from secondary effluent of CAS treatment by 
MF and followed by RO: 75,000 m3/day) (Semião and Schäfer, 2010).  
 
 
2.2.4 MEMBRANE BIOREACTORS (MBR) 
INTRODUCTION. The idea of membrane bioreactors (MBR) as a combination of the activated 
sludge process (see 3.2.2) and membrane separation (see 3.2.3) was introduced as long ago as 
the 1960s and 1970s (Smith et al., 1969; Sammon, 1974). The early use of MBRs was mainly in 
the treatment of industrial wastewater, to enhance the quality of final effluent water by tertiary 
treatment with MBR (Radjenović et al., 2008). At the end of the 1980s, MBRs with submerged 
membranes were developed, where vacuum-driven membranes are directly immersed into the 
bioreactor (Yamamoto et al., 1989). This led to a significant drop in energy costs and 
subsequently to a rapid increase in both the overall use of MBRs and their implementation in the 
treatment of municipal wastewater. Judd and Judd, 2006 described a doubling of the global MBR 
market between 2000 and 2005 to a value of over $215 million in 2005. With wider use, 
followed by decreasing production costs (Fatone, 2010) and the availability of different technical 
variations, MBRs have developed into an alternative secondary treatment technology, mainly 
applying ultrafiltration or microfiltration (Radjenović et al., 2008).  
 
ADVANTAGES AND DRAWBACKS. In MBRs, the solid-liquid separation of activated sludge and water 
purely by gravity in the secondary clarifiers employed in CAS treatment is replaced by filtration, 
thus providing complete sludge retention. Furthermore, depending on the chosen membrane, 
complete disinfection of the effluent can be achieved (EPA, 2008b).  
Since sludge settling characteristics are of less importance, MBR systems can be operated at 
considerably prolonged SRTs where biomass growth is not restricted to fast-growing and floc-
forming microorganisms but where the development of specialised organisms and dispersed 
bacteria is possible (Radjenović et al., 2009b). Additionally, MBRs can be operated with higher 
sludge concentrations (typically up to 20 g/L instead of max. 6 g/L in conventional systems) 
which leads to a considerable reduction in required footprint, reactor volume and production of 
excess sludge (Cornel and Krause, 2006; Radjenović et al., 2009b). Drawbacks of the technique 
are higher total life costs, mainly due to high energy costs.   
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CONFIGURATIONS. MBRs are constructed either in side-stream configuration (Figure 2-11) or 
with submerged membranes (Figure 2-12). In side-stream the membrane separation is 
pressure-driven and carried out in an external sludge recirculation loop, primarily by in-to-out 
flow through tubular membranes (Lesjean and Judd, 2007). Aeration of the bioreactor is carried 
out by fine bubble aerators. The necessary shear over the membrane to prevent fouling is 
provided by pumping (Radjenović et al., 2008). With the development of submerged MBRs, side-
stream reactors lost importance. Today, they are mainly applied in industrial contexts and for 
the treatment of landfill leachates (Radjenović et al., 2008).  
 
SUBMERGED MEMBRANES. Submerged MBRs became known in the 1990s (Lesjean and Judd, 
2007). Here, the filtration module is immersed directly in the bioreactor. Turbulent cross-flow 
aeration is supplied both to scour the membrane and to provide oxygen for the biomass 
(Radjenović et al., 2008). For the filtration process, low negative pressure (out-to-in permeate 
suction) is applied (Lesjean and Judd, 2007; Kunst and Košutić, 2008; Radjenović et al., 2008).  
Without the energy-eating sludge recirculation loop, submerged MBRs are less energy 
demanding than side-stream MBRs. Additionally, in MBRs with submerged membranes, both 
permeate flux and trans-membrane pressure (TMP) are considerably lower than in side-stream 
configuration, leading to significantly lower costs for cleaning and maintenance. Even with the 
additional aeration, the energy costs for submerged MBRs are considered to be two magnitudes 
lower than for side-stream MBRs (Radjenović et al., 2008). Thus, submerged MBRs are the 
leading configuration nowadays.  
Because the membranes are in direct contact with the activated sludge, the problem of fouling is 
very prominent in MBR systems. As well as the fouling preventions already mentioned (flux 
reduction or cleaning (physical/chemical) of the membrane), in submerged MBRs increasing the 
crossflow is a third possibility (Cornel and Krause, 2006). The energy demand for oxygen supply 
in a submerged MBR is calculated to be approximately 0.3 kWh/m3 for the treatment of 
municipal wastewater, while the pumping energy for fouling prevention by coarse bubble 
aeration accounts for around 0.4 – 1 kWh/m3 (Cornel and Krause, 2006).  
 
SOLID RETENTION TIME (SRT). In MBR microbial communities, new activated sludge is 
continuously generated while at the same time parts of the sludge are decomposed by so-called 
endogenous respiration, which describes all forms of biomass loss and loss of energy for 
requirements that are not involved in growth (Radjenović et al., 2008). As the energy available 
for these processes stems from the substrate in the feed water, with long SRT (which results in 
increased biomass concentration), the limited nutrient supply ultimately limits the growth of 
new biomass. A higher biomass concentration reduces the food-to-microorganism ratio (F/M), 
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leading to a decrease in excess sludge production (Yamamoto et al., 1989; Muller et al., 1995; 
Stephenson et al., 2000). On the other hand, with higher concentration of activated sludge 
(mixed-liquor suspended solids, MLSS) the viscosity of the sludge increases, resulting in reduced 
oxygen transfers (Cornel and Krause, 2006), which demands greater amounts of aeration. 
Additionally, long SRTs can lead to the accumulation of inorganic and non-biodegradable 
compounds in the reactor which could lead to toxic effects. Furthermore, in sludge of greater age 
the enzymatic activity is lower, while cell dormancy and death reduce the viability of the 
biomass population (Cicek et al., 2001). Thus, at short SRTs, the adaptation and response of the 
microbial community to xenobiotic exposure should be faster (Cicek et al., 2001), which partly 
contradicts findings that long SRTs lead to a better adapted community. Long SRTs are one of 
the major advantages of MBR, with the MLSS concentrations in MBR (10–25 g MLSS/L) being 
much higher than in CAS (1.5–5 mg MLSS/L) (Rosenberger et al., 2000; Cicek et al., 2001). The 
control of sludge growth can be achieved not only by nutrition supply, but also by artificial 
sludge decay through e.g. chemical agents or heat. The dead biomass then acts as a nutrient 
supply for the active sludge. Additionally, temperature and pH affect biomass growth. 
Temperatures between 15 and 25 C have been found to be optimal for sludge growth, while 
reduced treatment efficiency was reported at lower temperatures (Marsili-Libelli and Tabani, 
2002).  
 
COMMERCIAL IMPLEMENTATIONS AND THE STATE OF AFFAIRS OF MBRS. At present, microbial and 
physiological characteristics are in many aspects not fully understood (Radjenović et al., 2008). 
Recent studies show somewhat contradicting results about the optimal operation of MBRs, 
revealing the high need for further research and a larger data base. Still, the technology has 
shown its feasibility for not only industrial but also municipal application. In recent years, 
submerged MBR treatment systems have been installed in a rapidly rising number of municipal 
wastewater treatment plants. In Europe, the first pilot-scale submerged MBR for municipal 
wastewater treatment was built in 1996 in Kingston Seymour (UK), soon followed by full-scale 
plants in Porlock (UK) in 1998 (3,800 p.e.), Büchel (Germany, 1999, 1,000 p.e.), Rödingen 
(Germany, 1999, 3000 p.e.) and Perthes-en-Gâtinais (France, 1999, 4,500 p.e.). In 2004, the 
largest MBR plant worldwide at the time was commissioned in Kaarst (Germany, 80,000 p.e.). In 
Europe in 2006, around 100 full-scale plants with a capacity of more than 500 p.e. were used in 
the treatment of municipal wastewater, complemented by approximately 300 large industrial 
plants (capacity > 20 m3/d) (Lesjean and Judd, 2007). Due to the spread of MBR use, the 
technology became increasingly competitive regarding capital and operating costs and in the 
municipal sector it is considered a comparable technology to CAS. Still, the energy costs are 
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estimated to be 30% higher with MBR than CAS, preventing MBR from becoming the process of 
choice for municipal wastewater treatment (Lesjean and Judd, 2007).  
 
 
Figure 2-11: MBR in side-stream configuration with external pressure-driven membrane filtration 
module. 
 
 
 
 
Figure 2-12: MBR with submerged, vacuum-driven filtration membrane.  
Chapter 2 
 
page | 70  
2.3 LEGAL ASPECTS, REGULATORY DIRECTIVES, TOOLS AND GUIDELINES 
Substances of environmental or toxicological concern may be subject to various legal regulations 
at different stages of their life cycle, such as the regulation of their production and marketing on 
one side and, on the other, the control of their disposal and their fate in the environment after 
consumption.  
 
PHARMACEUTICALS. In general, in the EU, the USA and other industrial countries, the acute and 
chronic toxicological potential of pharmaceuticals in animals and humans are reviewed before 
their release onto the market, e.g. in the EU by the Directive 2001/82/EC (relating to veterinary 
medicinal products), the Directive 2001/83/EC (relating to medical products for human use) 
and the amending Directive 2004/27/EC. Consequently, only substances newly introduced to 
the market are investigated whereas older ones are not examined.  
Regarding their occurrence in wastewater and environmental water bodies, pharmaceuticals are 
rarely considered by national or international bodies of law at all. Thus, to date, they are not 
targeted by European law, but the awareness of their importance as a possible environmental 
risk is growing. After two decades of intensive scientific effort, concerns about the widespread 
presence of pharmaceutically active compounds and their transformation products in water 
resources are starting to take hold in legislation. In 2011, the EU commission launched a 
proposal for an amendment to the Directives 2000/60/EC (EU Water Framework Directive) and 
2008/105/EC (Directive on environmental quality standards in the field of water policy) with 
regard to priority substances in the field of water policy (European Commission, 2012b), in 
which three pharmaceutical substances (diclofenac, 17-alpha-ethinylestradiol and 17-beta-
estradiol) were introduced as possible priority substances for the first time. While the two 
hormones are considered because of their endocrine potential, diclofenac is listed among the 
potential additional substances because of its direct and indirect toxicity to vertebrates, as 
proved in scientific studies (European Commission, 2012a). Legislation on maritime water 
bodies like the Directive 2008/56/EG (maritime strategy framework directive (MSFD); 
European Commission, 2008) and the HELCOM project “Development of HELCOM Core Set 
indicators (HELCOM CORESET)” (HELCOM, 2010) are considering the inclusion of 
pharmaceuticals in routine monitoring programs, while the OSPAR Commission has already 
identified a few pharmaceuticals as “substances for priority action” (OSPAR, 2011) and a wider 
range as “substances of possible concern” (OSPAR). In a unique national effort, Sweden 
developed an environmental classification of pharmaceuticals which is available online 
(www.fass.se) which characterises pharmaceuticals according to the potential environmental 
risk and hazard they pose, on the basis of PEC/PNEC ratios (environmental risk) and their 
biodegradation and bioaccumulation (environmental hazard).   
Chapter 2 
 
page | 71  
ANTIBIOTICS. Despite the fact that by the early 1970s antibiotic resistance was clearly identified 
as a risk (WHO, 2011a) and in 1984 the World Health Assembly issued a resolution demanding a 
rational use of pharmaceuticals (WHO, 1984), antibiotics in the aquatic environment have not 
been taken into legislative account. In 2001, the WHO published a global strategy for the 
containment of antimicrobial resistance (WHO, 2001) focusing on efforts in surveillance, 
prevention and control of resistance, followed by a resolution demanding the enhancement of 
efforts in 2005 (WHO, 2005b). Yet the consumption rate of antibiotics is still rising, with no sign 
of more reasonable use (Schwabe and Paffrath, 2007). In light of the fact that in the last 30 years 
only two new antibacterial classes have been released onto the market, both of them targeting 
Gram-positive bacteria (WHO, 2011a), the European Centre for Disease Prevention and Control 
(ECDC) recently reported the severe gap in the development of new drugs against multi-drug-
resistant bacteria. In the few cases where research is under way, the development is in its early 
stages and rarely targets Gram-negative bacteria (ECDC, 2009). Preventing the failure of existing 
antibiotics is, therefore, a major issue in WHO efforts (WHO, 1998b; WHO, 2001; WHO, 2005b; 
WHO, 2011a) which to date is not mirrored in legislative tools or guidelines. They neither 
encourage the reduction of the application of antibiotics in human and veterinary medicine nor 
prevent their entrance into the (aquatic) environment.  
 
ORGANOPHOSPHATE ESTERS. Being high production volume (HPV) compounds, organophosphate 
esters had to be registered under the EU REACH procedure before the first deadline of 1st 
December 2010 (registration of substances with production or import amounts of more than 
1,000 t per year in the EU). Comprehensive ecotoxicological information is currently not 
available for most compounds; however, the aquatic toxicity of some OPs is seen as being 
unlikely (e.g. tris(2-ethylhexyl) which is in contradiction to scientific opinion (DiGangi et al., 
2010). 
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3. OCCURRENCE OF XENOBIOTIC ORGANIC MICROPOLLUTANTS IN 
RAW MUNICIPAL WASTEWATER AND THEIR REMOVAL BY A 
MEMBRANE BIOREACTOR EQUIPPED WITH NANOFILTRATION (NF-
MBR) 
 
{Water is} the one substance from which the earth can conceal nothing; it sucks out its 
innermost secrets and brings them to our very lips. 
– Jean Giraudoux (1882-1944), The Madwomen of Chaillot, 1946 – 
 
 
3.1 INTRODUCTION 
Xenobiotics such as pharmaceuticals and industrial chemicals have been detected in raw and 
treated wastewater, surface water, and ground water (see Chapter 2.1) since they are not 
effectively removed by conventional biological wastewater treatment with activated sludge 
(CAS, see Chapter 2.2.1).  
 
MEMBRANE BIOREACTORS. Advanced treatment technologies are discussed with regard to their 
removal capacities for xenobiotic micropollutants. Membrane bioreactors (MBRs) combine 
activated sludge treatment with liquid-solid separation by membrane filtration (for a detailed 
description of the characteristics and underlying principles, see Chapter 2.2.4). A major 
advantage of MBR systems with regard to xenobiotic micropollutants is that they produce no 
artificial transformation products, in contrast to other advanced treatment techniques such as 
oxidation (Semião and Schäfer, 2010). MBRs utilised for wastewater treatment are usually 
equipped with microfiltration (MF, separation 100–1,000 nm) or ultrafiltration (UF, separation 
5–100 nm) membranes (Radjenović et al., 2008). Such MBRs showed enhanced removal rates 
for a range of micropollutants compared to CAS, while for others no improved elimination was 
found (Kimura et al., 2005; Bernhard et al., 2006; Radjenović et al., 2007; Reif et al., 2008; Bo et 
al., 2009; Tambosi et al., 2010). With increasing demand for high quality effluents in terms of 
xenobiotics, nanofiltration (NF, separation 1–5 nm) could possibly become a membrane 
filtration technique of choice in MBR technology. However, tight NF membranes with 
characteristics bordering on those of reverse osmosis (0.1–1 nm, Radjenović et al., 2008) are 
difficult to maintain permanently in the complex, heavily matrix-loaded environment of a MBR 
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operating in raw wastewater. A workable solution could be the use of a loose NF treatment, 
which would be closer to ultrafiltration and e.g. characterised by low salt retention (Nghiem et 
al., 2006), in combination with MBR treatment. 
 
SCOPE OF THE STUDY. In this study, the occurrence of 52 xenobiotics – pharmaceuticals, 
metabolites, transformation products and OPs – in raw wastewater was investigated over the 
course of one week, including both weekdays and the weekend. The fate of these 
micropollutants during wastewater treatment by a NF-MBR pilot plant equipped with a loose NF 
and situated at the influent of a municipal WWTP (population equivalent: 300,000) was 
investigated by analysing hydraulic retention time-related daily samples of influent and effluent. 
Furthermore, these results were compared to the elimination performance of pure NF-treatment 
without biological treatment.  
 
3.2 MATERIALS AND METHODS  
3.2.1 REFERENCE COMPOUNDS, CHEMICALS AND STANDARDS 
The following compounds (all analytical grade > 98% purity) were analysed:  
roxithromycin (ROX), carbamazepine (CBZ), oxazepam (OZP), temazepam (TZP), oxycodone 
(OCN), doxepin (DXP), primidone (PMD), diazepam (DZP), nordiazepam (NZP), methadone 
(MTD), sulfamerazine (SMA), sulfisoxazole (SSX), sulfadimidine (SDI), sulfadimethoxine (SMI), 
sulfamethoxazole (SMX), trimethoprim (TMP), tri-iso-butyl phosphate (TiBP) (all provided by 
Sigma-Aldrich, Seelze, Germany); clarithromycin (CLA), diatrizoic acid (DTZ), iopromide (IMI) 
(provided by LGC Promochem Wesel, Germany); bezafibrate (BZF) diclofenac (DCF), ibuprofen 
(IBP), naproxen (NPX), tiamulin (TAM), tributyl phosphate (TnBP), tris(2-butoxyethyl) 
phosphate (TBEP), triphenyl phosphate (TPP), tris(1,3-dichloro-2-propyl) phosphate (TDCPP), 
tris(2-chloroethyl) phosphate (TCEP), tris(2-ethylhexyl) phosphate (TEHP), tris(chloropropyl) 
phosphate (TCPP) (all purchased from Dr. Ehrenstorfer, Augsburg, Germany); iopamidol (IPM), 
iomeprol (IOP) (Bayer-Schering Pharma, Berlin, Germany); codeine (CDN), dihydrocodeine 
(DHC, Th. Geyer, Renningen, Germany); 10,11-dihydrocarbamazepine (DH-CBZ) (Alltech, USA); 
10,11-Dihydro-10,11-dihydroxycarbamazepine (DHH) (µ-Mol, Luckenwalde, Germany); 
morphine (MPN, Cambridge Isotopes Lab., Saarbrücken, Germany); N4-acetylsulfamethoxazole 
(N-Ac-SMX, EAWAG self-synthesis, Dübendorf, Switzerland); iopromide TP 805 A (IMI-TP 805 
A), iopromide TP 805 B (IMI-TP 805 B), iopromide TP 819 (IMI-TP 819), iopromide TP 729 A 
(IMI-TP 729 A), iopromide TP 817 A (IMI-TP 817 A), iopromide TP 787 A (IMI-TP 787 A), 
iopromide TP 731 A (IMI-TP 731 A), iopromide TP 731 B (IMI-TP 731 B), iopromide TP 759 
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(IMI-TP 759), iopromide TP 701 B (IMI-TP 701 B), iopromide TP 701 A (IMI-TP 701 A), 
iopromide TP 643 (IMI-TP 643) were laboratory-prepared as described by Kormos et al., 2009. 
The internal standards (IS, analytical grade > 98% purity) were purchased from the following 
suppliers: codeine-d6, diazepam-d5, methadone-d9, morphine-d6, nordiazepam-d5, 
tributylphosphate-d27 (Cambridge Isotopes Lab., Saarbrücken, Germany); oxazepam-d5 (Sigma, 
Deisenhofen, Germany); 13C-15N-carbamazepine, diatrizoic acid-d6 , diclofenac-d4, ibuprofen-
d3, iomeprol-d3, iopamidol-d8 (Campro Scientific, Berlin, Germany); bezafibrate-d4, 
sulfadimethoxine-d4, sulfadimidine-d4, sulfamerazine-d4, sulfamethoxazole-d4, and N4-
acetylsulfamethoxazole-d4 (Toronto Research Chemicals, North York, ON, Canada); desmethoxy-
iopromide (DMI) (Bayer-Schering Pharma, Berlin, Germany); (E)-9-[O-(2-methyloxime)]-
erythromycin (EM-ERY) was self-synthesised according to Schlüsener et al., 2003; 
triphenylphosphate-d15 (TPP-d15) was self-synthesised according to Andresen et al., 2004.  
All organic solvents (n-heptane, n-hexane, acetone, methanol, acetonitrile, ethyl acetate) were 
picograde and purchased from Merck (Darmstadt, Germany). Pure water was obtained from a 
Milli-Q system (Integral 3/5/10/15, Millipore, Billericis, MA, USA). Formic acid (98–100%) was 
ACS grade and purchased from Merck (Darmstadt, Germany).  
For each analytical compound group (antibiotics, psycho-active drugs and organophosphorus 
compounds) a standard solution of all target analytes and an internal standard mix at a 
concentration of 10 µg/mL (OPs: 5 µg/mL) and 1 µg/mL respectively were prepared in 
methanol and stored in the dark at 4 °C.  
 
 
3.2.2 THE NF-MBR PILOT PLANT 
The NF-MBR pilot plant (Weise Water System GmbH & Co. KG (WWS), Giessen, Germany; Figure 
3-1) was installed at the influent of a municipal WWTP, with a population equivalent (p.e.) of 
300,000. It consisted of two tanks (total volume: 1.34 m3) of which the first was an anaerobic 
denitrification tank while the second tank holding the submerged nanofiltration module was 
aerobic. Aeration was continuous. Two submerged polyethersulfone NF modules of flat sheet 
design were used for filtration, each of 7 m2 (NAPIR NP010, Microdyn-Nadir, Wiesbaden, 
Germany, polyethersulfone, nominal retention Na2SO4: 35–75% (40 bar); nominal retention 
NaCl: 10% (40 bar), water flux: > 200 L/(m2*h)). Wastewater from the effluent of the primary 
clarifier was fed into the MBR discontinuously at intervals of < 20 min, with filling levels 
automatically controlled by sensors. The biocenosis of the MBR was developed from return 
activated sludge from the WWTP. The MBR was allowed to reach stable biological conditions for 
158 days before the start of the sampling campaign, with the NF membranes being changed 86 
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days prior to the sampling campaign. Sludge concentration (SC, MLSS) was 7.2 g/L and 13.4 g/L 
in the denitrification tank and the NF module respectively. The solid retention time (SRT) was 
infinite since no sludge was discharged from the reactor, and the average hydraulic retention 
time (HRT) was 44.4 h. Permeation was intermittent, in response to the water volume pumped 
into the system. The average transmembrane pressure (TMP) was 0.7 (± 0.01) bar, the average 
permeate flux (J) was 26.2 (± 3.4) L/(m x day). The average membrane permeability (K) was 1.6 
(± 0.2) L m-2 h-1 bar-1. The average pH values over the period of the sampling campaign were 7.8 
(± 0.15), 7.9 (± 0.06) and 7.8 (± 0.12) for influent, permeate and concentrate respectively. The 
amount of dissolved oxygen was 0.21 mg/L and 9.9 mg/L for the denitrification tank and the NF 
module respectively. The mean liquid temperature was 12.3 °C in the denitrification tank and 
11.8 °C in the NF tank. The sampling campaign was carried out during a period of dry weather 
with an average maximum air temperature of 11.5 °C and an average minimum air temperature 
of 2.9 °C (Figure 3-2).  
 
 
3.2.3 THE NF PILOT INSTALLATION (BENCH-SCALE)  
The bench-scale NF pilot system consisted of a 55 L HDPE tank, which was filled with 40 L of 
water from the WWTP influent (the feed water of the MBR). The tank’s inner surface was 
allowed to saturate before the installation of a submerged NF module of flat sheet design 
(NAPIR NP010, Microdyn-Nadir, Wiesbaden, Germany, polyethersulfone, 3.5 m² membrane 
surface; nominal retention Na2SO4: 35–75% (40 bar); nominal retention NaCl: 10% (40 bar), 
Water flux: > 200 [l/(m2h)]). The system was pre-conditioned with an intermitted flow (15 min 
duration every 15-75 min) for five days. Feed water in the tank was replenished daily. The 
surrounding room temperature was kept at 20 °C. Sampling of feed water from the tank and 
permeate was carried out on day five. Sampling procedure, preparation and analytical 
procedures followed the same protocols as described for MBR samples (see below).  
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Figure 3-1: NF-MBR pilot plant at the influent of a municipal WWTP. 
 
 
Figure 3-2: Meteorologic conditions during the sampling campaign (data: Deutscher Wetterdienst (DWD), 
Germany's National Meteorological Service)  
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3.2.4 SAMPLING AND SAMPLE PREPARATION  
Samples of influent and permeate from the MBR were continuously collected as 24-h-composite 
samples by a peristaltic pump over the course of ten days. Since permeate samples were taken 
with a delay of two days to match them with the corresponding influent samples according to 
the HRT, the sampling period represents an actual time series of eight days. Grab samples of the 
concentrate with mixed-liquor suspended solids were collected three times during the study. All 
samples were taken in clean glass bottles rinsed with ultra pure water, heptane and acetone and 
subsequently heated overnight at > 240 °C. Samples were kept in the dark and transported on 
ice. Extraction was carried out within six hours of sampling.  
Regarding acidic compounds and ICMs, the influence of direct acidification during sampling (by 
providing acid in the sampling bottles beforehand) and acidification in the laboratory after 
sampling before extraction was investigated (data not shown). For the majority of analytes, the 
different procedures yielded results which differed only slightly (< 10%), with no clear 
preference for one method, so subsequently samples were acidified after collection.  
The liquid phase of the concentrate was separated from the MLSS by centrifugation directly after 
arrival at the laboratory. Samples were centrifuged for 60 min with 3500 r/min in a 
temperature-controlled centrifuge (Rotanta 460R, Hettich Lab Technology, Tuttlingen, 
Germany).  
Samples of influent and supernatant of the concentrate were passed through binder-free glass 
fibre filters (MN 85/70 BF, Machery-Nagel, Düren, Germany; average retention capacity: 0.6 µm; 
diameter: 55 mm) which were conditioned prior to filtration by sequentially soaking them in 
heptane, acetone and methanol for 15 min each, rinsing with Milli-Q water twice and storing in 
Milli-Q water overnight before use.  
Before extraction, samples were separated into aliquots for the determination of neutral 
analytes and the analysis of acidic drugs, bezafibrate and ICMs. The latter aliquots were acidified 
with H2SO4 to a pH of 2.3–2.8, while the native samples of the first aliquot were controlled to 
have a pH of 7–8. All samples were augmented with internal standards before SPE (see below).  
 
3.2.5 ANALYTICAL PROCEDURES  
The analytical protocols used in this study followed in large parts procedures previously 
described by Hirsch et al., 2000, Hummel et al., 2006, Magdeburg et al., 2014 (antibiotics, acidic 
compounds: NSAIDs and bezafibrate, psycho-active compounds, ICMs), Schulz et al., 2008 and 
Kormos et al., 2009 (TP of iopromide).  
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3.2.5.1 SOLID PHASE EXTRACTION AND CLEAN-UP 
NEUTRAL ANALYTES: ANTIBIOTICS, PSYCHO-ACTIVE COMPOUNDS, OPS. Neutral analytes were 
extracted with Oasis HLB cartridges (500 mg, 6 mL, Waters, Milfort, U.S.). Prior to extraction, the 
cartridges were conditioned with 1 x 5 mL heptane, 1 x 5 mL acetone, 2 x 5 mL methanol and 
3 x5 mL Milli-Q water (Figure 3-3). Samples were passed through the cartridges with a flow rate 
of approximately 5 mL/min. Following SPE, the HLB material was dried completely under a 
steady nitrogen stream for approximately 60–90 min. Elution was accomplished with 5 x 2 mL 
acetone. Extracts were evaporated to approximately 100 µL by a gentle nitrogen stream before 
the vials were rinsed with 300 µL of methanol, followed by a second reduction to 100 µL and a 
final addition of 400 µL Milli-Q water resulting in a final sample volume of 500 µL. Samples were 
kept at 4 °C in the dark until LC-MS/MS analysis. 
 
ACIDIC ANALYTES: NSAIDS AND BEZAFIBRATE. For the extraction of acidic compounds, Oasis MCX 
cartridges (500 mg, 6 mL, Waters, Milfort, U.S.) were used. The procedure was in principle as 
described above except for the final dilution, which was carried out with formic acid (Figure 3-
3). 
 
ICMS AND TP. ICMs and their TP were extracted with Isolute ENV+ cartridges (200 mg; 3 mL, 
Biotage, Uppsala, Sweden) following the scheme depicted in Figure 3-3.  
 
Since the SPE procedure for ICMs is highly sensitive to matrix material in the water sample, after 
conditioning the MCX cartridges were mounted on top of the ENV+ cartridges and the water 
extraction was performed in one step to shield the ENV+ cartridges from matrix material (Figure 
3-4). 
 
3.2.5.2  LC-MS/MS-ANALYSIS 
For chromatographic separation, an Agilent 1200 Series (Agilent Technologies, Waldbronn, 
Germany) liquid chromatographic system equipped with membrane degasser, binary high-
pressure gradient pump, autosampler and column thermostat was used. The detection was 
carried out on a tandem mass spectrometer (Applied Biosystems/MDS Sciex 4000 Q Trap Qq-
LIT-MS; Applied Biosystems, Langen, Germany) using multiple reaction monitoring (MRM). For 
the analysis, electrospray ionization (ESI) was used except for organophosphorus compounds, 
which were analysed by atmospheric pressure chemical ionization (APCI). The specific modes 
are detailed below. For each target compound two MRM transitions were monitored for 
quantification (transition 1) and confirmation (transition 2). Instrument control, peak detection 
and integration and quantification were carried out using Analyst 1.4 software.   
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Antibiotics, psycho-active 
compounds, OPs 
 NSAIDs and bezafibrate  ICMs 
 
Figure 3-3: Overview of the SPE procedures for antibiotics, psycho-active compounds, OPs (left), NSAIDs 
and lipid regulators (middle) and ICMs (right). 
ACIDIC ANALYTES: NSAIDS AND BEZAFIBRATE. Chromatography was performed with a Zorbax 
Eclipse XDB-C8 (150 x 4.6 mm; 5 µm) equipped with a Zorbax XDB-C8 guard column 
(4.6 x 12.5 mm, 5 µm, both purchased from Agilent Technologies (Waldbronn, Germany). The 
solvents used were acetonitrile (A) and 10 mM formic acid (B). Separation started with 60% A 
changing to 5% A within 6 min, was kept isocratic for 8 min before it was returned to the 
starting conditions within 1 min and was held isocratic for the final 5 min of the 
chromatographic run. Flow rate was set to 400 µL/min, injection volume was 15 µL. Mass 
spectrometry was carried out with ESI in negative mode with the following conditions: CAD: 
5 psi; curtain gas: 30 psi; ion source gas 1: 45 psi; ion source gas 2: 50 psi; source temperature: 
650 °C, entrance potential (EP): -10 V. Other parameters are shown in Table 3-1.  
 
ANTIBIOTICS. Chromatography was carried out with a Chromolith Performance RP-18e column 
(100 x 4.6 mm, 130 Å, 2 µm) preceded by a Chromolith RP-18e (5 x 4.6mm) guard column, both 
supplied by Merck, Darmstadt, Germany. Mobile phase A consisted of a 10 mM ammonium 
formiate buffer adjusted to pH 4 with formic acid. Acetonitrile served as mobile phase B.  
LC-MS/MS-analysis
Addition of 400 µL 0.01 M formic acid
Volume reduction to 100 µL
Rinsing of the glass vial 
with 500 µL MeOH
Volume reduction 
with nitrogen to 100 µL
Elution with 5 x 2 mL acetone 
into 10 mL glass vial
Drying of the cartridges with nitrogen 
(60 – 90 min) 
Percolation of sample through cartridge
(flux approx. 5 mL/min)    
Conditioning of  Oasis MCX cartridge (500 mg; 
6 mL ): 1 x 5 mL heptane, 1 x 5 mL acetone, 2 x 
5 mL MeOH, 3 x 5 mL Milli-Q water (pH 2) 
LC-MS/MS-analysis
Reconstitution with 500 µL phosphate buffer  
(0.02 mol/L Na2HPO4 , 
0.02 mol/L KH2PO4; 5:4 (v/v), pH 7.2)
Evaporation to dryness with nitrogen 
Elution with 5 x 2 mL MeOH
Drying of the cartridges with nitrogen 
(60 – 90 min) 
Percolation of sample through cartridge
(flux approx. 5 mL/min)    
Conditioning of ISOLUTE ENV+ cartridge (200 
mg; 3 mL): 1 x 5 mL heptane, 1 x 5 mL acetone, 
2 x 5 mL MeOH, 3 x 5 mL Milli-Q water (pH 2) 
LC-MS/MS-analysis
Addition of 400 µL Milli-Q water
Volume reduction to 100 µL
Rinsing of the glass vial 
with 500 µL MeOH
Volume reduction
with nitrogen to 100 µL
Elution with 5 x 2 mL acetone 
into 10 mL glass vial
Drying of the cartridges with nitrogen 
(60 – 90 min) 
Percolation of sample through cartridge
(flux approx. 5 mL/min)    
Conditioning of Oasis HLB cartridge (500 mg; 
6 mL ): 1 x 5 mL heptane, 1 x 5 mL acetone, 2 x 
5 mL MeOH and 3 x 5 mL Milli-Q water 
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Table 3-1: Target compounds and the corresponding ESI-MS/MS parameters for the analysis of acidic 
analytes (RT: retention time; DP: declustering potential; CE: collision energy; CXP: collision cell exit 
potential). 
Compound 
CAS  
No. 
RT 
[min] 
Transition 
11 (T1) 
[m/z] 
Transition 
21 (T2) 
[m/z] 
Dwell 
time 
[msec] 
DP 
 [V] 
CE  
[V] 
CXP 
(T1/T2) 
[V] 
related 
IS 
DCF 
15307-
86-5 
10.8 
293.85/ 
249.9 
293.85/ 
213.90 
50 -50 -10 -10/-26 DCF-d4 
IBP 
15687-
27-1 
11.2 
204.85/ 
160.90 
204.85/ 
158.80 
50 -30 -10 -10/-6 IBP-d3 
NPX 
22204-
53-1 
9.5 
228.82/ 
184.70 
228.82/ 
169.90 
50 -30 -10 -8/ -20 IBP-d3 
BZF 
41859-
67-0 
9.4 
359.89/ 
273.80 
359.89/ 
153.90 
50 -65 -10 -22/ -36 IBP-d4 
IS 
IBP-d3 
121662-
14-4 
11.2 
208.01/ 
164.00 
50 -55 -10 -10 
 
DCF-d4 
153466-
65-0 
10.8 
298.91/ 
254.88 
50 -50 -10 -16 
 
BZF-d4 
1189452
-53-6 
9.3 
364.89/ 
158.00 
50 -65 -10 -38 
 
 
 
 
Figure 3-4: SPE installation for acidic analytes and ICMs. 
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Chromatography started with 0% B, held for 10 min, followed by an increase of B to 26% in 
5 min, further increase to 38% within 2 min and held isocratic for 6 min before increasing B to 
100% within 6 min, holding isocratic for 4 min before returning to initial conditions within 
2 min which were held for 4 min. The flow rate was 400 µL/min. Injection volume was 5 µL; the 
temperature of the column oven was set to 25 °C.  
Electrospray ionization (ESI) was executed in positive mode. Conditions for ESI were set as 
followed: collision gas: 5 psi; curtain gas: 35 psi; ion source gas 1: 45 psi; ion source gas 2: 
40 psi; source temperature: 650 °C; entrance potential: 10 V; ionspray voltage: 5.5 kV. Further 
details of the MS/MS analysis are listed in Table 3-2. 
Table 3-2: Target compounds and the corresponding ESI-MS/MS parameters for the analysis of antibiotics 
(RT: retention time; DP: declustering potential; CE: collision energy; CXP: collision cell exit potential). 
Compound 
CAS 
No. 
RT 
[min] 
Transition 
11 (T1) 
[m/z] 
Transition 
21 (T2)  
[m/z] 
Dwell 
time 
[msec] 
DP  
[V] 
CE 
(T1/T2) 
[V] 
CXP 
(T1/T2) 
[V] 
related 
IS 
Macrolide antibiotics 
CLA 
81103-
11-9 
26.5 
748.4/ 
158.1 
748.4/ 
590.3 
25 86 39/27 14/12 EM-ERY 
ROX 
80214-
83-1 
26.9 
837.5/ 
158.1 
837.5/ 
679.2 
25 106 47/29 12/26 EM-ERY 
Sulfonamides 
SMX 
723-46-
6 
23.7 
253.94/ 
155.8 
253.94/ 
188 
25 66 23/21 12/14 SMX-d4 
N-Ac-SMX 
21312-
10-7 
23.7 
296.06/ 
134.0 
296.06/ 
197.9 
25 81 35/25 12/14 
N-Ac-
SMX-d4 
SMI 
122-11-
2 
24.9 
310.96/ 
156 
310.96/ 
245 
25 71 29/27 12/8 SMI-d4 
SSX 
127-69-
5 
23.7 
268.0/ 
156.0 
268.0/ 
113.0 
25 66 21/23 4/10 SMX-d4 
SMA 
127-79-
7 
21.7 
265.0/ 
155.9 
265.0/ 
171.9 
25 56 25/23 14/12 SMA-d4 
SDI 57-68-1 22.3 
279.0/ 
185.9 
279.0/ 
124.0 
25 71 25/33 16/10 SMA-d4 
 
 23.7 
296.1/ 
134.0 
296.1/ 
197.9 
25 81 35/25 12/14 
N-Ac-
SMX-d4 
Other antibiotics 
TAM 
55297-
95-5 
26.3 
494.2/ 
192.1 
494.2/ 
118.9 
25 81 31/55 6/10 EM-ERY 
TMP 
738-70-
5 
21.1 
291.0/ 
229.9 
291.0/ 
261.0 
25 86 33/35 8/10 EM-ERY 
EM-ERY  27.3 
763.5/ 
605.5 
25 86 27/-- 28/--  
SMX-d4 1020719
-86-1 
23.7 
258.0/ 
160.0 
25 66 23/-- 12/--  
N-Ac-SMX-d4 
21312-
10-7 
23.7 
301.1/ 
202.7 
25 81 27/-- 18/--  
SMA-d4 --- 21.6 
267.0/ 
160.0 
25 66 25/-- 12/--  
SDI-d4 
1020719
-82-7 
22.2 
282.9/ 
186.0 
25 71 25/-- 12/--  
CBZ-13C15N --- 26.0 
239.0/ 
191.9 
25 61 41/-- 8/--  
SMI-d4 --- 24.8 
315.0/ 
160.0 
25 71 53/-- 6/--  
1 Precursor ion/product ion  
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ICMS AND TRANSFORMATION PRODUCTS OF IOPROMIDE. A Chromolith Performance RP-18e 
(100 x 4.6 mm, 130 Å, 2 µm) column preceded by a Chromolith RP-18e (5 x 4.6 mm) guard 
column (both supplied by Merck, Darmstadt, Germany) was used for chromatographic 
separation. Mobile phase A was produced by mixing 980 mL Milli-Q water (additioned with 
20 mmol/L NH3 and adjusted to pH 5.7 with acetic acid) with 20 mL acetonitrile. Mobile phase B 
was produced by mixing 40% of mobile phase A with 60% acetonitrile. The gradient started 
with 100% A for six minutes, changed to 20% A within further 6 min and was held for 3 min 
before returning to 100% A within 0.5 min and held isocratic at these conditions for the final 
4.5 min. Flow rate was 600 µL/min, injection volume was 25 µL and the temperature of the 
column oven was adjusted to 30 °C.  
Detection was performed with electrospray ionization (ESI) in positive mode (collision gas: 
medium; curtain gas: 30 psi; ion source gas 1 and 2: 40 psi; source temperature: 600 °C; 
entrance potential: 10 V; see Table 3-3). 
The transformation products of iopromide were analysed according to Schulz et al., 2008, where 
all details of the procedure are described.  
Table 3-3: Target compounds and the corresponding ESI-MS/MS parameters for the analysis of ICMs  (RT: 
retention time; DP: declustering potential; CE: collision energy; CXP: collision cell exit potential). 
Compound 
CAS 
No. 
RT 
[min] 
Transition 
11 (T1) 
[m/z] 
Transition 
21 (T2) 
[m/z] 
Dwell 
time 
[msec] 
DP 
[V] 
CE 
(T1/T2) 
[V] 
CXP 
(T1/T2) 
[V] 
related 
IS 
DTZ 
117-96-
4 
7.00 
614.72/ 
147.9 
614.72/ 
233.1 
120 51 79/63 4/8 DTZ-d6 
IOP 
78649-
41-9 
12.70 
777.87/ 
405.2 
777.87/ 
531.8 
120 106 59/41 14/18 IOP-d3 
IPM 
60166-
93-0 
6.70 
777.8/ 
558.7 
777.88/ 
386.9 
120 106 31/53 20/14 IPM-d8 
IMI 
73334-
07-3 
15.1/
14.8 
791.87/ 
572.7 
791.87/ 
558.7 
120 101 33/39 20/18 DMI 
IPM-d8 --- 12.50 
781.1/ 
562 
781.1/ 
689.9 
120 120 29/21 6/6 
 
IOP-d3 
118514
6-41-1 
12.50 
781.1/ 
408.3 
781.1/ 
689.9 
120 115 55/29 6/6 
 
DTZ-d6 --- 6.70 
620.9/ 
343.1 
620.9/ 
367.1 
120 92 21/25 6/6 
 
DMI 
76350-
28-2 
13.10 
761.89/ 
528.8 
--- 120 106 47/--- 18/--- 
 
1 Precursor ion/product ion 
 
PSYCHO-ACTIVE COMPOUNDS. Chromatographic separation was accomplished with a Synergi 
Polar-RP 80 Å column (150 x 3 mm, 4 µm) with a SecurityGuard column (Polar-RP, 
4 mm × 3 mm) (both purchased from Phenomenex, Aschaffenburg, Germany). Two mobile 
phases were used: (A) 10 mM ammonium formiate buffer adjusted to pH 4 with formic acid and 
(B) acetonitrile. Chromatography started with 10% B, held isocratic for 5 min, then increased 
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within 13 min to 80% B, which was kept for 7 min before returning to starting conditions within 
1 min. Starting conditions were held for 10 min for re-equilibration. The flow rate was 
500 µL/min, injection volume was 25 µL, and the temperature of the column oven was kept at 
25 °C. Electrospray ionization (ESI) was executed in positive mode with the following 
parameters: collision gas: 6 psi; curtain gas: 25 psi; ion source gas 1 and ion source gas 2: 40 psi; 
source temperature: 450 °C; entrance potential: 10 V; ionspray voltage: 5.5 kV. Further details of 
the MS/MS analysis are shown in Table 3-4. 
Table 3-4: Target compounds and the corresponding ESI-MS/MS parameters for the analysis of psycho-
active compounds (RT: retention time; DP: declustering potential; CE: collision energy; CXP: collision cell 
exit potential). 
Compound 
CAS  
No. 
RT  
[min] 
Transition 
11 (T1) 
[m/z] 
Transition 
21 (T2) 
[m/z] 
Dwell 
time 
[msec] 
DP 
[V] 
CE 
(T1/T2) 
[V] 
CXP 
(T1/T2) 
[V] 
related 
IS 
CBZ 
298-46-
4 
15.3 
237.0/ 
193.9 
237.0/ 
179.1 
25 71 27/49 16/12 
CBZ-
13C15N 
DH-CBZ 
3564-
73-6 
15.4 
238.9/ 
196.0 
238.9/ 
180.0 
25 66 31/55 14/14 
CBZ-
13C15N 
DHH 
35079-
97-1 
12.3 
271/ 
236 
--- 25 41 19/-- 6/-- 
CBZ-
13C15N 
 PMD 
125-33-
7 
11.4 
218.9/ 
162.1 
218.9/ 
90.9 
25 46 19/39 14/8 
CBZ-
13C15N 
 DXP 
1668-
19-5 
18.9 
280.0/ 
107.0 
280.0/ 
90.9 
25 46 37/59 10/6 
CBZ-
13C15N 
 CDN 
76-57-3 
10.7 
300.1/ 
215.0 
300.1/ 
164.9 
25 71 37/53 16/12 CDN-d6 
 DHC 
125-28-
0 
9.6 
302.1/ 
128.0 
302.1/ 
200.9 
25 71 85/39 12/16 CDN-d6 
 MTD 
76-99-3 
18.8 
310.0/ 
105.0 
310.0/ 
76.9 
25 51 37/75 6/6 MTD-d9 
MPN 
57-27-2 
4.26 
286.1/ 
201.0 
286.1/ 
152.0 
25 86 35/77 6/14 MPN-d6 
 OCN 
76-42-6 
11.7 
316.0/ 
256.0 
316.0/ 
212.0 
25 56 35/59 8/14 CDN-d6 
DZP 
439-14-
5 
17.8 
284.9/ 
221.9 
284.9/ 
193.0 
25 76 35/45 20/14 DZP-d5 
 NZP 
1088-
11-5 
16.6 
271.0/ 
140.0 
271.0/ 
208.0 
25 71 41/39 12/6 NZP-d5 
 OZP 
604-75-
1 
15.6 
287.0/ 
103.9 
287.0/ 
76.9 
25 61 47/81 8/6 OZP-d5 
 TZP 
846-50-
4 
16.8 
301.0/ 
254.8 
302.9/ 
256.9 
25 56 31/31 18/6 NZP-d5 
CBZ-13C15N 
--- 
15.3 
239.0/ 
191.9 
25 61 29/-- 12/-- 
 
CDN-d6 
1007844
-34-9 
10.4 
306.0/ 
165.0 
25 91 57/-- 12/-- 
 
MTD-d9 
--- 
18.9 
319.0/ 
105.0 
25 61 41/-- 8/-- 
 
MPN-d6 
1334606
-17-5 
4.22 
293.0/ 
152.0 
25 91 45/-- 14/-- 
 
DZP-d5 
65854-
76-4 
17.7 
290.0/ 
198.0 
25 86 43/-- 12/-- 
 
NZP-d5 
65891-
80-7 
16.5 
276.0/ 
164.9 
25 81 31/-- 20/-- 
 
OZP-d5 
65854-
78-6 
15.5 
291.9/ 
235.9 
25 61 29/-- 12/-- 
 
1 precursor ion/product ion   
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OPS. Chromatographic separation was achieved with a Synergi Polar-RP 80 Å column 
(150 x 3 mm, 4 µm) with a SecurityGuard guard column (Polar-RP, 4 mm × 3 mm) (both 
purchased from Phenomenex, Aschaffenburg, Germany). The used mobile phases were Milli-Q 
water (A) and MeOH (B). Chromatography started with 64% B, was increased to 76% B within 
0.5 min and further increased to 100% B within 15.5 min, held isocratic for 4 min and returned 
to initial conditions with 64% B within 0.1 min and then was kept isocratic for 4.9 min. The flow 
rate was set to 400 µL/min, injection volume was 10 µL, and the temperature of the column 
oven was 25 °C. Mass-spectrometric analysis was carried out in positive mode, utilizing 
atmospheric pressure chemical ionization (APCI), using the following parameters: collision gas, 
medium; curtain gas: 30 psi, nebulizer current, 3 µA; ion source gas 1: 60 psi; source 
temperature: 500 °C; entrance potential: 10 V. Declustering potential was 80 V and collision cell 
exit potential 10 V. Further details are given in Table 3-5. 
 
Table 3-5: Target compounds and the corresponding APCI-MS/MS parameters for the analysis of OPs (RT: 
retention time; DP: Declustering potential; CE: Collision energy; CXP: Collision cell exit potential). 
for all analytes: DP [V]:80, CXP [V]: 10; 1 Precursor ion/product ion; 
 
 
3.2.6 METHOD VALIDATION 
Calibration curves with 12, 12, 13, 10 and 8 calibration points ranging from 0.2 to 2,000 ng/L, 
0.5 to 2,000 ng/L, 0.5 to 4,000 ng/L, 1 to 1,000 ng/L and 5 to 3,000 ng/L for acidic drugs, 
antibiotics, ICMs, psycho-active compounds and organophosphorus compounds respectively 
were prepared by spiking the eluent mixtures used for LC-MS/MS analysis.  
A fixed amount of the associated internal standard was added (see Table 3-1 to Table 3-5). The 
linearity range of the calibration lay generally between 0.2 to 10 ng/L, 0.5 to 200 ng/L, 0.5 to 
200 ng/L, 1 to 200 ng/L and 5 to 300 ng/L for acidic drugs, antibiotics, ICMs, psycho-active 
Compound 
CAS 
No. 
RT  
[min] 
Transition 
 11 (T1) 
 [m/z] 
Transition 
21 (T2) 
[m/z] 
Dwell 
time 
[msec] 
CE 
(T1/T2) 
[V] 
related IS 
TBEP 78-51-3 8.3 399/299 399/199 60 20/23 TPP-d15 
TnBP 126-73-8 7.2 267/211 267/155 60 13/17 TnBP-d27 
TiBP 126-71-6 6.8 267/211 267/155 60 13/17 TnBP-d27 
TEHP 78-42-2 14.0 435/323 435/99 60 12/43 TnBP-d27 
TPP 115-86-6 7.9 327/152 327/77 60 55/65 TnBP-d27 
TCEP 13674-84-5 4.7 285/223 287/225 60 19/20 TnBP-d27 
TCPP 13674-84-5 6.0 329/253 329/175 60 15/19 TnBP-d27 
TDCPP 13674-87-8 7.6 431/321 431/209 60 19/24 TnBP-d27 
TnBP-d27 --- 7.01 294/102 60 27/-- 
 
TPP-d15 --- 7.81 342/82 60 65/-- 
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compounds and organophosphorus compounds respectively. A quadratic fit (y=ax2+bx+c) with 
the weighing 1/x was used for the exceeded range of the calibration. Correlation coefficients 
higher than 0.998 were accepted. Concentrations of the target compounds were calculated by 
plotting the peak area ratio of analyte and internal standard in the samples against the same 
ratio in the calibration samples. The limit of quantification (LOQ) was set as the second lowest 
calibration point so long as the signal/noise ratio (S/N) for this calibration point exceeded 10 for 
the quantifying transition (T1) and 3 for the confirming transition (T2). Considering both the 
enriched sample volume and the difficult matrix, the calculated LOQ was multiplied by 10 for 
concentrate and influent samples, while the permeate samples were processed with a fivefold 
LOQ. Still, the required S/N ratios for quantification (T1) and confirmation (T2) had to be 
fulfilled. In some cases LOQ was individually adapted to fit the required S/R ratio. The stability 
of the analytical acquisition and any possible fluctuation in signal intensity and retention time 
was supervised by injecting a standard solution after every 5 to 7 native samples. Carryover 
from sample to sample was checked for by injecting a mixture of pure eluent at an interval of 5 
samples.  
Instrumental precision was determined by repeated injection of a standard solution during 
analysis at the same day (intraday: n = 4–8) and over the whole period of analysis (interday: 
n = 8 - 12) and is indicated by the relative standard deviation of the measurements (% RSD). 
Quality assurance and quality control (QA/QC) of the applied instrumental methods have 
already been reported elsewhere (Hirsch et al., 2000; Hummel et al., 2006; Schulz et al., 2008; 
Kormos et al., 2009; Magdeburg et al., 2014). In addition to this, the accuracy of the full 
analytical procedure was assessed by studying the relative recovery in fortified native samples 
of all matrices (raw influent wastewater, concentrate and permeate of the MBR) over the 
complete analytical protocol. The accuracy was determined by spiking native samples with 
analyte standards (100 ng/100 mL for influent and concentrate, 50 ng/100 mL for effluent 
samples) and internal standards before extraction and analysis (n = 2–6 per sample type). The 
background amounts present in unfortified native samples were subtracted from the results of 
the spiked samples and the latter were subsequently related to standard solutions containing 
the same amount of analytes as was spiked into the fortified native samples. Blank values (Milli-
Q water spiked with internal standards undergoing the whole analytical procedure) were 
determined for every set of 10–15 environmental samples to assess possible sample 
contamination during the laboratory process. Eventual blank contamination was not subtracted 
from environmental results. 
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3.3 RESULTS AND DISCUSSION  
3.3.1 METHOD VALIDATION 
Quantification, based on peak areas, was carried out by internal standard calibration. Calibration 
curves all showed a correlation coefficient (r2) of at least 0.998. Validation data are given in 
Table 3-6. LOQ in samples of influent and concentrate ranged from 5 ng/L to 50 ng/L for 
pharmaceuticals and from 14 ng/L to 150 ng/L for OPs, while LOQ for the permeate ranged from 
2.5 ng/L to 25 ng/L and from 12.5 ng/L to 75 ng/L for pharmaceutical compounds and OPs 
respectively. The accuracy of the method was determined by estimating relative recoveries in 
native samples of all matrices, which were spiked with the target compounds and internal 
standards before extraction. Accuracy was then estimated by subtracting the analyte amount 
measured in the native samples from the amounts measured in the spiked ones and 
subsequently relating the amounts to standards of the same concentration (Table 3-6). Accuracy 
was satisfactory, especially since for most analytes, precision was < 20% RSD. For ICMs, spiked 
samples of influent and concentrate yielded concentrations outside the calibration range, 
therefore accuracy for ICMs in these sample types was not determinable. In some cases, the 
accuracy of the method is low (Table 3-6). Since sometimes multi-compound analytical methods 
do not provide perfect conditions for every analyte, this is considered to be no shortcoming as 
long as at the same time satisfactory LOQs and high instrumental precision are achieved (Gros et 
al., 2006b; Gros et al., 2008). For the majority of the studied compounds, blank values in all 
sample types were below LOQ. For temazepam, iomeprol and TiBP, the LOQ for effluent samples 
was exceeded. Blanks values of trimethoprim, doxepin, ibuprofen, iopromide, TBEP and TCEP 
surpassed LOQ in all matrixes but were not greater than 5% of environmental samples in 
influent samples expect for TCEP and temazepam (Table 3-7). The latter showed relatively high 
blank values throughout, thus, results for this substance should be considered semi-quantitative. 
For iomeprol and iopromide, blank samples showed high varieties (ranging from not detected to 
322 ng/L and 33 ng/L to 363 ng/L for iomeprol and iopamidol, respectively), more likely 
suggesting singular interferences during mass-spectrometric analysis than high ubiquitous 
contamination.  
 
3.3.2 OCCURRENCE OF XENOBIOTIC MICROPOLLUTANTS IN MUNICIPAL WASTEWATER  
Out of 52 investigated substances, 6 pharmaceuticals and metabolites as well as one OP were 
found in neither raw municipal wastewater nor the concentrate or permeate of the NF-MBR. The 
absence of the antibiotic compounds sulfadimidine, sulfisoxazole, sulfamerazine and tiamulin 
can be explained by their exclusive use as veterinary drugs in Germany; as such they are less 
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prone to be discharged in wastewater but are largely released into the environment by diverse 
sources like runoff, leakage or drift from agricultural soils fertilized with manure (Christian et 
al., 2003; Sarmah et al., 2006). Furthermore, the psycho-active compounds diazepam and 
nordiazepam were not detected in quantifiable concentrations, while oxycodone was found in 
concentrations either very near or below LOQ. These results are in good accordance with earlier 
reports from studies in Germany, Spain and the USA (Carballa et al., 2004; Hummel et al., 2006; 
Wick et al., 2009; Hass et al., 2012; Du et al., 2014). Additionally, the organophosphorus 
compound TEHP was not quantifiably detected.  
 
3.3.2.1  Untreated wastewater  
In raw municipal wastewater, 39 pharmaceuticals, metabolites, transformation products and 
OPs were quantified (Table 3-8). Figure 3-5 shows the maximum concentrations in the influent 
from the NF-MBR (cmax influent) found for each compound during the sampling campaign. The 
highest concentrations were found for the ICMs iopamidol (150,602 ng/L) and iomeprol 
(20,829 ng/L). 18 substances, which equals 45% of the quantified xenobiotics, were present in 
maximum concentrations of more than 1,000 ng/L: five ICMs (iopromide, iomeprol, diatrizoic 
acid, iopamidol, iopromide TP 819), four NSAIDs (diclofenac, ibuprofen, bezafibrate, naproxen), 
four psycho-active drugs (10,11-dihydro-10,11-dihydroxycarbamazepine, primidone, 
carbamazepine, oxazepam), three OPs (TBEP, TiBP, TCPP) and the antibiotic sulfamethoxazole 
as well as its metabolite N4-acetylsulfamethoxazole. Table 3-8 shows that, with the exception of 
naproxen, the average concentrations of these substances also exceeded 1,000 ng/L, revealing 
that these substances are present in raw wastewater at constantly high levels and are not 
introduced in isolated peak events. However, in some cases high SD values indicated 
considerable fluctuations over the course of the sampling period. This was especially true for 
ICMs, which indicates a heterogeneous, variant input over the course of the sampling campaign 
(see Chapter 3.3.2.2). In addition, wide variations in SD were found for substances with values 
close to LOQ, such as sulfadimethoxine, methadone and oxycodone.  
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Table 3-6: LOQ [ng/L] and accuracy of the analytical procedure [%] for the three investigated matrices 
(influent, permeate, concentrate) and instrumental precision (intraday/interday) for the five analytical 
compound groups. 
 
LOQ [ng/L] Accuracy [%] 
Instrumental 
precision [RSD, %] 
 
Influent/ 
Concentrate 
Permeate 
Influent1 Permeate2 Concentrate3 
Intraday7 Interday8 
 
Average SD Average SD Average SD 
Antibiotics 
CLA 5 2.5 102 12 100 1 100 9 7 7 
ROX 5 2.5 96 6 102 5 103 6 3 21 
SMI 5 2.5 119 23 95 1 90 16 7 18 
SDI 5 2.5 99 5 94 0 95 5 3 17 
SSX 5 2.5 95 7 77 6 75 3 5 8 
SMA 5 2.5 106 4 99 4 101 0 3 13 
SMX 5 2.5 100 8 94 4 97 0 4 11 
N-Ac-SMX 20 10 79 38 103 5 130 29 5 6 
TAM 10 5 92 14 120 5 120 6 3 11 
TMP 5 2.5 31 5 105 6 110 10 8 15 
min --- --- 31 4 77 0 75 0 3 6 
max --- --- 131 38 134 7 130 29 17 21 
ICMs 
DTZ 50 25 a.r.6 a.r.6 99 ---5 a.r.6 a.r.6 8 8 
IOP 50 25 a.r.6 a.r.6 100 14 a.r.6 a.r.6 8 12 
IPM 50 25 a.r.6 a.r.6 106 1 a.r.6 a.r.6 10 12 
IMI 50 25 a.r.6 a.r.6 88 19 a.r.6 a.r.6 4 9 
min --- --- --- --- 88 1 --- --- 4 8 
max --- --- --- --- 106 19 --- --- 10 12 
NSAIDs and bezafibrate 
BZF 10 5 73 10 78 1 76 23 4 26 
DCF 10 5 52 12 87 17 56 0 4 13 
IBP 10 5 120 3 50 1 64 8 5 4 
NPX 10 5 86 22 45 4 41 7 9 12 
min --- --- 52 3 45 1 41 0 4 4 
max --- --- 120 22 87 17 77 23 9 26 
Psycho-active compounds 
CBZ 10 5 113 8 107 1 113 9 2 3 
DH-CBZ 10 5 99 5 99 2 100 1 1 8 
DHH 20 10 123 24 86 12 131 ---5 8 8 
PMD 25 12.5 n.d.4 n.d.4 122 12 135 ---5 8 11 
DXP 10 5 119 33 75 23 86 15 18 20 
CDN 50 25 93 8 99 8 100 4 3 6 
DHC 20 10 101 16 88 9 98 5 6 7 
MTD 10 5 88 3 84 0 88 2 3 8 
MPN 30 15 62 5 29 4 32 5 12 n.d. 
OCN 20 10 39 4 82 10 79 4 6 17 
DZP 20 10 111 10 99 1 101 1 3 6 
NZP 10 5 103 6 101 3 106 7 3 3 
OZP 50 25 182 13 115 11 109 0 10 9 
TZP 10 5 89 6 81 1 78 2 4 6 
min --- --- 39 3 29 0 32 0 1 3 
max --- --- 182 33 122 23 135 15 18 20 
OPs 
TBEP 25 12.5 113 7 164 --- 5 n.d. 4 n.d. 4 1 7 
TnBP 50 25 62 30 24 2 91 3 2 5 
TiBP 150 75 57 18 28 0 n.d. n.d. 4 6 
TEHP 50 25 46 13 46 8 127 --- 5 2 10 
TPP 25 12.5 50 2 35 2 49 3 1 9 
TCEP 14 7 79 9 56 2 56 1 3 9 
TCPP 110 55 77 8 63 --- 5 112 3 3 8 
TDCPP 60 30 75 5 45 2 46 8 2 7 
min --- --- 46 2 5 0 46 1 1 5 
max --- --- 113 30 164 8 127 8 4 10 
1n=3-6; 2n=2; 3n=2-3; 4n.d. = not determined; 5n=1; 6a.r. = above concentration range; 7n=4-8; 8n=8-12 
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Table 3-7: QA/QC results for substances with blank values > LOQ. All blank values for substances not 
shown: < LOQ. 
 
Blank values1 
[ng/L] 
% of LOQ % of environmental values
2 
Influent/ 
Concentrate 
Permeate Influent Permeate 
TMP 4 +5 85 170 3 +0 8 +2 
TZP 11 +0 227 453 29 +3 47 +5 
DXP 6 +0 383 767 5 +9 45 +19 
IBP 12 +22 121 242 0 +0 56 +9 
IOP 113 +228 57 115 2 +4 46 +91 
IMI 192 +130 105 210 1 +1 58 +87 
TBEP 36  142 284 1 +0 23 +8 
TiBP 94  63 125 4 +4 69 --- 
TCEP 16  116 232 10 +2 12 +2 
      1 n=3; n=1 for TBEP, TiBP, TCEP; 2 given as the average value per sample type 
 
DIVERSE USE PATTERNS. Different consumption habits might lead to diverse occurrence patterns 
in wastewater in different countries (Behera et al., 2011). Consequently, comparing 
pharmaceutical concentrations between countries can be difficult (Lindqvist et al., 2005). 
Additionally, pharmaceutical values can vary during different seasons. For example, Göbel et al., 
2005b, Gao et al., 2012a, Yu et al., 2013 and Du et al., 2014 described variant occurrence of 
NSAIDs, psycho-active compounds and antibiotics around the year for WWTP influent waters, 
while on the other hand Alexy et al., 2006 found only minor seasonal variations in the 
occurrence of antibiotics in influent wastewater.  
According to Petrović et al., 2009, the highest concentrations of pharmaceuticals in WWTP 
influents are commonly those of NSAIDs since they are sold in large amounts as OTC drugs in 
many countries. This is not confirmed in this study, where the two highest concentrations in the 
influent are two ICMs with average concentrations 8 times (iopamidol) and 1.7 times (iomeprol) 
higher than those of the highest concentrated NSAID, ibuprofen. A possible reason for this is the 
presence of a large university hospital with several institutes providing ICM-related diagnostics 
in the service area of the WWTP. This is confirmed by the fact that when comparing the 
occurrence of ICMs in this study with earlier reports, highly specific, diverse use patterns for 
ICMs seem to be reflected in the wastewater. For example, Ternes and Hirsch, 2000 reported 
ICM values in WWTP influent from near Frankfurt (Germany) that were comparable with the 
findings in this study with regard to iopamidol and diatrizoic acid, while the reported values of 
iomeprol and iopromide were about eight times lower than the values found in this study. On 
the other hand, Carballa et al., 2004 reported equally high values of iopromide (6,000 –
 7,000 ng/L) in the influent of a WWTP in Galicia (NW Spain), which correspond well with the 
data presented here.   
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Table 3-8: Mean concentration of analytes in influent, effluent and concentrate of the MBR over the 
investigation period [ng/L]. For the calculation of average values, single values < LOQ were accounted for 
as 0.5*LOQ and single values which not yielded a signal (not detected = n.d.) were taken into account as 0. 
 
NF-MBR NF 
 
Influent [ng/L]1 Effluent [ng/L] 1 Concentrate [ng/L] Influent2 Effluent2 
 
Average SD Average SD Average SD [ng/L] [ng/L] 
Antibiotics 
CLA 544 67.7 103 31.2 103 57.7 
 
11.7 
ROX 123 20.4 65.9 21.5 82.7 18.8 19.8 n.d. 
SMI 28.1 43.1 3.78 2.14 6.60 3.80 n.d. n.d. 
SDI < LOQ 
 
< LOQ 
 
< LOQ 
 
44.6 n.d. 
SSX n.d. 
 
n.d. 
 
< LOQ 
 
n.d. 4.00 
SMA < LOQ 
 
n.d. 
 
< LOQ 
 
n.d. n.d. 
SMX 1,297 126 679 156 626 172 887 257 
N-Ac-SMX 2,573 334 < LOQ 
 
< LOQ 
 
807 250 
TAM < LOQ 
 
< LOQ 
 
< LOQ 
 
n.d. n.d. 
TMP 136 14.4 59.2 16.1 65.3 25.6 12.3 n.d. 
ICMs 
DTZ 7,331 3,760 7,549 1,970 9,346 2,250 9,705 2,781 
IOP 14,131 7,164 716 402 416 130 31,818 7,325 
IPM 1,727 2,000 1,564 695 1,248 1,075 1,214 310 
IMI 67,244 56,260 1,950 1,640 1,291 1,074 94,505 22,613 
IMI-TP 805 A 123 80.0 2,749 2,295 2,824 2,396 n.a. n.a. 
IMI-TP 805 B < LOQ 
 
1,325 1,074 1,390 1,177 n.a. n.a. 
IMI-TP 819 791 603 1,657 1,334 2,462 2,006 n.a. n.a. 
IMI-TP 817 A < LOQ 
 
2,023 1,560 4,735 3,382 n.a. n.a. 
IMI-TP 787 A < LOQ 
 
5,200 2,265 14,404 4,509 n.a. n.a. 
IMI-TP 731 A < LOQ 
 
4,918 2,955 4,300 3,398 n.a. n.a. 
IMI-TP 731 B < LOQ 
 
201 116 202 135 n.a. n.a. 
IMI-TP 729 A n.d. 
 
17,187 9,735 20,247 12,930 n.a. n.a. 
IMI-TP 759 476 202 8,754 3,621 19,007 8,421 n.a. n.a. 
IMI-TP 701 A 116 81.3 18,263 9,819 20,084 14,480 n.a. n.a. 
IMI-TP 701 B < LOQ 
 
756 383 1,102 638 n.a. n.a. 
IMI-TP 643 < LOQ 
 
2,254 1,309 1,975 1,692 n.a. n.a. 
NSAIDs and bezafibrate 
BZF 1,270 204 16.6 5.17 < LOQ 
 
n.a. n.a. 
DCF 1,322 245 866 77.6 911 16.2 n.a. n.a. 
IBP 8,135 1,352 21.9 3.68 < LOQ 
 
n.a. n.a. 
NPX 898 261 20.1 4.68 18.1 11.4 n.a. n.a. 
Psycho-active drugs 
CBZ 1,165 288 1,255 267 1,156 18.0 1,214 355 
DH-CBZ 52.8 6.66 57.8 1.56 59.2 2.88 76.8 23.9 
DHH 7,652 1,458 2,189 291 2,608 542 4,382 1,524 
DXP 291 82.9 14.8 5.69 24.8 1.78 245 66 
PMD 2,362 455 543 100 578 125 647 306 
CDN 231 27.9 < LOQ 
 
< LOQ 
 
376 100 
DHC 32.7 16.5 < LOQ 
 
n.d. 
 
125 83.0 
MTD 59.1 31.4 41.9 2.50 52.2 2.49 13.8 n.d. 
MPN 396 70.8 < LOQ 
 
n.d. 0.00 n.a. n.a. 
OCN < LOQ 
 
< LOQ 
 
< LOQ 
 
n.d. n.d. 
DZP n.d. 
 
n.d. 
 
n.d. 
 
41.0 n.d. 
NZP n.d. 
 
n.d. 
 
n.d. 
 
22.7 8.79 
OZP 1,024 125 295 40.6 244 5.85 < LOQ <LOQ 
TZP 36.8 3.91 22.8 2.71 32.3 4.88 92.3 40.6 
OPs 
TBEP 7,447 2,274 182 105 250 131 3,873 699 
TnBP 123 40.7 < LOQ 
 
n.d. 
 
n.d. n.d. 
TiBP 4,293 2,515 < LOQ 
 
< LOQ 
 
n.d. n.d. 
TEHP < LOQ 
 
n.d. 
 
n.d. 
 
n.d. n.d. 
TPP 27.7 6.33 n.d. 
 
n.d. 
 
n.d. n.d. 
TCEP 166 33.4 144 23.2 195 89.8 435 101 
TCPP 1,088 224 753 112 1,091 670 1,750 302 
TDCPP 222 53.5 150 19.6 245 101 <LOQ <LOQ 
1 n=8; 2 n=1; < LOQ = below the limit of quantification; n.d. = not detected; n.a. = not analysed 
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NSAIDS AND BEZAFIBRATE. An example of the considerable diversity in reported values in 
wastewater for even globally used pharmaceuticals is ibuprofen. In many countries ibuprofen is 
available as an OTC drug and, consequently, high consumption rates are reported from around 
the globe (Alder et al., 2006). Additionally, it is listed as a core drug for a basic healthcare system 
in the WHO’s List of Essential Medicines (WHO, 2011c). Nonetheless, very diverse data about its 
occurrence in raw wastewater can be found in the literature. Lindqvist et al., 2005 and 
Hedgespeth et al., 2012 reported concentrations of over 19,000 ng/L and 24,000 ng/L found in 
influents to WWTPs in Finland and the USA respectively. Other researchers found ibuprofen in 
concentrations closer to those presented here (e.g. 385–1,260 ng/L in the area of Bangkok, 
Thailand (Tewari et al., 2013), 2,265 ng/L in influents in South Korea (Behera et al., 2011). 
Carballa et al., 2004 reported concentrations between 2,600–5,700 ng/L in a WWTP in Galicia 
(NW Spain), while in Sevilla (southern Spain) influent concentrations no higher than 
373.11 ng/L were found (Santos et al., 2007). Kosma et al., 2014 found highly diverse ibuprofen 
concentrations in several WWTPs in Greece, ranging from 2,634 ng/L to the complete absence of 
the substance in the wastewater. Such profound differences in the concentrations reported for a 
widespread drug can be explained by differences in the composition of the wastewater. 
Lindqvist et al., 2005 found that in the WTTPs of smaller municipalities, concentrations of 
NSAIDs were higher than in the WWTPs of big cities since they were less diluted by industrial 
wastewater.  
Taking this into consideration, the values of diclofenac and naproxen found in this study 
accorded well with previous studies from Croatia (Gros et al., 2006a), Greece (Kosma et al., 
2014), Japan (Kimura et al., 2007), Korea (Behera et al., 2011) and Spain (Celiz et al., 2009; 
Carballa et al., 2004). In contrast, in another raw wastewater study from Spain, diclofenac values 
of below the limit of detection were reported, while naproxen values were found that were more 
than 30 times higher than in this study (Santos et al., 2007).  
Bezafibrate concentrations presented here are considerably higher than those found by 
researchers in Croatia (Gros et al., 2006a), Greece (Kosma et al., 2014) and Spain (Rosal et al., 
2010) and lower than values reported from Finland (Lindqvist et al., 2005).  
 
ANTIBIOTICS. Regarding antibiotics, the results are in good agreement with several studies from 
Europe and Asia (Carballa et al., 2004; Göbel et al., 2005b; Gros et al., 2006a; Behera et al., 2011; 
Gao et al., 2012a; Kosma et al., 2014). In contrast, Tewari et al., 2013 reported a very dissimilar 
antibiotic pattern in raw wastewater from Bangkok (Thailand) with considerably lower values 
of roxithromycin (over tenfold less) and concentrations of sulfamethoxazole over 40 times lower 
than in this study, while the trimethoprim values are comparable. For raw wastewater from two 
plants in Japan, low antibiotic values are reported, being 10-fold, 20-fold and 48-fold lower for 
Chapter 3 
 
page | 92  
trimethoprim, sulfadimethoxine and sulfamethoxazole, respectively, than the concentrations 
reported here (Tewari et al., 2013). Overall, veterinary antibiotics are detected in raw 
wastewater only in small quantities or not at all, confirming the results presented here (Göbel et 
al., 2005b; Gao et al., 2012a; Gao et al., 2012b; Tewari et al., 2013).  
 
PSYCHO-ACTIVE COMPOUNDS. In a previous study analysing the same cluster of psycho-active 
compounds as in this study, similar results were found for twelve WWTPs in Germany (Hummel 
et al., 2006). Carbamazepine, the most extensively studied psycho-active drug in wastewater, 
was reported in similar concentrations in wastewater in Canada, Croatia, Germany and Spain 
(Miao and Metcalfe, 2003; Zuehlke et al., 2004; Gros et al., 2006a; Celiz et al., 2009; Leclercq et 
al., 2009). Concentrations about tenfold lower than reported here were found in wastewater in 
studies in Greece, Korea and the USA (Behera et al., 2011; Gao et al., 2012b; Kosma et al., 2014). 
 
OPS. TBEP and TiBP were the highest concentrated OPs in influent wastewater. This is in 
agreement with data given in studies from Spain (Rodil et al., 2009: TBEP: 1,004 ± 63 ng/L; 
TnBP 1,246 ± 123 ng/L; TiBP 664 ± 144 ng/L) and Sweden (Marklund et al., 2005: TBEP: 5,200–
35,000 ng/L, TBP: 6,600–52,000 ng/L). However, the ratio of about 1:0.5 for TiBP and TnBP 
reported by Rodil et al., 2009 is fundamentally different from what was found in the presented 
study (1:34). The influent concentrations of TPP were low, which concurs with the average value 
of data given by other researchers (Marklund et al., 2005, Rodil et al., 2009).  
TCEP influent concentrations reported from Norway (Green et al., 2008, cited in van der Veen 
and Boer, 2012) are over ten times higher than those found in the presented study. Other 
researchers found concentrations closer to those presented here (Marklund et al., 2005; Rodil et 
al., 2009). Average TCPP concentrations of 500–600 ng/L – i.e. lower than the concentrations 
found in the presented study – were reported from WWTPs in Germany and Spain (Bester, 2005; 
Rodil et al., 2009), while concentrations found in Norway and Sweden were usually comparable 
or higher (Marklund et al., 2005; Green et al., 2008, cited in van der Veen and Boer, 2012). TDCP 
concentrations reported are consistent with those found here (Marklund et al., 2005; Rodil et al., 
2009).  
Equally, as reported here, previous studies of OPs did not find TEHP in wastewater (e.g. 
Marklund et al., 2005; Rodil et al., 2009). According to van der Veen and Boer, 2012, this is based 
on analytical failure of sample extraction by liquid-liquid extraction or SPE with Oasis HLB 
material, rather than the absence of the substances. However, QA/QS for TEHP both in the 
presented study and in the literature data given above show acceptable results.  
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Figure 3-5: Maximum concentrations (cmax influent [ng/L]) of each target compound in the influent of the NF-
MBR. Colour codes show the compound group (including metabolites). 
 
3.3.2.2  Weekly concentration profiles  
Concentration profiles of the investigated xenobiotics for influent, concentrate and effluent as 
well as the removal rates over the course of the sampling campaign are shown in Figures 3-6 to 
3-11. Removal rates were calculated by the equation: (cinf−ceffl)×100/cinf, where cinf is the 
substance’s concentration measured in the influent and ceff the concentration found in the 
effluent (Santos et al., 2007). For reasons of clarification, values below LOQ were set to zero for 
the illustration of the removal rates in the graphs. Details regarding removal are discussed in 
Chapter 3.3.3. 
 
ANTIBIOTICS. The amounts of antibiotics (Figure 3-6) used for the treatment of humans generally 
do not show a significant change in raw wastewater over the course of the week, whereas the 
veterinary antibiotic sulfadimethoxine shows a concentration profile suggesting isolated input 
events on particular days, such as run-off from agricultural land freshly top-dressed with 
manure.  
 
 
< LOQ/ 
not detected 
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ICMS. The ICMs show reduced concentrations at weekends with low inputs at Saturday and 
Sunday, which reflects their exclusive utilisation for diagnostics in radiological practices on 
working days (Figure 3-7). This pattern of occurrence was reported in previous studies (e.g. 
Ternes and Hirsch, 2000; Seitz et al., 2006). Moreover, whilst diatrizoic acid and iomeprol 
display high concentrations in raw wastewater throughout the week, with an evident drop only 
at the weekend, iopamidol shows distinctly elevated influent concentrations between 
Wednesday and Friday, which could possibly be explained by different temporal local use 
patterns due to specialised medical centres only being open certain days per week. The same can 
be assumed for iopromide, which shows elevated influent concentrations on Monday, Tuesday 
and Friday and concentrations similar to those at weekends on Wednesday and Thursday.  
 
NSAIDS, BEZAFIBRATE AND PSYCHO-ACTIVE SUBSTANCES. As with antibiotics, the variations in the 
concentrations of NSAIDs and bezafibrate in raw wastewater show no distinct differences 
between weekdays and the weekend (Figure 3-8). Among the psycho-active drugs, only doxepin 
shows a distinct weekly pattern, with pointedly elevated concentrations at weekends (Figure 3-
9, Figure 3-10). 
 
OPS. The weekly distribution patterns of OPs are heterogeneous and do not show any particular 
trend (Figure 3-11). While most of the substances are present in the wastewater at stable levels, 
TBEP and TiBP show fluctuating amounts during the investigation period. It could be assumed 
that they are introduced to the wastewater through distinct events, by periodic activities or by 
periodically active point sources. Wide variations in the wastewater inflow were previously 
reported for TCPP (Bester, 2005), which is not in accordance with the presented data but 
emphasises possible inconsistencies in OP occurence in wastewater. 
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Figure 3-6: Concentrations [ng/L] of antibiotics in influent, permeate and concentrate from the NF-MBR 
pilot plant and correlating removal [%] over the course of the sampling campaign. Concentrations below 
LOQ are indicated by black-filled data point symbols. 
  
< LOQ: 
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Figure 3-7: Concentrations [ng/L] of ICMs in influent, permeate and concentrate from the NF-MBR pilot 
plant and correlating removal [%] over the course of the sampling campaign. Concentrations below LOQ 
are indicated by black-filled data point symbols.  
  
< LOQ: 
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Figure 3-8: Concentrations [ng/L] of NSAIDs and bezafibrate in influent, permeate and concentrate from 
the NF-MBR pilot plant and correlating removal [%] over the course of the sampling campaign. 
Concentrations below LOQ are in indicated by black-filled data point symbols.   
< LOQ: 
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Figure 3-9: Concentrations [ng/L] of psycho-active drugs (opioids) in influent, permeate and concentrate 
from the MBR pilot plant and correlating removal [%] over the course of the sampling campaign. 
Concentrations below LOQ are indicated by black-filled data point symbols. For oxycodone no removal 
rates are given since most concentrations are below LOQ.   
< LOQ: 
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Figure 3-10: Concentrations [ng/L] of psycho-active drugs (carbamazepine and carbamazepine 
metabolites, doxepin, primidone and benzodiazepines) in influent, permeate and concentrate from the 
MBR pilot plant and correlating removal [%] over the course of the sampling campaign. Concentrations 
below LOQ are indicated by black-filled data point symbols.   
< LOQ: 
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Figure 3-11: Concentrations [ng/L] of organophosphorous substances in influent, permeate and 
concentrate from the MBR pilot plant and correlating removal [%] over the course of the sampling 
campaign. Concentrations below LOQ are indicated by black-filled data point symbols.  
  
< LOQ: 
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3.3.3 REMOVAL OF XENOBIOTICS FROM THE AQUEOUS PHASE BY THE NF-MBR 
 
Figure 3-12: Average removal of xenobiotic compounds in the NF-MBR pilot plant. Colours of columns 
show very high (> 95% - dark green), high (75–95% - light green), moderate (50–75% - orange), poor (0–
50% - red) and negative (< 0% - lilac) removal. Numbers above the columns depict the percentage of 
average removal and by colour code the compound group (colour code see Figure 3-5). The grey columns 
show the RSD [%]. 
 
Removal rates of the xenobiotics from the aqueous phase were estimated as mean values over 
the length of the studied period and classified into five categories (very high, high, moderate, 
poor, negative) as presented in Figure 3-12. As described before, removal in this context is to be 
understood as a summary of degradation and (bio-) transformation processes as well as 
elimination by NF filtration during treatment. Removal rates reaching the limit of quantification 
are given as 100%.  
 
OVERVIEW. Very high removal rates were found for 12 compounds (4 psycho-active compounds, 
1 antibiotic metabolite, 4 OPs, 3 NSAIDs). 6 substances showed high removal rates (2 ICMs, 2 
NSAIDs, 2 psycho-active compounds). For 4 compounds moderate removal rates were found (1 
psycho-active compound and 1 metabolite of a psycho-active compound, 2 antibiotics). 8 
analytes were found to be poorly removed by the NF-MBR (2 antibiotics, 2 psycho-active drugs, 
3 OPs, 1 NSAID). For 4 substances, carbamazepine and its metabolite DH-CBZ as well as for 
diatrizoic acid and iopamidol, negative removal was found. Possible errors in the determination 
of removal efficiency could have occurred by the exclusive use of filtered water without the 
consideration of pharmaceuticals possibly bound to particulate matter (for more details see 
Chapter 5). No correlations were found between removal and the physico-chemical properties of 
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the substances (see Chapter 2.1) (data not shown) except for a strong negative correlation with 
water solubility (r = –0.8).  
 
NSAIDS. Earlier investigations studied the fate of xenobiotics in both laboratory-scale and pilot-
plant MBRs typically equipped with MF- or UF-membranes. Radjenović et al., 2007 found high 
removal rates comparable to those presented here for ibuprofen (100%), naproxen (99%) and 
bezafibrate (96%) for a flat sheet MF-MBR (SRT indefinite) in which the effective porosity was 
that of an UF-membrane (0.01 µm), due to fouling processes on the membrane surface. In 
contrast, diclofenac removal was higher (88%) than in this study. In a later study (Radjenović et 
al., 2009b), the same author described similar results for ibuprofen (99%), naproxen (91%), 
bezafibrate (91%) and carbamazepine (no elimination) for a flat sheet MF-MBR (nominal 
porosity of 0.4 µm, fouling effect unknown), while the removal of diclofenac (66%) differed from 
the earlier study. Celiz et al., 2009 reported diclofenac reduction of 78% in a MF-MBR with 
indefinite SRT. In contrast to this, diclofenac removal in CAS treatment is reported to be very 
poor (approx. 20%) (Radjenović et al., 2009b; Rosal et al., 2010). A probable explanation is the 
presence of chlorine in the structure of this drug, which results in enhanced persistence and 
slow microbial degradation (Kimura et al., 2005; Reif et al., 2008; Tadkaew et al., 2011). MBR 
treatment offers longer SRTs than CAS treatment which allow for higher removal of a number of 
xenobiotic compounds, including diclofenac, due to longer contact time between microbes and 
xenobiotics, as well as the development of a more diverse microbial population (Kimura et al., 
2007; Tambosi et al., 2009; for details about microbial specification, see Chapters 2.2.1, 2.2.2 and 
2.2.4). In addition, not only sludge volume and sludge characteristics but also the pH at which 
the reactor is operated influence the removal efficiency of MBR treatment (Joss et al., 2006). 
Better removal of acidic compounds was found for pH values below the substances’ pKa values 
(Urase et al., 2005) and put down to higher sorption to sludge when the substances change from 
their hydrophilic ionic forms to more hydrophobic forms. The high number of variants 
influencing MBR processes may explain why various studies reported no or very poor removal 
of diclofenac in MBR, despite SRTs over 70 days (Reif et al., 2008; Tadkaew et al., 2011).  
The high removal rates (> 95%) for ibuprofen in MBR treatment consistently reported in the 
literature (Radjenović et al., 2007; Reif et al., 2008; Radjenović et al., 2009b; Tadkaew et al., 
2011) are explained by the drug’s readily biodegradable structure, with neither chlorine nor 
double aromatic rings (Kimura et al., 2005).  
Previously reported naproxen removal rates in MBR treatment range from 40% (Tadkaew et al., 
2011) to over 80% (Reif et al., 2008; Tambosi et al., 2010). No improvement in naproxen 
removal was found for prolonged SRTs by Tambosi et al., 2010, while Kimura et al., 2007 
reported distinct improvements in removal with increasing SRT.  
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MACROLIDE ANTIBIOTICS. Regarding antibiotics, high removal rates (> 80%) for clarithromycin 
and sulfadimethoxine found in the presented study are contrasted by removal rates < 60% for 
sulfadoxine, trimethoprim, sulfamethoxazole and roxithromycin. While no literature data 
regarding MBR treatment are available for sulfadimethoxine, up to 90% removal of 
clarithromycin at SRTs of 60-80 days has previously been reported (Göbel et al., 2007). Under 
the conditions given in the presented study (pH-value in the MBR: 7.8–7.9), macrolides (pKa 
> 8.9) are positively charged through the protonation of the tertiary amino group (Göbel et al., 
2005b) and removal is expected to be based largely on sorption to the predominantly negatively 
charged surface of activated sludge and only to a lesser extent on biodegradation (Abegglen et 
al., 2009). However, Göbel et al., 2005b found ionic interactions being of minor importance for 
the sorption of macrolides to sludge and pointed out that sorption must be influenced by other 
parameters which can vary in sewage, the latter being naturally a highly heterogeneous medium.  
The poor removal rate (39%) of the second macrolide investigated, roxithromycin, seems to 
emphasize the hypothesis that sludge sorption in the MBR studied is not strong. Additionally, 
low removal efficiency for roxithromycin can be explained by its complex chemical structure 
(see Chapter 2.1.1.1), which protects the drug against biological attacks (Tambosi et al., 2009). 
However, much higher removal rates of 57–82% were previously reported (Reif et al., 2008; 
Tambosi et al., 2010). Göbel et al., 2007 found removal rates rising from 39% for SRTs of 16 days 
to 60% for SRTs of over 33 days. This does not concur with the presented study, in which SRTs 
were well beyond 33 days. For a more detailed review of sorption behaviour of xenobiotics in 
activated sludge in the studied MBR, refer to Chapter 5.  
 
INFLUENCE OF TEMPERATURE ON BIODEGRADATION. A possible explanation for the comparably low 
removal rates for compounds otherwise described as biodegradable can be found in the low 
temperatures the NF-MBR worked at: water temperatures of about 10 °C and a mean air 
temperature of 6.9 °C. These are conditions very unlike those normally used, especially for 
laboratory studies and, to a lesser degree, for indoor pilot plants. Besides the higher 
temperatures in indoor environments, small laboratory installations can additionally experience 
increases in water temperature resulting from the use of the filtration equipment when not 
actively cooled (Comerton et al., 2008). Biological processes in the MBR are temperature 
dependent (Zuehlke et al., 2006). Clara et al., 2005 showed that microbial activity in activated 
sludge doubles with every 10 °C increase in temperature, leading to a higher biodegradation of 
xenobiotics. Consequently, since the majority of MBR studies work at the laboratory scale or 
with indoor pilot plants, discrepancies between the results given in the literature and those 
found in the presented study are to be expected.  
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SULFONAMIDES & TRIMETHOPRIM. Unlike macrolides, the sulfonamide sulfamethoxazole is 
negatively charged at pH-values above 5.8, which renders sorption to sludge as a removal path 
negligible (Tambosi et al., 2009). At the same time, biodegradation is deterred by the 
antimicrobial properties of the compound (Tambosi et al., 2009). Thus, moderate to poor 
removal of about 50–60%, as was found in the presented study as well as in other investigations 
(Radjenović et al., 2007; Reif et al., 2008; Tambosi et al., 2010) seems plausible. However, higher 
removal rates of > 80% have also been reported (Radjenović et al., 2009b; Tadkaew et al., 2011). 
Increased SRTs seem to elevate removal (Tambosi et al., 2010). The apparently low removal 
rates found in several studies can be explained by the cleavage of the human metabolite N4-
acetylsulfamethoxazole in wastewater, which is subsequently detected as the parent compound 
again (Radjenović et al., 2009b). In the presented study, the metabolite is amongst the ten 
highest concentrated substances in raw wastewater (see Chapter 3.3.2 and Figure 3-5), but 
practically completely absent in MBR permeate (see Figure 3-6), which points to the 
retransformation of N4-acetylsulfamethoxazole to sulfamethoxazole (Göbel et al., 2005b).  
In the presented study, trimethoprim values were found to be halved by MBR treatment. 
Removal rates for the drug reported in the literature differ widely (e.g. 17% (Tadkaew et al., 
2011), 36% (Reif et al., 2008), 67% (Radjenović et al., 2009b), 86%, 94% (Tambosi et al., 2010) 
and 97% (Celiz et al., 2009)). Enhanced removal with increasing SRTs was reported. Göbel et al., 
2007 found 30% removal with SRTs of 33 days and less, while SRTs of 60–80 days resulted in 
removal rates of 87%. Similar results were reported by Tambosi et al., 2009. However, they are 
not consistent with the results of the presented study, where comparatively low removal was 
achieved at SRTs > 80 days.  
  
PSYCHO-ACTIVE COMPOUNDS. Frequently, no or very poor elimination was reported for the 
psycho-active drug carbamazepine in MBR treatment (Clara et al., 2004b; Reif et al., 2008; Celiz 
et al., 2009; Radjenović et al., 2009b; Tadkaew et al., 2011), which is consistent with the results 
presented here. Changes in SRT have no influence on the elimination rate (Clara et al., 2004b). 
Possible reasons for the failing removal are retransformation processes in which human 
metabolites present in the raw wastewater are cleaved back into the parent compound (Miao et 
al., 2005). This could be supported by the fact that DHH is reduced considerably during 
treatment.  
Removal rates of 12% were reported for primidone (Tadkaew et al., 2011), which is similar to 
the zero removal found for CAS treatment (Hummel et al., 2006). This is contradictory to the 
results of the presented study (77%). The reason for this could be the very high SRT in this 
study, which enables greater biodegradation.  
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ICMS. In accordance with the presented study, other researchers found that iopamidol and 
diatrizoic acid were not biologically degradable by MBR treatment (Abegglen et al., 2009). For 
iopromide and iomeprol, however, minor biodegradation was found, which is not supported by 
the presented study. A possible reason for different removal rates might lie in the details of the 
MBR treatment, since e.g. iopromide biodegradation is reported to be dependent of aerobic 
conditions (Abegglen et al., 2009).  
 
THE MEMBRANE’S ROLE. To my knowledge, to date no data regarding the use of a NF-MBR for the 
treatment of raw wastewater have been published. In studies using the permeate of 
conventional MBRs as feed for downstream nanofiltration, profound improvement in the 
removal of xenobiotics was reported (Kim et al., 2007; Chon et al., 2011). While the elimination 
capacity of the MBR treatment in these studies was comparable to – or for some substances 
considerably less than – the elimination capacity in the presented study (e.g. Kim et al., 2007, 
removal of naproxen: 36%; trimethoprim, diclofenac: negative removal rates), concentrations 
for a range of compounds with moderate, poor or no removal in the NF-MBR of the presented 
study were reported to drop below the limit of detection after NF filtration, and the flame 
retardant TCEP was 85% removed (Kim et al., 2007; Chon et al., 2011).  
These higher removal rates reported from downstream NF filtration of MBR permeate are likely 
to have been achieved by the use of tighter NF membranes than those applied in the presented 
study. Tighter membranes, however, would be difficult to use in direct contact with raw 
wastewater which has not been pre-treated. The combination of a full MBR treatment with a 
connected NF treatment downstream would, on the other hand, increase energy and 
maintenance costs drastically (see Chapter 2.2.4).  
To summarise, the performance of the NF-MBR studied was for most compounds in the range 
reported for conventional MBR treatment. This suggests that a loose NF membrane as used here 
does not add greatly to the removal efficiency compared to UF, since many of the compounds not 
detained in UF filtration pass through loose NF membranes as well. Fouling processes seem not 
to improve their performance with regard to the substances in question.  
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3.3.4 FATE OF METABOLITES AND TRANSFORMATION PRODUCTS DURING MBR TREATMENT  
In this study, TPs of iopromide and metabolites of carbamazepine and sulfamethoxazole were 
investigated. As depicted in Figure 3-5 and Table 3-8, 6 out of 12 TPs of iopromide were found in 
influent samples as well as all three studied metabolites. In particular, the existence of 
environmental TPs in raw municipal wastewater indicates the likelihood of transformation 
processes taking place in the sewer system even before it reaches the WWTP.  
 
TPS OF IOPROMIDE. When comparing the maximum concentrations in the permeate from the MBR 
(Figure 3-13) with those in the influent (Figure 3-5), a drastic change is visible, with 9 out of the 
10 highest concentrated analytes being TPs of iopromide in the permeate. Overall, all studied 
TPs are found in the permeate samples, 10 out of 12 with average concentrations higher than 
1,000 ng/L (Table 3-8). This clearly demonstrates a) the formation of these substances within 
the MBR and b) the inability of the NF to retain them. The removal of the parent compound 
iopromide of over 90% (see above chapter and Figure 3-12) can be assumed to be completely 
caused by transformation, even though Figure 3-14 shows that the stacked concentrations of the 
TPs in the effluent do not equal the amount of the parent substance in the influent. This probably 
indicates more existing TPs which were not investigated in this study.  
 
 
 
Figure 3-13: Maximum concentrations (cmax permeate [ng/L]) of each target compound in the permeate from 
the NF-MBR. Colour codes show the compound group.  
 
< LOQ/ 
not detected 
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Figure 3-14: Concentration patterns of iopromide and its TPs in influent and effluent samples from the NF-
MBR over the course of the study in [ng/L] and in [%] (small graph at the top right). 
 
SULFAMETHOXAZOLE METABOLITE. The human metabolites investigated show a different pattern. 
While the amount of the parent drug, sulfamethoxazole, is approximately halved during NF-MBR 
treatment, its metabolite N4-acetylsulfamethoxazole is removed completely from the permeate 
water (Table 3-8; Figure 3-15). In previous studies, higher effluent values of sulfamethoxazole 
compared to corresponding influent values were described for CAS (Göbel et al., 2005b; Chang et 
al., 2008a), suggesting that a large amount of the metabolite present in the wastewater is 
cleaved, and re-transformation of the parent compound occurs. This mechanism is likely to 
occur in the NF-MBR as well; thus the estimated removal rate of 47% for sulfamethoxazole 
(Figure 3-12) is probably lower than the “true” elimination.  
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Figure 3-15: Concentration patterns of sulfamethoxazole and its metabolite N4-acetylsulfamethoxazole in 
influent and effluent samples from the NF-MBR over the course of the study in [ng/L] and in [%] (small 
graph at the top right). 
 
CARBAMAZEPINE METABOLITES. The amounts of carbamazepine do not show any decrease during 
NF-MBR treatment (Figure 3-10, Table 3-8), which tallies well with earlier findings in both CAS 
and various MBR systems (Öllers et al., 2001; Clara et al., 2004b; Kreuzinger et al., 2004; Zuehlke 
et al., 2004; Bernhard et al., 2006; Gros et al., 2006a; Vieno et al., 2006; Radjenović et al., 2007; 
Santos et al., 2007; Vieno et al., 2007; Zhang and Zhou, 2007; Bo et al., 2008; Reif et al., 2008; Bo 
et al., 2009; Radjenović et al., 2009b; Ying et al., 2009; Pedrouzo et al., 2011; Ryu et al., 2011). In 
a study by Miao et al., 2005, amounts of the metabolite 10,11-Dihydro-10,11-
dihydroxycarbamazepine (DHH) in wastewater were found to be up to three times higher than 
the parent compound. This is less than found in this study, where the DHH amount was 6.5 times 
higher than the parent substance in the influent of the system. During NF-MBR treatment, the 
DHH values were reduced by a factor of three. The second metabolite studied, DH-CBZ, shows 
low concentrations in the same range in both influent and effluent. Overall, the distribution 
pattern of carbamazepine and its metabolites is relatively stable during MBR treatment (Figure 
3-16).  
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Figure 3-16: Concentration patterns of carbamazepine and its metabolites DHH and DH-CBZ in influent 
and effluent samples from the NF-MBR over the course of the study in [ng/L] and in [%] (small graph at 
the top right) 
 
3.3.5 REMOVAL OF XENOBIOTICS FROM THE AQUEOUS PHASE BY PURE NF 
OVERVIEW. To compare the performance of NF-MBR technology with that of a pure NF process 
without biological treatment, feed water of the NF-MBR plant was treated with a NF lab-scale 
module and analysed for selected antibiotics, psycho-active compounds, ICMs and OPs. The 
module was operated for 5 days before sampling (for operation details see Chapter 3.2.3), and 
lost water was replaced daily with fresh influent water from the treatment plant. It was found 
that the feed water, despite the fact it came from the same treatment plant, showed a slightly 
different pattern of xenobiotic substances than the feed water of the NF-MBR: Ten substances 
which were regularly detected in the influent of the NF-MBR were not detected in the feed of the 
NF (sulfadimethoxine, morphine, oxycodone, oxazepam, TnBP, TiBP, TEHP, TPP, TCEP, TCPP). 
On the other hand, three substances (sulfadimidine, diazepam and nordiazepam) were detected 
in the NF feed which were not found even once in the feed of the NF-MBR (Figure 3-17). The 
nonappearance of a number of substances suggests sorption processes in the NF system were 
occurring despite the equilibration time of 5 days which was allowed before sampling, which 
should be sufficient for the establishment of membrane saturation according to results found in 
the literature (Verliefde et al., 2006; Comerton et al., 2008; Botton et al., 2012). 
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Figure 3-17: Removal of xenobiotics in pure NF treatment [%]. n.d. = not detected; < LOQ = below the limit 
of detection. 
 
COMPARISON WITH NF-MBR. As illustrated in Figure 3-18, several xenobiotics show lower 
removal rates in pure NF treatment compared to NF-MBR treatment (removalNF-MBR/removalNF 
> 1), while for other compounds, higher removal rates were found during NF filtration 
(removalNF-MBR/removalNF < 1). For the substances showing less removal during NF treatment, 
biological degradation can be assumed to be the essential elimination path. Although it can be 
supposed that biological activity was not totally absent in the NF reactor due to the test 
conditions (surrounding temperature of 20 °C, presence of light and nutrients in the raw 
wastewater), it was certainly very low compared to that in the NF-MBR reactor, which accounts 
for the insufficient removal of dihydrocodeine, primidone, N4-acetylsulfamethoxazole, codeine, 
doxepin, iopromide and TBEP. The exclusive use of NF filtration is clearly not effective for their 
elimination in wastewater. Likely reasons lie in their physico-chemical properties, such as 
molecular weight, and their water solubility. Nonetheless, no correlations were found between 
retention by pure NF and physico-chemical properties of the xenobiotics (data not shown), 
which concurs with results reported in the literature (Comerton et al., 2008). For 10,11-
Dihydro-10,11-dihydroxycarbamazepine and iomeprol, comparable removal between 70 and 
80% was found for NF-MBR and NF treatment. This could suggest either that the bioprocesses 
necessary for the degradation are active even in the NF reactor or that their removal is governed 
by different processes during NF treatment. These processes are of especial interest with regard 
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to substances which show higher removal rates in pure NF treatment compared to NF-MBR 
treatment. For the positively charged antibiotics clarithromycin, roxithromycin and 
trimethoprim, sorption processes to the negatively charged membrane are the most likely 
reason for removal from the water phase. The properties of a new membrane are not yet altered 
by biofouling, thus the sorption could be greater than in a fouled membrane (Semião and 
Schäfer, 2010). For negatively charged compounds like sulfamethoxazole and sulfadimidine, 
high removal by a loose NF membrane can be put down to charge repulsion between the 
xenobiotic and the equally negatively charged membrane surface. Accordingly, Comerton et al., 
2008 described 90% removal of sulfamethoxazole by a loose membrane from WWTP effluent 
water after a short membrane pre-treatment time (48 h). The repulsion effect as well as sorption 
processes are pronounced in unfouled membranes and are likely to change significantly with 
biofilm development over the course of the usage (Semião and Schäfer, 2010).  
The seemingly higher removal of temazepam and 10,11-dihydrocarbamazepine in pure NF 
treatment could be explained by the missing microbial degradation of other benzodiazepines or 
benzodiazepine metabolites and carbamazepine and carbamazepine metabolites, respectively, in 
the NF reactor. As written before (see Chapter 3.3.3), microbial activity can lead to apparently 
increasing amounts of a substance during biological treatment, masking removal by continuous 
“production” of the substance by e.g. cleavage processes. Therefore, in the absence of 
considerable bioactivity, a seemingly higher removal rate is possible.  
A similar process might be supposed to cause the occurrence of diazepam and nordiazepam in 
the feed water of the NF. Water refills of the feed water tank were carried out exclusively in the 
early mornings. Considering the low night temperatures during the sampling campaign, it could 
be assumed that microbial activity in the first clarifier (a relatively shallow, wide, open water 
basin) was low during the night. This might have prevented the biodegradation of diazepam and 
nordiazepam, which during the day was higher, and therefore the substances were not present 
in 24 h composite samples at concentrations above LOQ, whereas the concentration of the 
substances in the feed tank (very slightly) exceeded LOQ. This would be consistent with the fact 
that oxazepam, which is at the end of the metabolic pathway of a number of benzodiazepines 
(Hummel et al., 2006), was not found in the feed water of the NF. The complete removal by NF 
treatment of the small amounts of diazepam and nordiazepam cannot with certainty be 
attributed to true filtration elimination, but could be due to sorption – which is especially 
significant for compounds in low concentrations, where practically the whole amount of the 
substance finds sorption sites on the membrane and is temporarily removed from the aquatic 
phase (Semião and Schäfer, 2010).  
Elimination of carbamazepine of about 70% by treatment with a loose NF membrane, as found 
in the presented study, has been reported before for pre-treated wastewater (Comerton et al., 
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2008). Such high removal rates are not explainable by the physico-chemical properties of the 
substance. Due to its small molecular size, carbamazepine is not filtered out by loose NF 
membranes, and since the compound is neutral, neither charge repulsion nor sorption are 
expected to play any role. Several studies have suggested, though, that the dipole moment of a 
substance might be important for retention processes (Semião and Schäfer, 2010). As with other 
substance-membrane interactions, these processes change with the fouling of the membrane.  
In the same way, the high removal rate of several further substances by pure NF treatment 
(methadone, TCEP, TCEP, diatrizoic acid and iopamidol), as well as the absence of substances 
from the feed water (sulfadimethoxine, morphine, TnBP, TiBP, TPP, TCPP), are probably also 
based on the above-mentioned mechanisms. Since specifications of the properties of the fouling 
layers of the membranes from NF- and NF-MBR reactors are beyond the scope of this study, the 
contradictory results cannot be conclusively explained. The fact that, even for well studied 
substances, removal mechanisms are neither completely clear nor safely predictable, illustrates 
the complexity of membrane related treatment. 
 
 
 
Figure 3-18: Removal comparison of the effectiveness of NF-MBR and pure NF treatment described as the 
ratio (RENF-MBR/RENF) with RE = removal [%]; colour code see Figure 3-5. Note that the negative values for 
CBZ, DH-CBZ, DTZ and IPM are based on negative removals (average removal rates from -9 to -219%) 
during NF-MBR treatment (see Figure 3-12) while NF treatment of these substances yielded positive 
removal rates of 69 to 74% (see Figure 3-17).  
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3.4 CONCLUSIONS  
In this study, the presence and fate of 52 xenobiotics in municipal wastewater was studied. Their 
removal from raw wastewater by an NF-MBR equipped with a loose NF membrane was 
investigated. NF is thought to increase xenobiotic retention in comparison to conventional MBR 
treatment. At the same time, a loose NF is less cost- and maintenance-intensive than a tight 
membrane, which is prone to clogging up rapidly. However, despite higher removal capacities 
for some compounds, the utilisation of a loose membrane in a MBR reactor did not overall yield 
better results than have been reported for MBRs equipped with UF- or MF membranes. This was 
especially true for substances known to be biodegradable. This was caused by low microbial 
activity in the NF-MBR operated outdoors under winter conditions and reveals general 
restrictions to be taken into account in the use of MBRs.  
The performance of the NF-MBR was compared to pure NF treatment. In the latter, 
biodegradable substances were removed less effectively, while comparably high removal of 
several substances could be assigned to physico-chemical xenobiotic-membrane interactions. 
Since these interactions are bound to change with membrane fouling, the positive results have to 
be assumed to be temporary and reversible.  
In recent years there have been several attempts to provide schemes for the prediction of 
xenobiotic elimination in wastewater treatment. Thus, Joss et al., 2006 proposed a classification 
scheme for biological degradation in wastewater treatment which in principle could be applied 
to MBR treatment as well because of fundamental similarities (see Chapter 2.2). Tadkaew et al., 
2011 proposed a qualitative framework for the prediction of trace organic removal by MBR 
treatment based on the molecular features hydrophobicity and molecular weight, and chemical 
structure. Bellona et al., 2004 developed a rejection scheme for organic micropollutants in 
membrane treatment. However, to date, the mechanisms contributing to the removal of 
xenobiotics in wastewater are far from being fully understood and are in some areas still 
unpredictable, thus obstructing the prediction of xenobiotic removal (Semião and Schäfer, 
2010), as the results of this study have shown.  
 
Chapter 4 
 
page | 114  
4. OCCURRENCE OF XENOBIOTIC ORGANIC MICROPOLLUTANTS IN 
RAW HOSPITAL WASTEWATER AND THEIR REMOVAL BY USE OF A 
PARTICLE-SUPPORTED BIOFILM REACTOR (PS-BFR) 
 
Water has no taste, no colour, no odour; it cannot be defined, art relished while ever mysterious. 
Not necessary to life, but rather life itself.  
– Antoine de Saint-Exupery (1900-1944), Wind, Sand, and Stars, 1939 –  
 
 
4.1. INTRODUCTION 
DECENTRALISED WASTEWATER TREATMENT: HOSPITALS. In recent years, hospitals have been 
discussed as possible point sources of large amounts of pharmaceuticals which normally reach 
the municipal wastewater stream untreated, where they are diluted and finally add to the 
pharmaceutical load of municipal WWTPs (for details, see Chapters 1 and 2.1). One possible way 
to reduce xenobiotic loads in both wastewater and receiving waters is source treatment, 
meaning the decentralised treatment of specific wastewater sources. Joss et al., 2006 identified 
this procedure as favourable since (biological) treatment is more promising in high-strength, 
undiluted raw wastewater at a point source.  
  
PARTICLE-SUPPORTED BIOFILM. For numerous reasons, one being the high spatial footprint, 
conventional activated sludge treatment (CAS) is poorly suited to decentralised wastewater 
treatment at point sources (see Chapter 2.2.1). Suspended carrier biofilm processes (SCBPs), 
also referred to as particle-supported biofilm reactors (PS-BFRs), present a possible alternative. 
The PS-BFR set-up allows for a higher SRT resulting in a different composition of the microbial 
community, including slow growing microorganisms that are not present in suspended-growth 
systems involved in activated sludge treatment (Hall, 1987; van Loosdrecht and Heijnen, 1993; 
Nicolella et al., 2000b; for a detailed description of the principles of biofilm reactor and of the 
characteristic features of PS-BFRs, see Chapter 2.2.2).  
 
XENOBIOTIC REMOVAL. PS-BFRs have proven their general suitability for wastewater treatment 
(Nicolella et al., 2000a,). However, to date very few studies have been published on the subject of 
the xenobiotic removal capacity of PS-BFRs. Results given in the literature are mainly based on 
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bench-scale installations, and are inconclusive. Thus, in a study utilising a fixed-bed reactor for 
the removal of diclofenac from wastewater, no removal was found to have taken place (González 
et al., 2006). This indicates that PS-BFRs are less efficient than CAS treatment, which usually 
achieves removal rates for diclofenac of some 10–60% (Verlicchi et al., 2012b). In contrast, other 
researchers reported that PS-BFRs are more effective than CAS treatment at removing several 
pharmaceuticals, including diclofenac (Falås et al., 2012; Falås et al., 2013). To my knowledge 
there are no studies reporting the use of particle-supported biofilm reactors for the treatment of 
xenobiotics in hospital wastewater.  
 
AIM OF THIS STUDY. However, PS-BFRs seem to hold promise for this application since the 
undiluted raw wastewater is suspected to be sufficiently nutrient-rich to support a dense 
particle-supported microbial community. By providing a favourable environment for specialised, 
slow-growing microorganisms, the PS-BFR allows for the adaptation of the biocenosis to the 
specific environmental conditions in raw hospital wastewater (e.g. infrequent inflow, the 
possible presence of large amounts of disinfectants etc.). In turn, these specialised 
microorganisms might facilitate increased removal of xenobiotics e.g. by cometabolic 
degradation. Thus, a PS-BFR pilot plant was installed at the effluent of a municipal hospital. After 
a start-up phase of 199 days, concentration profiles of 47 xenobiotics – pharmaceuticals and 
organophosphorus compounds (OPs) – in influent and effluent were created over a period of one 
week. These profiles were used for characterising xenobiotic occurrence in hospital wastewater 
and estimating removal rates. The aim of this study was to investigate a) the temporal 
distribution patterns of pharmaceuticals (including metabolites and transformation products) 
and OPs in raw wastewater from a general hospital, and b) the removal capacity of a PS-BFR 
pilot plant (anoxic-oxic) with regard to these compounds in raw hospital wastewater.  
 
4.2 MATERIALS AND METHODS  
4.2.1 REFERENCE COMPOUNDS, CHEMICALS AND STANDARDS 
Roxithromycin (ROX), carbamazepine (CBZ), oxazepam (OZP), temazepam (TZP), oxycodone 
(OCN), doxepin (DXP), primidone (PMD), diazepam (DZP), nordiazepam (NZP), methadone 
(MTD), sulfamethoxazole (SMX), trimethoprim (TMP) and tri-iso-butyl phosphate (TiBP) were 
purchased from Sigma-Aldrich, Seelze, Germany; clarithromycin (CLA), diatrizoic acid (DTZ), 
iopromide (IMI) were purchased from LGC Promochem Wesel, Germany; bezafibrate (BZF) 
diclofenac (DCF), ibuprofen (IBP), naproxen (NPX), tributyl phosphate (TnBP), tris(2-
butoxyethyl) phosphate (TBEP), triphenyl phosphate (TPP), tris(1,3-dichloro-2-propyl) 
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phosphate (TDCPP), tris(2-chloroethyl) phosphate (TCEP), tris(2-ethylhexyl) phosphate (TEHP), 
tris(chloropropyl) phosphate (TCPP) were purchased from Dr. Ehrenstorfer, Augsburg, 
Germany; iopamidol (IPM), iomeprol (IOP) were provided from Bayer-Schering Pharma, Berlin, 
Germany; codeine (CDN), dihydrocodeine purchased from DHC, Th. Geyer, Renningen, Germany; 
10,11-dihydrocarbamazepine (DH-CBZ) (Alltech, USA); 10,11-Dihydro-10,11-
dihydroxycarbamazepine (DHH) bought from µ-Mol, Luckenwalde, Germany; morphine was 
purchased from MPN, Cambridge Isotopes Lab., Saarbrücken, Germany; N4-
acetylsulfamethoxazole (N-Ac-SMX) was a self-synthesis by EAWAG, Dübendorf, Switzerland); 
iopromide TP 805 A (IMI-TP 805 A), iopromide TP 805 B (IMI-TP 805 B), iopromide TP 819 
(IMI-TP 819), iopromide TP 729 A (IMI-TP 729 A), iopromide TP 817 A (IMI-TP 817 A), 
iopromide TP 787 A (IMI-TP 787 A), iopromide TP 731 A (IMI-TP 731 A), iopromide TP 731 B 
(IMI-TP 731 B), iopromide TP 759 (IMI-TP 759), iopromide TP 701 B (IMI-TP 701 B), iopromide 
TP 701 A (IMI-TP 701 A), iopromide TP 643 (IMI-TP 643) were laboratory-prepared as 
described by Kormos et al., 2009. (E)-9-[O-(2-methyloxime)]-erythromycin (EM-ERY) was self-
synthesised according to Schlüsener et al., 2003.  
From the following suppliers the internal standards (IS, analytical grade > 98% purity) were 
purchased: codeine-d6, diazepam-d5, methadone-d9, morphine-d6, nordiazepam-d5, 
tributylphosphate-d27 (Cambridge Isotopes Lab., Saarbrücken, Germany); oxazepam-d5 (Sigma, 
Deisenhofen, Germany); 13C-15N-carbamazepine, diatrizoic acid-d6, diclofenac-d4, ibuprofen-
d3, iomeprol-d3, iopamidol-d8 (Campro Scientific, Berlin, Germany); bezafibrate-d4, 
sulfadimethoxine-d4, sulfadimidine-d4, sulfamerazine-d4, sulfamethoxazole-d4, and N4-
acetylsulfamethoxazole-d4 (Toronto Research Chemicals, North York, ON, Canada), desmethoxy-
iopromide (DMI) (Bayer-Schering Pharma, Berlin, Germany); triphenylphosphate-d15 (TPP-
d15) was self synthesised according to Andresen et al., 2004.  
All organic solvents (n-heptane, n-hexane, acetone, methanol, acetonitrile, ethyl acetate) were 
picograde and purchased from Merck (Darmstadt, Germany). Pure water obtained from a Milli-Q 
system (Integral 3/5/10/15, Millipore, Billericis, MA, USA) was used. Formic acid (98–100%) 
was ACS grade and purchased from Merck (Darmstadt, Germany).  
For each analytical compound group (antibiotics, psycho-active drugs and organophosphorus 
compounds) a standard solution of all target analytes and an internal standard mix at a 
concentration of 10 µg/mL (OPs: 5 µg/mL) and 1 µg/mL respectively were prepared in 
methanol and stored in the dark at 4 °C.  
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4.2.2 THE PS-BFR PILOT PLANT 
FACILITY. The PS-BFR pilot plant (EMW Filtertechnik GmBH, Diez, Germany and Aquadetox 
International GmBH, Altmannshofen, Germany) was installed at the main effluent of the 
municipal hospital in Giessen. The hospital has 186 beds and about 200 medical staff. The 
hospital treats roughly 10,000 inpatients as well as 17,250 outpatients per year (Agaplesion 
Evangelisches Krankenhaus, 2013). Additionally, the hospital hosts a range of specialised 
healthcare centres exclusively for the treatment of outpatients. These include a group radiology 
practice where some 10,000 computer tomographies (CT) and 10,000 magnetic resonance 
tomographies (MRT) are carried out per year, the majority of them using X-ray contrast media 
(Evangelisches Krankenhaus Mittelhessen, 2009). The hospital and clinics together offer the 
whole range of medical services (e.g. surgery, internal medicine including cardiology and 
angiology, maternity clinic and geriatric medicine). The hospital’s annual wastewater discharge 
has been estimated as some 20,000m3. The main sewer receives water from the different wards, 
clinics and departments as well as from the hospital kitchen, but not water from the laundry or 
rainwater, which are discharged via a separate sewer.  
 
REACTOR SETUP. Water from the main sewer was pumped into the pilot plant approximately 
every 15-30 min between 7 a.m. and 7 p.m., depending on the wastewater volume in the sewer, 
with filling levels automatically controlled by sensors. At night, no wastewater was fed into the 
pilot plant. The pilot plant was housed in a 6 metre overseas shipping container and consisted of 
a primary settling tank, two sequential biofilm reactors and a secondary settling tank. All tanks 
and reactors were made of stainless steel. The biofilm reactors were constructed to hold a 
volume of 2 m3 each. 30% of the volume of each reactor was filled with polyurethane carriers 
(polyurethane foam in the form of 30 x 30 x 30cm cubes, bulk density: 22.5–27.5 kg/m3, specific 
surface area: 2,000 m2/m3, EMW Filtertechnik GmBH, Diez, Germany, Figure 4-1), which equals 
0.7m3 of carrier material per reactor. One third of the carrier material used consisted of 
PORET®aqua carriers pre-inoculated by the manufacturer with bacteria cultures typically used 
for wastewater treatment (EMW Filtertechnik GmBH, Diez, Germany), before being installed in 
the reactors.  
 
MODE OF OPERATION. The pilot plant was allowed a start-up phase of 199 days before the 
beginning of the sampling campaign to reach a stable state. 35 days prior to the sampling a final 
adjustment was made to the aeration, in which the first biofilm reactor was set up as a 
denitrification unit. The mean amount of dissolved oxygen in the first reactor during the 
sampling period was 0.355 mg/L, while the second biofilm reactor displayed a higher mean 
value of 3.41 mg/L. Gas sparging was used to keep the biofilm carriers in suspension. The 
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reactors incorporated 6 aerator candles each. By operating only the two middle aerators in 
reactor 1 and the two outer ones in reactor 2, liquid circulation in the reactors was achieved due 
to the gas hold-up difference between sparged and unsparged zones with different fluid 
densities, thus creating in principle a biofilm airlift suspension reactor (BAS, see Chapter 2.2.2). 
However, aeration was discontinuous, with aeration periods of 15 sec and 100 sec followed by 
aeration-free intervals of 750 sec and 380 sec in reactor 1 and 2 respectively. During the 
unsparged intervals the particles did not sink to the bottom of the reactors but created a 
fluidised bed of biofilm carriers in the upper half of the reactors. The pilot plant thus combined 
in one application the two typical types of suspended carrier biofilm processes (SCBP, see 
Chapter 2.2.2). 
The wastewater feed volume into the pilot plant was 2m3/d. 8m3/d of treated wastewater was 
recirculated from the secondary settling tank back into biofilm reactor 1 (denitrification). The 
HRT of the pilot plant during the sampling time ranged from 44 to 51 h (average HRT: 47.5 h). 
The chemical oxygen demand (COD) was 327 mg/L and 69.4 mg/L in influent and effluent, 
respectively. 
The average water temperature during the sampling period was 22 + 1.5 °C, 18 + 0.8 °C and 19 + 
0.9 °C in the influent, the first and second biofilm reactor, respectively. The average pH values of 
influent and effluent were 7.95 + 0.247 and 7.44 + 0.058, respectively.  
 
4.2.3 SAMPLING AND SAMPLE PREPARATION  
24-h-composite samples of influent (primary clarifier tank) and effluent (secondary clarifier 
tank) of the biofilm reactor were continuously collected by a peristaltic pump over a period of 9 
days with an offset of 48 h between influent and effluent samples to account for the HRT (see 
Chapter 4.2.2). Thus, an actual time series over 7 days was accomplished. All glassware used 
during sampling and extraction was pre-cleaned with ultra pure water, heptane and acetone, 
and subsequently heated overnight at > 240 °C. All samples were cooled during sampling, 
transported on ice in the dark to the laboratory directly after sampling was terminated, and 
were extracted within 4 h after arriving.  
 
4.2.4 ANALYTICAL PROCEDURES AND METHOD VALIDATION 
The details of the entire analytical procedure are described elsewhere (see Chapter 3.2.5). In 
short, samples were filtered, subsequently diverted in aliquots for the analysis of various 
compound groups (neutral analytes, acidic analytes, iodinated x-ray contrast media and their 
TP), cleaned, and pre-concentrated via off-line solid phase extraction. Analysis was then carried 
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out by multiple LC-MS/MS runs for acidic analytes, antibiotics, ICMs and TPs of iopromide, 
psycho-active compounds and OPs. 
 
   
Figure 4-1: Biofilm carriers. Left: 1st generation, unused and after biofilm development. Middle: Carriers 
applied in PS-BFR 1. Right: 2nd generation of carrier material (PORET®aqua). Photo: J. Krisam (left), U. 
Kraus (middle), EMW (right) 
 
4.3 RESULTS AND DISCUSSION  
4.3.1 METHOD VALIDATION 
Quality assurance and quality control (QA/QC) of the applied analytical procedures as well as 
calibration data, LOQ and blank values have already been described elsewhere (see Chapter 
3.3.1).  
The accuracy of the analytical protocols for the matrix of the studied hospital wastewater was 
determined by estimating the relative recovery of target compounds spiked into native influent 
and effluent samples before extraction, and subsequently subtracting the amount of native 
samples from the results found in the spiked samples (Table 4-1, see also Chapters 3.2.6 and 
3.3.1).  
For ICMs, spiked samples yielded concentrations above the calibration range, and therefore the 
accuracy of ICM measurement was not determinable for the hospital wastewater. However, the 
accuracy of ICM measurement in other wastewater types has been described previously and was 
found to be satisfactory (see Chapter 3.3.1). 
 
  
Chapter 4 
 
page | 120  
Table 4-1: Accuracy of the analytical procedure [%] for influent and effluent and instrumental precision 
(intraday/interday) for the five analytical compound groups. 
 
Accuracy [%] 
 
Instrumental precision 
[RSD, %] 
 
Influent 1 Effluent 2 
 
intraday6 interday7 
 
Average SD Average SD 
   
Antibiotics 
CLA 89 9 113 23 
 
7 7 
ROX 93 10 100 16 
 
3 21 
SMX 125 40 89 3 
 
4 11 
N-Ac-SMX 93 36 83 ---3 
 
5 6 
TAM 76 23 84 31 
 
3 11 
TMP 38 6 90 20 
 
8 15 
min 38 6 83 3 
 
3 6 
max 125 40 113 31 
 
8 21 
ICMs 
DTZ a.r.5 a.r.5 a.r.5 a.r.5 
 
8 8 
IOP a.r.5 a.r.5 a.r.5 a.r.5 
 
8 12 
IPM a.r.5 a.r.5 a.r.5 a.r.5 
 
10 12 
IMI a.r.5 a.r.5 a.r.5 a.r.5 
 
4 9 
min a.r.5 a.r.5 a.r.5 a.r.5 
 
4 8 
max a.r.5 a.r.5 a.r.5 a.r.5 
 
10 12 
NSAIDs and bezafibrate 
BZF 86 18 148 ---3 
 
4 26 
DCF 48 6 93 ---3 
 
4 13 
FNP 90 15 68 ---3 
 
8 12 
IBP 87 ---3 38 ---3 
 
5 4 
NPX 57 9 43 ---3 
 
9 12 
min 48 6 38 ---3 
 
4 4 
max 90 18 148 ---3 
 
9 26 
Pycho-active compounds 
CBZ 103 8 108 0 
 
2 3.4 
DH-CBZ 88 5 99 1 
 
1 8.2 
DHH 103 18 152 ---3 
 
8 8.2 
PMD 175 12 169 ---3 
 
8 10.8 
DXP 39 7 40 ---3 
 
18 19.6 
CDN 85 10 90 10 
 
3 5.9 
DHC 127 18 97 17 
 
6 6.8 
MTD 84 3 79 9 
 
3 8.5 
MPN 71 10 46 ---3 
 
12 n.d.4 
OCN 65 9 108 ---3 
 
6 16.6 
DZP 107 6 109 1 
 
3 5.8 
NZP 90 5 98 1 
 
3 2.7 
OZP 127 23 131 3 
 
10 9.0 
TZP 64 5 76 2 
 
4 5.7 
min 39 3 40 0 
 
1 3 
max 175 23 169 17 
 
18 20 
OPs 
TBEP 94 23 n.d.4 n.d.4 
 
1.45 7.3 
TnBP 51 3 48 4 
 
2.01 4.9 
TiBP 49 12 47 7 
 
3.50 5.9 
TEHP 43 3 62 8 
 
1.68 10.3 
TPP 67 7 20 3 
 
0.92 8.5 
TCEP 96 11 97 11 
 
3.36 8.7 
TCPP 96 8 91 14 
 
3.00 8.0 
TDCPP 100 11 86 18 
 
1.76 6.8 
min 43 3 20 3 
 
1 5 
max 100 23 97 18 
 
4 10 
1n=3-6; 2n=2; 3n=1; 4n.d. = not detected; 5a.r. = above concentration range; 6n=4-8; 7n=8-12 
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4.3.2 OCCURRENCE OF XENOBIOTIC MICROPOLLUTANTS IN HOSPITAL WASTEWATER 
Table 4-2 shows the average concentrations of the target substances over the course of the 
study. Out of 47 analytes in total, 3 were not found in any samples (methadone, diazepam, 
TEHP) while 7 more were only detected in concentrations below LOQ: the ICM iopamidol, 5 
transformation products of the ICM iopromide (IMI-805 b, IMI-787 a, IMI-731 b, IMI-729 a, IMI-
701 b) and the OP TPP. OPs are generally regarded as being ubiquitously distributed. However, 
the most common applications of TPP (e.g. use in automobiles, electronic housings, varnishes, 
lubricant and hydraulic fluids, see Chapter 2.1.2) seem to be of minor importance in the case of 
hospital wastewater. The absence of ICM transformation products in raw hospital wastewater is 
to be expected, since no environmental degradation can have taken place since excretion after 
being administered.  
 
4.3.2.1  UNTREATED HOSPITAL WASTEWATER 
While one of the ICMs investigated was not found in any samples at all (see above), by far the 
most highly concentrated target substances in raw hospital wastewater were also substances in 
this compound class (Figure 4-2): diatrizoic acid, for which a maximum concentration of over 1.6 
mg/L (1,605,781 ng/L) was found, and iomeprol, at over 0.6 mg/L (656,846 ng/L). While the 
other target analytes were considerably less concentrated, still 20 substances were found in 
maximum concentrations of over 1,000 ng/L: nine ICMs and TPs of ICMs (diatrizoic acid, 
iomeprol, IMI-TP 805 A, IMI-TP 819, iopromide, IMI-TP 731 A, IMI-TP 701 A, IMI-TP 759, IMI-TP 
817 A), two antibiotics (sulfamethoxazole, clarithromycin) and an antibiotic metabolite (N4-
acetylsulfamethoxazole), two NSAIDs (ibuprofen, diclofenac), one lipid regulator (bezafibrate), 
three psycho-active substances and one of their metabolites (Oxazepam, Primidone, 
Carbamazepine, 10,11-dihydro-10,11-dihydroxycarbamazepine) as well as the organophosphate 
TBEP.  
 
ANTIBIOTICS. Amounts of antibiotics found in raw hospital wastewater have been reported as 
differing widely, both over time at the same hospital and also between hospitals with different 
specifications and medical services (Lindberg et al., 2004; Chang et al., 2010; Gros et al., 2013; 
Santos et al., 2013). Taking this into account, the concentrations of antibiotics found in the 
presented study largely corroborate those previously reported (e.g. Gómez et al., 2006; Sim et 
al., 2010). Considerably higher roxithromycin values, with average values exceeding 2,000 ng/L, 
were reported from hospital effluents in China (Chang et al., 2010), while various European 
studies showed roxithromycin concentrations similar to those found in the presented study 
(Kovalova et al., 2012; Gros et al., 2013). Verlicchi et al., 2012a, investigating the composition of 
the same Italian hospital wastewater in summer and winter times, only found roxithromycin 
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during the winter season (Verlicchi et al., 2012a). Remarkably higher trimethoprim 
concentrations than found in other studies – and tenfold higher than found in the presented 
study – were reported from two hospitals in Oslo, Sweden (Thomas et al., 2007).  
 
 
 
Figure 4-2: Maximum concentrations (cmax influent [ng/L]) of each target compound in the influent of the 
PS-BFR. Colour codes show the compound group (including metabolites). 
 
ICMS. Diatrizoic acid concentrations found in raw wastewater from a Swiss hospital (Kovalova et 
al., 2012) were only a third of those in the presented study. On the other hand, the same study 
reported iopamidol concentrations of 2,599,000 ng/L, whereas this ICM was not quantifiably 
detected in the presented study. An investigation of raw wastewater from a university hospital 
and a general hospital in Portugal reported considerably higher average concentrations of 
iopromide (195,683 ng/L and 260,908 ng/L, respectively) than were found in the presented 
study; on the other hand fluctuations in the ICM concentrations were similarly high (Santos et 
al., 2013). For a hospital in Switzerland, iopromide concentrations up to 40 times higher than 
presented here were reported (Weissbrodt et al., 2009). Average iomeprol concentrations 
reported in literature corroborate those found in this study (Weissbrodt et al., 2009; Kovalova et 
al., 2012). Overall, it can be assumed that very specific application patterns are reflected in the 
concentrations found in raw hospital wastewater from different sources.  
< LOQ/ 
not detected 
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As mentioned before, the transformation products of ICMs were not expected to be found in raw 
hospital wastewater because – as presumably inert substances – they have been described as 
being excreted completely unchanged after treatment (Pérez and Barceló, 2007; see Chapter 
2.1.1.2). However, no biodegradation could have taken place after excretion due to the extremely 
short time the wastewater was in the main hospital sewer before reaching the sampling point 
(less than 30 min). 
Likewise, photodegradation was impossible since the wastewater ran through an underground 
sewer. Thus, another degradation pathway had to be responsible for the occurrence of the ICM 
transformation products. A possible reason for the rapid degradation of iopromide could have 
been the presence of high concentrations of aggressive substances (e.g. diagnostic agents, 
disinfectants) in the undiluted hospital effluent water, but the investigation of such cross-
interactions lies beyond the scope of this study.  
 
NSAIDS AND BEZAFIBRATE. Ibuprofen amounts reported in hospital wastewater differ widely 
(Thomas et al., 2007; Lin and Tsai, 2009; Verlicchi et al., 2012a; Santos et al., 2013). While the 
substance was not detected at all in wastewater of 4 Korean hospitals (Sim et al., 2011), mean 
values of about 20,000 ng/L were found in composite samples from a private health care centre 
in Spain (Gómez et al., 2006), which concurs with the results of presented study. 
Comparable diclofenac concentrations in hospital wastewater have been reported in various 
studies from Spain (Gómez et al., 2006), Korea (Sim et al., 2011), and Sweden (Thomas et al., 
2007), while Santos et al., 2013 reported average concentrations of roughly one tenth of that for 
various hospitals in Portugal.  
The observed naproxen concentrations are about 10 to 100 times lower than those reported in 
hospital wastewaters in Taiwan (Lin and Tsai, 2009), Portugal (Santos et al., 2013), Korea (Sim 
et al., 2011) and Italy (Verlicchi et al., 2012a), reflecting very specific use patterns in different 
countries (Behera et al., 2011). 
Bezafibrate concentrations in wastewaters of different types of hospitals in Italy (Verlicchi et al., 
2012a) and Portugal (Santos et al., 2013) revealed mean values from one-fifth to less than one-
twentieth of those in the presented study.  
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Table 4-2: Mean concentration of analytes in influent and effluent of the PS-BFR over the investigation 
period [ng/L]. For the calculation of average values, single values < LOQ were accounted for as 0.5*LOQ 
and single values which not yielded a signal (not detected = n.d.) were taken into account as 0. 
 
Influent [ng/L]1 Effluent [ng/L] 1 
 
Average SD Average SD 
Antibiotics 
 CLA 1,168 718 1,407 468 
ROX 29.7 30.0 44.6 21.4 
SMX  2,717 3,099 1,812 1,518 
N-Ac-SMX  1,262 1,217 751 478 
TMP 402 280 687 292 
ICMs 
DTZ 1,058,819 450,313 890,270 297,836 
IOP 497,530 77,557 483,037 14,717 
IPM < LOQ 
 
< LOQ 
 
IMI 3,449 1,290 10,688 20,258 
IMI-TP 805 A 6,908 7,809 20,540 11,730 
IMI-TP 805 B < LOQ 
 
< LOQ 
 
IMI-TP 819 2,282 2,084 7,260 3,389 
IMI-TP 817 A 570 606 2,139 1,117 
IMI-TP 787 A < LOQ 
 
< LOQ 
 
IMI-TP 731 A 1,147 1,318 3,247 1,936 
IMI-TP 731 B < LOQ 
 
< LOQ 
 
IMI-TP 729 A < LOQ 
 
< LOQ 
 
IMI-TP 759 1,311 1,007 3,652 1,263 
IMI-TP 701 A 1,261 1,158 3,830 1,632 
IMI-TP 701 B < LOQ 
 
< LOQ 
 
IMI-TP 643 197 72.3 199 27.3 
NSAIDs and bezafibrate 
BZF 5,538 4,402 4,730 4,900 
DCF 3,518 5,284 3,803 4,306 
IBP 26,567 27,075 3,192 3,705 
NPX 54.4 90.3 39.3 80.6 
Psycho-active drugs 
CBZ 561 286 478 41.1 
DH-CBZ 27.7 16.0 24.9 3.51 
DHH 11,642 2,335 6,487 1,319 
DXP 101 50.1 20.7 11.1 
PMD 2,061 642 79.8 46.3 
CDN 116 41.5 167 29.9 
DHC 137 71.4 164 69.3 
MTD n.d. 
 
n.d. 
 
MPN 77.7 42.7 < LOQ 
 
OCN 116 36.9 111 26.8 
DZP n.d. 
 
n.d. 
 
NZP  19.4 11.2 20.1 27.1 
OZP 3,837 395 3,144 906 
TZP 19.7 5.52 20.7 4.61 
OPs 
TBEP 12,857 11,677 5,529 3,950 
TnBP  68.9 23.9 37.1 25.2 
TiBP  < LOQ 
 
78.7 57.6 
TEHP  n.d. 
 
n.d. 
 
TPP  < LOQ 
 
< LOQ 
 
TCEP  67.8 12.7 111 27.8 
TCPP  < LOQ 
 
86.5 67.6 
TDCPP  < LOQ 
 
43.0 35.5 
1 n=7   
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PSYCHO-ACTIVE COMPOUNDS. Carbamazepine has been investigated repeatedly in raw hospital 
wastewater all over the world (e.g. Brazil: 461–590 ng/L (Almeida et al., 2013), China: 88–
161 ng/L (Yuan et al., 2013), Italy: 640–1,200 ng/L (Verlicchi et al., 2012a); Korea: 827 ng/L 
(Sim et al., 2011), Portugal: 64.5–771 ng/L (Santos et al., 2013), Switzerland: 222 ng/L 
(Kovalova et al., 2012)) and shows far less variation in reported concentrations than other 
pharmaceuticals. The reported concentrations concur with those found in the presented study. It 
might be assumed that, in most cases, carbamazepine in hospital wastewater stems from its 
most common application as an antiepileptic drug (see Chapter 2.1.1.5), for which purpose it is 
typically administered to the patient at unvarying doses for life. The number of epilepsy patients 
per head of population can be expected to be roughly the same. Other uses of the drug, e.g. as an 
anti-anxiety drug or for the treatment of ADHD, personality disorders or alcohol withdrawal, are 
assumed to be negligible as far as general hospitals are concerned. Thus, comparable dosages of 
the drug in long-term treatment could result in less variant concentrations in wastewater from 
different hospitals.  
While diazepam was not detected in the presented study, several researchers have found the 
drug in hospital wastewater in concentrations of up to 645 ng/L (Kovalova et al., 2012; Almeida 
et al., 2013; Santos et al., 2013). Codeine in similar concentrations to those in the presented 
study was found in several Portuguese hospitals of different types (university, general, 
paediatric and maternity hospitals, Santos et al., 2013). Lin et al., 2010 reported comparable 
morphine concentrations to those in the presented study for hospitals in Taiwan, while 66 times 
higher concentrations were found in the wastewater of a hospital in Switzerland (Kovalova et al., 
2012). In contrast, the same study reported oxazepam and primidone concentrations that were 
one third and one fifth, respectively, of those presented here. 
 
OPS. While OPs are not expected to be discharged in especially large amounts from hospitals, it 
is nonetheless fruitful to take them into account when looking at distribution patterns as a 
hospital provides a chance to investigate a single, defined wastewater source. A highly selective 
pattern of these assumedly ubiquitous substances was discovered in raw hospital wastewater, 
with only 3 out of the 8 OPs found in quantifiable concentrations. While TBEP (average amount 
12,857 ng/L) was among the highest concentrated target compounds, TnBP and TCPP were 
found in concentrations lower than 70 ng/L. Yet the wide standard deviation of TBEP points to 
heterogeneous influent amounts over the course of the study (see the following chapter).  
  
 
Chapter 4 
 
page | 126  
4.3.2.2  WEEKLY CONCENTRATION PROFILES 
Concentration profiles of the investigated xenobiotics for influent and effluent as well as the 
removal rates over the course of the sampling campaign are shown in the Figure 4-3 to Figure 4-
8. The equation for the calculation of removal rates is given elsewhere (see Chapter 3.3.2.2). For 
reasons of clarity, values below LOQ were set to zero for the illustration of the removal rates in 
the graphs. Details regarding removal are discussed in Chapter 4.3.3. 
The amounts of pharmaceuticals in the raw hospital wastewater were found to vary, in some 
cases profoundly, which is consistent with other studies of hospital effluent (Verlicchi et al., 
2012a; Santos et al., 2013).  
 
ANTIBIOTICS. The antibiotics roxithromycin, sulfamethoxazole, N4-acetylsulfamethoxazole and 
trimethoprim show roughly comparable influent patterns, with elevated influent concentrations 
at the beginning of the working week. Clarithromycin displays a dissimilar pattern with very 
large influent amounts on Wednesday and Thursday.  
 
ICMS. For the ICMs iomeprol and iopromide, unexpectedly even inputs were found over the 
course of the study with no general steep drop at the weekend. Even with iomeprol showing 
lower concentrations on Sunday, the input concentration on Saturday was not significantly 
lower than for most of the workdays. Since ICMs are rapidly excreted after ingestion, it had to be 
assumed that they occurred in the wastewater at about the same time as application, which for 
weekends does not fit with the regular office hours of the hospital’s radiological unit. A possible 
explanation for the occurrence of these substances in raw hospital wastewater on weekends 
could be their administration as part of an emergency treatment (angiographic diagnosis of e.g. 
strokes and heart-attacks). It can be assumed that fewer emergency patients are treated than 
regular patients on weekdays – however, since outpatients often undergo radiological 
examinations, it can be suggested that most of the ICMs these patients ingest are excreted away 
from the hospital. Thus, the lower number of emergency patients who are kept in for 
observation at the hospital could excrete equal amounts of ICMs into the wastewater as the 
higher number of outpatients. For diatrizoic acid, a dissimilar pattern was found with a peak 
concentration on Thursday followed by declining amounts. 
 
NSAIDS. Diclofenac and ibuprofen show fairly constant high concentrations over the course of 
the week with extraordinarily high peak values on Monday. In contrast, the third NSAID 
investigated, naproxen, was overall much less concentrated and only quantifiable in the influent 
on four days (Tuesday, and Thursday to Saturday) with a single peak of about a 10-fold higher 
concentration on Friday than on the other days. Since naproxen is comparatively rarely used in 
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Germany, this could indicate a special use, e.g. as a substitute painkiller used in pain 
management, and might be linked to the office hours of a specialised practice. Bezafibrate shows 
elevated amounts on Monday, Wednesday and Friday, which could probably be connected to the 
office hours of specialised practices as well.  
 
 
 
  
  
 
 
  
Figure 4-3: Concentrations [ng/L] of antibiotics in influent and effluent from the PS-BFR pilot plant and 
correlating removal [%] over the course of the sampling campaign. Concentrations below LOQ are 
indicated by black-filled data point symbols. 
  
< LOQ: 
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Figure 4-4: Concentrations [ng/L] of ICMs in influent and effluent from the PS-BFR pilot plant and 
correlating removal [%] over the course of the sampling campaign. Concentrations below LOQ are 
indicated by black-filled data point symbols. 
  
< LOQ: 
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Figure 4-5: Concentrations [ng/L] of NSAIDs and bezafibrate in influent and effluent from the PS-BFR pilot 
plant and correlating removal [%] over the course of the sampling campaign. Concentrations below LOQ 
are indicated by black-filled data point symbols. 
  
< LOQ: 
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Figure 4-6: Concentrations [ng/L] of psycho-active drugs (opioids) in influent and effluent from the PS-
BFR pilot plant and correlating removal [%] over the course of the sampling campaign. Concentrations 
below LOQ are indicated by black-filled data point symbols.  
< LOQ: 
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Figure 4-7: Concentrations [ng/L] of psycho-active drugs (carbamazepine and carbamazepine 
metabolites, doxepin, primidone and benzodiazepines) in influent and effluent from the PS-BFR pilot plant 
and correlating removal [%] over the course of the sampling campaign. Concentrations below LOQ are 
indicated by black-filled data point symbols.   
< LOQ: 
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Figure 4-8: Concentrations [ng/L] of organophosphorous substances in influent and effluent from the PS-
BFR pilot plant and correlating removal [%] over the course of the sampling campaign. Concentrations 
below LOQ are indicated by black-filled data point symbols.  
< LOQ: 
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PSYCHO-ACTIVE COMPOUNDS. With the exception of Sunday, oxycodone and dihydrocodeine show 
similar profiles, with higher concentrations in the raw wastewater at the beginning of the 
studied period and declining amounts in the following days. Codeine shows relatively even 
concentrations over the course of the week apart from a very much higher concentration on 
Monday. 
Carbamazepine and its metabolite 10,11-dihydrocarbamazepine show exactly matching weekly 
profiles, while the profile of the second metabolite 10,11-Dihydro-10,11-
dihydroxycarbamazepine is merely similar. The second anticonvulsant, primidone, shows a 
different profile from carbamazepine, which suggests a different application pattern. Doxepin 
shows two levels of input amounts with lower, comparable concentrations on Wednesday to 
Friday and Sunday to Monday and equivalent peak concentrations on Tuesday and Saturday. 
The concentrations of oxazepam are relatively constant over the course of the week. Oxazepam 
is a highly effective benzodiazepine which is commonly used in premedication for medical 
procedures and has a wide range of applications as tranquilizer, anticonvulsant and muscle 
relaxant. In contrast to diazepam and nordiazepam (which were not detected in the hospital 
wastewater), it is relatively easy to control, which may explain the consistent distribution 
pattern (see Chapter 2.1.1.5). The low concentrations of temazepam seem to point to its 
occurrence merely as a metabolite of other benzodiazepines, presumably oxazepam. 
 
OPS. The weekly profiles of OPs are inconsistent. While TnBP and TiBP show highly fluctuating 
inputs over the course of the week, TBEP and TCPP are found in higher concentrations on 
Sunday and Monday, while the latter is not quantifiable in the influent between Wednesday and 
Saturday. TDCPP, which is not quantifiable in the influent at all, and to a lesser degree TCEP, are 
obviously introduced into the wastewater during treatment in the pilot plant. Details of 
removals are given in the following chapter.  
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4.3.3 REMOVAL OF XENOBIOTICS FROM THE AQUEOUS PHASE BY THE PS-BFR 
Removal of the xenobiotics from the aqueous phase was estimated as mean values over the 
length of the studied period and classified into five categories (very high, high, moderate, poor, 
negative) as presented in Figure 4-9. Removal in this context is to be understood as a summary 
of degradation and (bio-)transformation processes during treatment. Removals reaching the 
limit of quantification are given as 100%. As shown in Figure 4-3 to Figure 4-8, removals over 
the course of the week are highly heterogeneous for the majority of substances. The 
determination of average removal rates, despite being a helpful tool for the assessment of the 
efficiency of the system, has to take these heterogeneities into account.  
 
 
 
Figure 4-9: Average removal of xenobiotic compounds in the PS-BFR pilot plant. Colours of columns show 
very high (> 95% - dark green), high (75–95% - light green), moderate (50–75% - orange), poor (0–50% - 
red) and negative (< 0% - lilac) removal. Numbers above the columns depict the percentage of average 
removal and by colour code the compound group (colour code see Figure 4-2). The grey columns show the 
RSD [%].  
Very high removal rates were found for primidone throughout the week. Likewise, ibuprofen 
and morphine showed high removal rates with small variations over the course of the study. One 
substance, doxepin, was moderately removed, and six more showed poor removal (10,11- 
dihydro-10,11-dihydroxycarbamazepine, TBEP, TnBP, oxazepam, diatrizoic acid, iomeprol). The 
two OPs among them displayed considerable variations in removal during the sampling period. 
Carbamazepine showed overall no removal. For 17 substances, average removal was found to be 
negative. The physico-chemical properties of these compounds vary widely (MW: 238 – 837 
g/mol; log KOW -2.05 – 4.51, pKa 1.83 – 9.20, HLC: 1.73x10-29 – 3.29x10-06 atm-m3/mole, Ws: 
0.0189 – 9000 mg/L, see also Chapter 2.1), which makes it unlikely that a single physical or 
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chemical attribute would be the cause. Neither does the form of excretion seem to be the reason 
for this removal pattern, since both substances which are excreted completely via urine (e.g. 
iopromide) and drugs which are to a great extent faeces-bound (e.g. roxithromycin), fall into this 
group. Some of these substances displayed overall uniform behaviour over the course of the 
study. With the exception of one or two days, codeine, roxithromycin and TCEP showed 
relatively regular patterns, with a constant offset between influent and effluent leading to a 
consistent negative removal. In contrast, bezafibrate showed the opposite behaviour with 
positive removals over the course of the study apart from only one day where there was a 
substantial negative removal, masking the otherwise noteworthy removal capacity of about 
50%. Other substances showed greatly varying removal patterns, often with changes between 
positive and negative removal (e.g. carbamazepine and 10,11-dihydrocarbamazepine, 
oxycodone, temazepam, clarithromycin, sulfamethoxazole, nordiazepam, naproxen). The high 
variability of removal rates was not caused by any factor monitored in this study (e.g. no pH 
changes were found). For many pharmaceuticals, the cleavage of conjugated metabolites present 
in wastewater resulting in higher parent drug concentrations, and seemingly low or negative 
removal during wastewater treatment has previously been reported (Lindqvist et al., 2005; 
Radjenović et al., 2009b; Kovalova et al., 2012). Taking the high variation regarding the influent 
concentrations themselves into account, such processes are likely to be the reason for the 
varying removal rates found in the presented study. Furthermore, the ICM iopromide seems to 
suggest that similar processes occur between TPs and parent compounds, too, with removal 
rates for the parent substance generally being from 40% to –70% with a maximum removal of –
1,358% (see Figure 4-4 and also Chapter 4.3.4).  
 
COMPLEX MATRIX. Overall, a generally very similar xenobiotic pattern was found in the effluent 
(Figure 4-10) compared to the influent (Figure 4-2) with only minor changes regarding both the 
compound composition and concentrations, indicating the generally low removal efficiency of 
the PS-BFR. With the exception of ibuprofen and carbamazepine, the PS-BFR treatment is less 
efficient at removal than conventional CAS treatment (see e.g. reviews by Onesios et al., 2009; 
Verlicchi et al., 2012b). However, as mentioned above, for most of the substances displaying 
unsatisfactory overall removal, drastic changes in removals over the course of the week were 
found. Possible reasons could derive from the extreme environment that highly concentrated 
hospital wastewater represents. For example, Zwiener and Frimmel, 2003 showed that organic 
solvents like acetone, that are expected to be found in hospital wastewater, can greatly inhibit 
the capacity of biofilm systems to remove pharmaceuticals from wastewater. However, a 
constantly changing composition of the feed water is expected to influence the microbiological 
community, thus leading to the development of a possibly highly specified microbial population 
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that can withstand temporarily unfavourable conditions. This, on the other hand, might 
eliminate fast-growers (see Chapter 2.2.2) and therefore degradation processes in this aquatic 
environment could be expected to take longer than in less demanding milieus.  
 
LITERATURE DATA. Very few studies have been published on the subject of the capacity of SCBPs 
to remove xenobiotics, and those available mostly operated on bench-scale. To my knowledge 
there are no studies that report using particle supported biofilm reactors for the treatment of 
pharmaceuticals in hospital wastewater. In a laboratory study, González et al., 2006 investigated 
the usefulness of a fixed-bed reactor for the removal of diclofenac from effluent water from a 
municipal WWTP and found no removal, regardless of whether the acclimatisation of the 
microorganisms to the target compound was brief or prolonged. In contrast, Falås et al., 2012 
reported higher SCBP removal of 5 pharmaceuticals, including diclofenac, than was found for 
activated sludge treatment, and postulates that moving bed biofilm reactors have superior 
removal potential compared to CAS treatment. However, the same study found that SCBP and 
CAS treatment removed ibuprofen and naproxen comparably, which is similar to the findings of 
the presented study (that is, in the case of naproxen, when excluding the days when influent 
concentrations were below LOQ, resulting in a removal rate of 97%).  
Anoxic conditions seem to be preferable for the removal of pharmaceuticals in SCBPs. Thus, 
Zwiener and Frimmel, 2003 found no removal of diclofenac under oxic conditions, while under 
anoxic conditions at least slight removal was achieved in a biofilm reactor. Accordingly, Zhou et 
al., 2006 reported only anaerobic conditions to be successful in the removal of two antibiotics 
(ampicillin and aureomycin) in high-strength pharmaceutical wastewater, while a BAS reactor 
showed no removal. However, other researchers found that for several pharmaceuticals, 
removal by oxic SCBP treatment were still higher than anoxic and oxic activated sludge 
processes (Falås et al., 2013). 
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Figure 4-10: Maximum concentrations (cmax effluent [ng/L]) of each target compound in the effluent from the 
PS-BFR. Colour codes show the compound group. 
 
4.3.4 FATE OF METABOLITES AND TRANSFORMATION PRODUCTS DURING PS-BFR TREATMENT  
Transformation products of iopromide and metabolites of carbamazepine and sulfamethoxazole 
were investigated in raw hospital wastewater and in the PS-BFR effluent. As depicted in Figure 
4-2 and Table 4-2, all three studied metabolites were found in raw hospital wastewater samples 
as well as 7 out of 12 TPs of iopromide. 
 
TPS OF IOPROMIDE. While the presence of human metabolites in raw hospital wastewater was 
expected, the existence of environmental ICM-TPs was not (see also Chapter 4.3.2). Although in 
laboratory studies iopromide had been found to be degradable during activated sludge 
treatment as well as in river water (see Chapter 2.1.1.2), the breakdown times were described as 
being in the range of days or weeks (Kalsch, 1999; Steger-Hartmann et al., 2002; Löffler et al., 
2005). However, in case of the raw wastewater investigated in the presented study, only 
minutes elapsed between its entering the drains and reaching the sampling point, preventing 
practically all biodegradation activities that might take place in sewer systems. In contrast, the 
results might point towards very fast, unknown transformation processes taking place in the 
hospital sewer, probably by interactions with aggressive xenobiotics present in the hospital 
< LOQ/ 
not detected 
 
Chapter 4 
 
page | 138  
effluent, degrading a supposedly stable ICM during extremely short contact times (see also 
Chapter 4.3.2). This would account for the fact that already in the influent to the pilot plant, the 
amount of the parent drug compared to the investigated TPs is only about 20% (Figure 4-11). 
The fact that the sum of parent drug and TPs in the effluent of the pilot plant is constantly higher 
than the sum estimated for raw wastewater could point to the presence of further, unknown TPs 
in the raw water that are (re-)transformed into compounds (both the parent substance and its 
TPs) which are being measured. This suggestion is supported by previous studies which 
reported different sets of TPs resulting from iopromide breakdown in different environmental 
settings (Kalsch, 1999). Additional transformation processes in the PS-BFR might be caused by 
the co-discharge of reactive substances in the hospital water. However, no explanation could be 
found for the high concentration of the parent compound in the effluent at the end of the 
sampling period.  
 
 
 
 
Figure 4-11: Concentration patterns of iopromide and its TPs in influent and effluent samples from the PS-
BFR pilot plant over the course of the study in [ng/L] and in [%] (small graph at the top right).  
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SULFAMETHOXAZOLE METABOLITE. For CAS treatment, sulfamethoxazole removal rates between 
10 and 100% have been reported (Verlicchi et al., 2012b). Some studies, however, found higher 
effluent values compared to corresponding influent values (Göbel et al., 2005b). The reason for 
this seemingly negative removal of sulfamethoxazole, which is often accompanied by the 
disappearance of its human metabolite N4-acetylsulfamethoxazole, is the cleavage of the 
metabolite and the retransformation of the parent compound during wastewater treatment (see 
Chapter 2.1.1). In the presented study, sulfamethoxazole showed a highly diverse removal 
pattern with considerable removal rates from 27 to 76% on four days of the sampling campaign, 
which contrasted with high negative removal rates (up to –295%) on two other days (see Figure 
4-3). The metabolite, however, was found to follow a similar pattern, with high removals 
between 40 and 81% contrasted by two days of negative removals up to –287%. Thus, negative 
removal of the parent compound cannot have been caused by a cleavage of the metabolite since 
it was present in the samples at the times in question (Figure 4-12). For four days there was 
substantial removal of SMX, while at the same time the metabolite was not greatly reduced. This 
suggests that the parent drug was subjected to a different transformation process. The cause for 
this could be a specialised, adapted microbial community in the PS-BFR which might be different 
from that in conventional suspended activated sludge treatment. The reverse removal rates on 
two days might be explained by temporarily dissimilar wastewater composition, e.g. the 
introduction of aggressive chemical substances, which could cut into the biological performance 
of the system and additionally might cause unknown transformation reactions. 
 
Chapter 4 
 
page | 140  
 
 
Figure 4-12: Concentration patterns of sulfamethoxazole and its metabolite N4-acetylsulfamethoxazole in 
influent and effluent samples from the PS-BFR pilot plant over the course of the study in [ng/L] and in 
[%](small graph at the top right).  
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CARBAMAZEPINE METABOLITES. Carbamazepine and its metabolites 10,11-Dihydro-carbamazepine 
and 10,11-Dihydro-10,11-dihydroxycarbamazepine seemed to pass through PS-BFR treatment 
without major changes in concentration patterns, and with no sign of retransformation to the 
parent drug (Figure 4-13). Regarding the total amount of parent compound and metabolites in 
the influent and effluent of the PS-BFR, a clear reduction was found over the whole course of the 
study, which was mainly due to the reduction of 10,11-Dihydro-10,11-dihydroxycarbamazepine 
(see Figure 4-7).  
 
UNKNOWN TRANSFORMATION MECHANISMS. To summarise, the transformation of pharmaceuticals 
as demonstrated for the three substances iopromide, sulfamethoxazole and carbamazepine, 
suggest the existence of unknown transformation mechanisms in hospital wastewater which 
seem to differ from the reported processes. This might be caused by a) the operation of a 
seasoned suspended particle biofilm reactor which allows a highly specified microbial 
community to develop on and within the carriers and b) by the presence of a variety of reactive 
substances in the raw wastewater which might induce unknown degradation processes of the 
studied compounds.  
4.4 CONCLUSIONS 
Out of 47 xenobiotics studied, 37 were quantified in raw and 38 in treated hospital wastewater. 
In raw wastewater, the highest amounts found were of ICMs, with maximum concentrations 
exceeding 1.5 mg/L. For many substances, temporal distribution patterns showed widely 
varying concentrations over the course of the study. Surprisingly, despite an extremely short 
time of 30 min elapsing between the discharge of the wastewater and its reaching the sampling 
point, environmental TPs of the ICM iopromide were found in raw hospital wastewater. This 
might point to the rapid degradation of this compound in undiluted hospital effluent water by 
highly reactive substances not included in the present study (e.g. diagnostic agents, 
disinfectants, etc). A further particularity of the hospitals’ discharge water is the absence of 
many of the OPs investigated in this study. OPs are regarded as being ubiquitous, but only 3 out 
of 8 were found in the raw hospital wastewater. A fourth OP was introduced at low levels (43.0 
+35.5 ng/L) during PS-BFR treatment, which might be attributed to abrasion of the carriers used 
in the reactors. In general, when comparing the results of xenobiotic occurrence in raw hospital 
wastewater found in this study with data from the literature, highly specific application patterns 
seem to be reflected in the concentrations found for different hospitals.  
PS-BFR treatment of the raw wastewater resulted in stable removal rates for only a small 
number of substances, while for many compounds wide variations in removal rates were found 
over the course of the study. This might be owing to wide variations in the composition of the 
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hospital wastewater and the irregular introduction of substances which temporarily impaired 
the performance of the biological treatment. However, high, stable removal rates for primidone, 
ibuprofen and morphine prove the effectiveness of the biological treatment and attest to the 
presence of an active microbial community throughout the study. It can be assumed that the 
biocenosis in the seasoned PS-BFR (start-up time prior to the study: 199 days) has successfully 
adapted to the wastewater matrix. Since specialised microbes often are slow-growers, 
biodegradation in the PS-BFR can be expected to be slower than in comparable systems in less 
demanding milieus. Between the presence of a specialised biocenosis on one side and a 
seemingly reactive wastewater matrix on the other, the uncharacteristic degradation patterns 
found for sulfamethoxazole and iopromide in this study could be explained. 
Overall, hospital wastewater presents a highly dynamic system with interactions that are only 
partly understood so far. Substances not subjects of the presented study should be taken into 
consideration to further investigate the processes taking place in this matrix, for example to 
explain the presence of ICM-TPs in raw wastewater, which could be a result of degradation by 
aggressive co-eluents in the waste stream. Further research on this subject is essential to better 
understand the fate of xenobiotics in urban water cycles. The same is true for gaining more 
detailed insight into the performance of biofilm systems operating in wastewaters from specific 
point sources. 
 
 
 
Figure 4-13: Concentration patterns of carbamazepine and its metabolites DHH and DH-CBZ in influent 
and effluent samples from the PS-BFR pilot plant over the course of the study in [ng/L] and in [%] (small 
graph at the top right). 
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5. DETERMINATION OF XENOBIOTIC ORGANIC MICROPOLLUTANTS IN 
BIOSOLIDS BY PRESSURISED LIQUID EXTRACTION (PLE) FOLLOWED 
BY LC-MS/MS AND THEIR OCCURRENCE IN SEWAGE SLUDGE FROM A 
NF-MBR AND IN SLUDGE AND CARRIER MATERIAL FROM A PS-BFR 
 
If you could tomorrow morning make water clean in the world, you would have done, in one fell 
swoop, the best thing you could have done for improving human health by improving 
environmental quality. 
– William C. Clark (1948- ), speech, Racine, Wisconsin, April 1988 – 
 
 
5.1 INTRODUCTION 
Xenobiotic substances such as pharmaceuticals and industrial chemicals can reach the 
environment after passing through treatment plants either in the water phase or sorbed to 
biosolids like sewage sludge. While recently much research has been directed at the fate of 
xenobiotics in the water phase (see Chapters 2, 3, and 4), their occurrence in sewage sludge has 
been much less investigated (Díaz-Cruz et al., 2009; Le-Minh et al., 2010). In many countries 
sewage sludge is still used as fertiliser, and there is concern about the amount and distribution 
of xenobiotics in soils treated with it (Kümmerer, 2004). Legislation has only very recently 
started to take this issue into account and, to date, there are no regulations in place in the EU for 
sewage sludge management with regard to organic xenobiotics (Díaz-Cruz et al., 2009, 
Lillenberg et al., 2009).  
 
COMPOUNDS OF CONCERN. Among the wide range of xenobiotics present in the environment, 
pharmaceuticals raise particular concerns regarding public health implications (see Chapters 
2.1.1). Among them, antibiotics are of special interest because of the unresolved issue of 
bacterial resistance (see Chapter 2.3), which is exacerbated by the presence of antibiotic 
compounds in the environment (Diwan et al., 2010; Bouki et al., 2013; Marti and Balcázar, 2013). 
Industrial substances are often regarded with concern because of the high volumes at which 
they enter wastewater (EPA, 2012a). 
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ANALYTICAL AND TECHNICAL IMPROVEMENTS. Recent improvements in analytical techniques and 
equipment allow for increasingly detailed studies of xenobiotics in environmental samples in 
lower and lower concentrations (Buchberger, 2007). Subsequently, numerous studies have been 
published investigating xenobiotics in sewage sludge. Göbel et al. developed sludge analysis 
procedures based on pressurised liquid extraction (PLE) and ultrasonic extraction followed by a 
solid phase extraction (SPE) clean-up step, and analysis by reversed-phase liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) using positive electrospray ionisation 
(ESI) (Göbel et al., 2005a) to investigate antibiotics in sludge from municipal wastewater 
treatment plants (WWTPs) in Switzerland (Göbel et al., 2005b). Lillenberg et al., 2009 identified 
several antibiotics in digested sewage sludge from various Estonian WWTPs, similarly using 
pressurised liquid extraction (PLE) and ESI-LC-MS/MS. Other researchers (Radjenović et al., 
2009a; Radjenović et al., 2009b; Wick et al., 2009; Jelic et al., 2011) investigated a wider range of 
pharmaceuticals, likewise using PLE and LC-MS/MS. Marklund et al., 2005 used PLE followed by 
a clean-up step with gel permeation chromatography (GPC) and GC-MS analysis to investigate 
the occurrence of OPs in sewage sludge from various WWTPs in Sweden. 
Recently, alternative wastewater treatment technologies such as membrane bioreactors or 
biofilm reactors are increasingly being used (see Chapters 2.2.2 and 2.2.4). Thus, sludge from 
bioreactors and biofilms are biosolids related to wastewater treatment that have to be taken 
into account.  
 
THE SCOPE OF THE STUDY. The aim of the presented study was to develop a multi-residue PLE 
method for subsequent LC-MS/MS analysis of 31 xenobiotics from different compound classes 
(pharmaceuticals, metabolites and OPs), from different kinds of biosolids. Antibiotics and 
psycho-active substances were chosen as model substance groups for pharmaceuticals and OPs 
as representative of industrial substances. The developed method was subsequently used for 
identifying these xenobiotics in a) sewage sludge from a nanofiltration membrane bioreactor 
pilot plant located at the influent of a WWTP (NF-MBRWWTP, see Chapter 3) and b) in sludge and 
carrier material from a particle-supported biofilm reactor pilot plant situated at the effluent of a 
municipal hospital (PS-BFRhospital, see Chapter 4). To my knowledge, this is the first study 
reporting the occurrence of organic xenobiotics in wastewater-related biofilms.  
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5.2 MATERIALS AND METHODS  
5.2.1 REFERENCE COMPOUNDS, CHEMICALS AND STANDARDS 
The following compounds were studied (all standards were of analytical grade with > 98% 
purity; information regarding the distributers of the standard materials is given elsewhere 
(Chapter 3)): Antibiotics: clarithromycin (CLA), roxithromycin (ROX), sulfadimethoxine (SMI), 
sulfadimidine (SDI) , sulfisoxazole (SSX), sulfamerazine (SMA), sulfamethoxazole (SMX), N4-
acetylsulfamethoxazole (N-Ac-SMX), tiamulin (TAM), trimethoprim (TMP). Psycho-active 
compounds: carbamazepine (CBZ), 10,11-dihydrocarbamazepine (DH-CBZ), 10,11-Dihydro-
10,11-dihydroxycarbamazepine (DHH) doxepin (DXP), primidone (PMD), codeine (CDN), 
dihydrocodeine (DHC), methadone (MTD), oxycodone (OCN), diazepam (DZP), nordiazepam 
(NZP), temazepam (TZP). OPs: tris(2-butoxyethyl) phosphate (TBEP), tributyl phosphate (TnBP), 
tri-iso-butyl phosphate (TiBP), triphenyl phosphate (TPP), tris(2-chloroethyl) phosphate 
(TCEP), tris(chloropropyl) phosphate (TCPP), tris(1,3-dichloro-2-propyl) phosphate (TDCPP). 
For analysis the following internal standards (analytical grade > 98% purity) were used: (E)-9-
[O-(2-methyloxime)]-erythromycin, sulfadimethoxine-d4, sulfadimidine-d4, sulfamerazine-d4, 
sulfamethoxazole-d4, N4-acetylsulfamethoxazole-d4 13C-15N-carbamazepine, primidone-d5, 
codeine-d6, methadone-d9, diazepam-d5, nordiazepam-d5, tri-butyl phosphate-d27, triphenyl 
phosphate-d15.  
 
All organic solvents used (n-heptane, n-hexane, acetone, methanol, acetonitrile, ethyl acetate) 
were picograde and purchased from Merck (Darmstadt, Germany). Pure water obtained from a 
Milli-Q system (Integral 3/5/10/15, Millipore, Billericis, MA, USA) was used. Formic acid (98–
100%) was ACS grade and purchased from Merck (Darmstadt, Germany).  
For each compound group (antibiotics, psycho-active drugs and organophosphorus compounds) 
a standard solution of all target analytes and an internal standard mix at a concentration of 10 
µg/mL (OPs: 5µg/mL) and 1µg/mL respectively were prepared in methanol and stored in the 
dark at 4 °C.  
 
5.2.2 SAMPLING AND SAMPLE PREPARATION  
SLUDGE. Grab samples of sludge were taken from (1) a membrane bioreactor pilot plant 
equipped with nanofiltration operated at the influent of a municipal WWTP with 300,000 
inhabitant equivalents (NF-MBRWWTP) and (2) a particle-supported biofilm reactor pilot plant fed 
with the raw wastewater from a municipal hospital (PS-BFRhospital). Details about the pilot plants 
were given elsewhere (see Chapters 3.2.2 for NF-MBRWWTP and 4.2.2 for PS-BFRhospital). For 
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sampling, clean glassware was used, which had been rinsed with MilliQ water, heptane and 
acetone and subsequently heated overnight at > 240 °C. Samples from the NF-MBRWWTP, 
consisting of a water-solid-suspension, were directly taken from the pilot plant by sinking glass 
bottles into the tank. Sludge from the PS-BFRhospital was collected from the bottom of the 
secondary settling tank via a pre-cleaned silicone tube. All samples were transported on ice in 
the dark and immediately after arrival at the laboratory centrifuged for 90 min at 3500 r/min in 
a temperature-controlled centrifuge (Rotanta 460R, Hettich Lab Technology, Tuttlingen, 
Germany) within these same glass bottles.  
The centrifuged sludge was freeze-dried and pestled before extraction. Since the sludge was not 
completely water-free, analytes in the remaining water were expected to dry onto the sludge 
during freeze-drying. However, the amount of these analytes originating from the water was 
calculated and generally found to be below 5% of the amount sorbed to the sludge (Table 5A-1). 
Exceptions were found for three substances with greater water-originating amounts (NF-
MBRWWTP-sludge: sulfamethoxazole (10%), primidone (16%) and 10,11-Dihydro-10,11-
dihydroxycarbamazepine (17%); PS-BFRhospital sludge: 10,11-Dihydro-10,11-
dihydroxycarbamazepine (9%), sulfamethoxazole (10%)).  
 
PS-BFRhospital CARRIERS. In the case of the PS-BFRhospital, in addition to the sludge samples, 
samples of the carriers were taken. They were collected with a coarse sieve and were 
transferred to perforated polyethylene bags to allow a gentle drying of the carriers by 
gravimetric drainage of the remaining water without disturbing the biofilm attached to the 
carriers. Afterwards, the carrier samples were freeze-dried and extracted in the same way as the 
sludge samples. To prevent possible trouble with the extraction cells blocking, the carrier 
material was not pulverised but was left in its natural form.  
Since mechanical stress was to be avoided during the process of drying the carrier material, so 
as not to dislodge the attached biofilm, it was expected that there would be more residual water 
in the carrier samples put up for freeze-drying than in the sludge samples (Table 5A-1). 
However, the water-originating amounts were only up to 2% of the amounts in the carriers for 
most compounds, with only three exceptions (13%, 26% and 58% for sulfamethoxazole, 10,11-
Dihydro-10,11-dihydroxycarbamazepine and primidone, respectively).  
 
5.2.3 PRESSURISED LIQUID EXTRACTION (PLE)  
Sludge samples were extracted by PLE with a Dionex ASE 200 instrument (Sunnyvale, CA, USA) 
(Figure 5-1). For PLE, 0.5 g and 1 g of sludge and approximately 3.5 g of carrier material were 
weighed into pre-cleaned 22 mL stainless steel extraction cells half-filled with baked out sea 
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sand. Internal standard was added (10 µL, i.e. 100 ng absolute) and the cells filled up with baked 
out sea sand (Riedel-de Haen, Seelze, Germany) previous to extraction. 
 
PHARMACEUTICALS. For the extraction of pharmaceuticals, a number of PLE protocols are already 
described in detail in the literature (Göbel et al., 2005a; Lillenberg et al., 2009; Radjenović et al., 
2009a; Wick et al., 2009; Jelic et al., 2011). Following the results of these studies, 
pharmaceuticals were extracted with methanol:water (1:1, v/v) using 3 cycles of 5 min (without 
preheating), 100 °C temperature and 100 bar. Flush volume was 140%, nitrogen purge time was 
60 sec. The set parameters were tested by spiking suspended matter from a river (see next 
paragraph for details) with 20 µL of a 10ng/µL standard solution, i.e. 200 ng of analytes before 
being applied to the native samples. 
 
OPS. For OPs fewer references are found in literature so a range of solvents was tested for 
extraction (Table 5-1). Since for time and work efficiency it would be best if the extraction 
method applied to pharmaceuticals could simultaneously be used for OPs, the mixture of 
methanol:water (1:1, v/v) was investigated. Furthermore, various solvents of different polarity 
were chosen: ethyl acetate, methanol, acetone and mixtures of the latter two (20:80; 50:50; 
80:20 v/v) as well as a mixture of hexane:acetone:heptane (9:5:1). Extraction conditions were 
set in the same way as described above for the extraction of pharmaceuticals. Additionally, for 
ethyl acetate and the mixture of hexane, acetone and heptane, different parameter settings were 
tested, taking into account the higher temperature stability of OPs compared to pharmaceuticals 
(Table 5-2). To introduce the impact of organic matrix as early as during the method 
development phase, the experiments were carried out by spiking 0.5 g dried suspended matter 
from the river Rhine with 20 – 100 µL of standard and 10 µL of internal standard (Table 5-1) 
instead of spiking the analyte in pure sea sand. Blanks of the suspended matter were determined 
and amounts of the spiked samples were corrected with the amounts found in the blank 
samples.  
Absolute recoveries were calculated from absolute peak areas without the correction of internal 
standards; they therefore revealed either analyte losses during preparation or extraction, or 
matrix effects during the analysis. In contrast, relative recoveries, calculated by using the 
analyte/standard ratios, demonstrate the accuracy of the analytical procedure as a whole.  
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Figure 5-1: Pressurised liquid extraction of sludge and biofilm carriers. The higher amount of matrix in 
samples from the carrier material (extract nos. 19 and 24) is reflected in a darker colour of the extract. 
 
5.2.4 SOLID PHASE EXTRACTION (SPE) 
Final PLE extracts (approximately 40 mL) were diluted with 900 mL Milli-Q water to reduce the 
organic content below 5%. Subsequently, they were purified and enriched by SPE using Oasis 
HLB cartridges (500 mg, 6 mL, Waters, Milfort, U.S.). Prior to extraction, the cartridges were 
conditioned with 1 x 5 mL heptane, 1 x 5 mL acetone, 2 x 5 mL methanol and 3 x 5 mL Milli-Q 
water. The diluted extracts were passed through the cartridges with a flow rate of 
approximately 5 mL/min. Extracts containing non-polar solvents were reduced in a water bath 
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(40 °C) to < 2 mL, re-established with 20 mL of acetone and diluted with 400 mL Milli-Q water 
prior to SPE. 
Following SPE, the HLB material was completely dried under a steady nitrogen stream for 
approximately 90–120 min. Elution was accomplished with 5 x 2 mL acetone. The extracts were 
evaporated to approximately 100 µL by a gentle nitrogen stream before the vial was rinsed with 
300 µL of methanol, followed by a second reduction to 100 µL and a final addition of 400 µL 
Milli-Q water, resulting in a final sample volume of 500 µL (Figure 5-2). Samples were kept at 
4 °C in the dark until LC-MS/MS analysis. 
 
Table 5-1: Tested extraction procedures for organophosphorus compounds. For all schemes applied: 
temperature: 100 °C, pressure: 100 bar, cycles: 3, heat: 5 min, static: 5 min, flush: 140%, purge: 60 sec. 
Experiments were carried out by spiking dried suspended matter. 
Test 
scheme 
No. 
Solvent 
Mixing ratio 
(v/v) 
Concentration 
of analytes 
spiked [ng] 
Concentration of 
internal standard 
spiked 
1 methanol:water 1:1 100, 500 100 
2 methanol  200 100 
3 acetone  200 100 
4 methanol:acetone 1:4 200 100 
5 methanol:acetone 1:1 200 100 
6 methanol:acetone 4:1 200 100 
71 ethyl acetate   200 100 
81 hexan:aceton:heptan 9:5:1 200 100 
1 additional PLE parameter tested, see Table 5-2. 
 
 
 
Table 5-2: PLE parameters tested for organophosphorus compounds. 
 Test schemes 1-8 Additional schemes 
7b/8b 
Temperature (°C) 100 120 
Pressure (bar) 100 160 
Cycles 3 3 
Heat (min) 5 5 
Static (min) 5 5 
Flush (%) 140 100 
Purge (sec) 60 60 
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Figure 5-2: Flowchart of the laboratory procedure. 
  
Freeze-drying and pestling of sample material 
PLE with 1 g of sample,  
fortified with internal standard  
Percolation through Oasis HLB cartridge (500 mg, 
6mL)  
(flux approx. 5 mL/min)     
Drying of the cartridges with nitrogen (approx. 90 
min)  
Elution with 5 x 2mL aceton  
Volume reduction with nitrogen to 100 µL 
Rinsing of the glass vial with 500 µL MeOH 
Volume reduction to 100 µL 
Adding of 400 µL Milli-Q water 
LC-MS/MS-analysis 
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5.2.5 LC-MS/MS-ANALYSIS 
The analytical procedures used were described elsewhere (see Chapter 3.2.5).  
5.2.6 METHOD VALIDATION 
Details regarding quantification (calibration, linearity range etc.) have been given above 
(Chapter 3). Instrumental precision was determined by repeated injection of a standard solution 
during analysis (n = 2–6) and is indicated by the relative standard deviation of the results 
(%RSD). The accuracy of the method was assessed by studying the relative recovery in fortified 
native sampling material. Absolute and relative recoveries were determined in samples of 
suspended matter during method development (see Chapter 5.2.3). To account for matrix effects 
resulting from the different compositions of native samples, recoveries were determined for all 
investigated matrices (sludge from the NF-MBRWWTP, sludge and carriers from the PS-BFRhospital) 
by spiking native samples with 30 µL and 60 µL of analyte standard for pharmaceuticals and OPs 
(equalling 300 ng), respectively, and 10 µL of internal standard before extraction. The 
background amounts present in native samples were subtracted from the results of the spiked 
samples and the latter were subsequently related to standard solutions. To investigate how the 
sample mass used for PLE influences sensitivity and matrix effects, PLE of NF-MBRWWTP sludge 
was carried out with both 0.5 g and 1 g of sample material.  
5.3 RESULTS AND DISCUSSION  
5.3.1 PLE METHODS  
PHARMACEUTICALS. Based on various published studies, an extraction method for 
pharmaceuticals was chosen and tested. Table 5-3 shows the absolute and relative recoveries. 
Generally, absolute recoveries in suspended matter were low, probably caused by ion 
suppression, resulting in averages ranging from 1 to 37% for antibiotics and 5 to 32% for 
psycho-active drugs (n = 3), with a maximal RSD of 30%. However, correction by internal 
standards was successful for most analytes, while two antibiotics (roxithromycin and 
sulfisoxazole) were excluded from further investigations due to insufficient relative recoveries. 
The relative recoveries for N4-acetylsulfamethoxazole, sulfadimethoxine, trimethoprim, 
dihydrocodeine, codeine, methadone, diazepam, nordiazepam, carbamazepine, 10,11-
dihydrocarbamazepine ranged between 69 and 109%, higher recoveries were accepted for 
clarithromycin, sulfamerazine, sulfadimidine, sulfamethoxazole, tiamulin, temazepam and 
oxycodone (131–156%), while for 10,11-dihydro-10,11-dihydroxycarbamazepine, primidone 
and doxepin lower recoveries were found (31–58%). RSD was below 15% for all compounds 
(Table 5-3).  
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The results show that literature data can provide a reliable basis for a fast method development 
with only slight adjustments. Nevertheless, the results clearly identify the need to verify 
published methods for each individual purpose. Reasons for problems with applying one 
method to different sample types can be found in the high variation within native sludge 
samples from different sampling sites. For native sludge samples, Ternes et al., 2005 showed 
large variations between activated and digested sludge, even from a single WWTP.   
Table 5-3: Recoveries of pharmaceuticals in spiked suspended matter. Substances in grey – excluded from 
further investigations because of unsatisfactory recovery.  
 
methanol:water 50:50, 500 ng (n=3) 
 
 
Absolute recovery Relative recovery 
 
 
% % 
 
Sample 
Name 
Median Average RSD Median Average RSD 
 
Antibiotics 
CLA 33.2 36.5 17.8 150 156 7.40 
ROX 35.3 37.3 16.1 214 218 3.65 
SMI 14.0 13.7 9.93 101 109 14.4 
SDI 4.76 4.52 9.32 154 155 2.82 
SDX 7.32 8.18 25.1 342 339 4.76 
SSX 0.820 0.914 21.3 19.1 19.2 1.38 
SMA 3.03 3.01 12.6 138 137 5.87 
SMX 4.01 4.35 25.6 132 132 3.42 
N-Ac-SMX 6.46 7.42 30.3 105 105 8.07 
TAM 18.1 18.1 15.8 129 131 3.04 
TMP 10.8 11.2 21.8 68.5 69.8 10.2 
min 3.03 3.01 9.32 68.5 69.8 2.82 
max 33.2 36.5 30.3 153.5 156.2 14.4 
 
Psycho-active compounds 
CBZ 14.4 14.2 5.88 110 109 4.67 
DH-CBZ 11.0 11.0 6.60 95.8 97.1 3.31 
DHH 7.77 7.93 3.39 55.8 53.8 10.7 
DXP 6.21 6.33 5.69 29.1 30.6 8.50 
PMD 6.45 6.62 13.0 60.0 57.5 9.88 
CDN 7.86 7.43 12.3 103 102 4.51 
DHC 5.29 5.12 8.91 69.0 67.8 6.44 
MTD 32.3 32.3 9.50 103 102 2.24 
OCN 8.96 8.98 5.16 138 139 14.1 
DZP 9.56 9.61 7.35 109 109 4.36 
NZP 9.66 9.76 4.07 100 102 4.18 
TZP 16.7 16.8 6.40 154 153 5.94 
min 5.29 5.12 4.07 29.05 30.55 2.24 
max 32.3 32.3 13.0 154.1 152.7 14.1 
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OPS. For the PLE of OPs, eight different solvents or solvent mixtures were tested through spiking 
experiments and were evaluated by absolute and relative recoveries (selected data see Table 5-
4; all other results are shown in Annex 5-A).  
For estimation of the method quality, in general recoveries between 70 and 140% were 
accepted. In some cases, deviating amounts were accepted as long as RSD was less than 20%.  
 
The test schemes 3 (acetone), 4 (methanol:acetone 1:4), 7 b (ethyl acetate with elevated 
temperature and pressure) and 8 a and b (hexan:acetone:heptanes in two different temperature 
and pressure sets) produced unsatisfying absolute recoveries for most analytes, revealing 
massive losses during extraction and measurement, which for these settings were not corrected 
by internal standards, resulting in equally low relative recoveries. In detail, scheme 3 for all 
analytes yielded very low absolute recoveries and while relative recoveries for some OPs were 
satisfactory, RSD was high with only one value below 20% (n = 2). Test scheme 4 equally led to 
unsatisfying absolute recoveries for all analytes which were only corrected by the use of IS for 
TBEP, leading to a relative recovery of 80% with RSD of 5% (n = 3). Within test scheme 7 b 
absolute recoveries which failed were only corrected for TnBP, leading to relative recovery of 
98% with RSD of 5% (n = 3).  
 
The test schemes 2 (methanol) and 6 (methanol:acetone 4:1) showed highly heterogeneous 
absolute recoveries for different substances, but within these experimental set-ups the 
correction by internal standards led to acceptable relative recoveries for most of the analytes. 
For test scheme 2, TDCPP, TPP, TnBP, and TiBP yielded relative recoveries of 92 and 125% with 
RSD of 6–16% (n = 2). Test scheme 6 yielded relative recoveries between 90 and 140% for five 
of the seven OPs (TDCPP, TPP, TCPP, TnBP, TiBP, TCEP). RSD ranged between 8 and 15% for 
four of these analytes while the RSD of TCPP was higher (28%) (n = 3).  
 
Best results for both absolute and relative recoveries were obtained using test schemes 1 
(methanol:water 1:1) and 5 (methanol:acetone 1:1). Test scheme 1 yielded absolute recoveries 
between 78 and 132% for five analytes, four of these with RSD below 13% (n = 3); relative 
recoveries showed a suitable correction by the use of IS, leading to relative recoveries between 
82 and 141% for five of the seven analytes with RSD below 10.5% except for TiBP (RSD 18%). 
Scheme 5 led to absolute recoveries between 77 and 88% (RSD: 4–20%) for five analytes; IS 
correction improved the method to achieve relative recoveries between 86 and 118% for the six 
analytes TDCPP, TPP, TCPP, TnBP, TiBP, TCEP, with RSD between 4 and 10% except for TCPP 
(RSD 31%) (n = 3).  
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Table 5-4: Recoveries of OPs in spiked suspended matter (only selected test schemes shown; for all other 
test schemes see Annex 5-A): spiking levels: * 100 ng, ** 500 ng. 
Test 
scheme 
No. 
1a* 
  methanol:water 50:50 (n=3) 
  Absolute recovery    Relative recovery    
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  159 151 10.4 228 224 8.78 
TnBP  117 116 9.18 103 103 2.31 
TiBP  155 152 13.2 141 134 18.0 
TCEP  132 132 1.40 121 121 10.3 
TPP  88.7 92.6 9.62 81.7 80.2 8.05 
TCPP  78.3 70.0 21.3 -1.33 1.17 1773 
TDCPP  94.0 92.2 12.6 82.2 81.7 1.91 
min 78.3 70.0 1.40 -1.33 1.17 1.91 
max 159 152 21.3 228 224 1773 
Test 
scheme 
No. 
1b**   
  methanol:water 50:50 500 ng (n=3)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  132 134 3.05 175 174 2.45 
TnBP  123 121 2.62 102 103 3.24 
TiBP  123 126 7.49 111 106 7.51 
TCEP  150 151 1.45 125 128 5.28 
TPP  88.0 88.2 3.13 75.2 74.9 4.28 
TCPP  119 108 21.1 90.1 85.5 10.3 
TDCPP  95.5 96.0 3.29 81.4 80.9 6.95 
min 88.0 88.2 1.45 75.2 74.9 2.45 
max 150 151 21.1 175 174 10.3 
Test 
scheme 
No. 
5*   
  methanol:acetone 50:50 (n=3)   
   Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  77.5 84.5 20.1 169 159 13.5 
TnBP  76.9 80.1 6.91 102 99.0 7.07 
TiBP  83.4 80.0 13.5 85.5 83.8 6.78 
TCEP  88.5 90.6 7.97 118 113 9.79 
TPP  78.2 79.0 4.21 117 119 4.44 
TCPP  22.1 23.5 47.3 92.0 101 31.2 
TDCPP  64.0 64.7 7.35 86.2 85.5 5.88 
min 22.1 23.5 4.21 85.5 83.8 4.44 
max 88.5 90.6 47.3 169 159 31.2 
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Since it was the goal of the method development not only to find an extraction method for the 
investigated OPs but also to combine the analysis of OPs with the PLE of pharmaceuticals, test 
scheme 1 (methanol:water (50:50, v/v)) was chosen for further investigation. In a second test 
with this set up, the spiking concentration in the samples was increased in expectation of 
relatively high concentrations in real sludge samples. In this test, absolute recoveries for six 
analytes lay within the required range from 70 to 140%. RSD were below 10% except for TCPP 
(21%). Correction by IS led to satisfactory relative recoveries (75–125%) for six out of seven 
analytes with RSD of 3–10% (n = 3). However, TBEP yielded in both spiking tests too high 
absolute recoveries (159 and 132% with RSD of 10 and 3%, respectively). Calculation against 
the internal standard TPP-d15 did not lead to a correction of the overestimation; relative 
recovery was 175% (RSD 3%; n = 3). The second available IS for OPs (TnBP-d27) did not yield 
better results (data not shown). However, since the main aim of the study was the development 
of a screening method for several compound groups, test scheme 1, which is also utilisable for 
pharmaceuticals, was kept for further analysis.  
 
5.3.2 METHOD VALIDATION 
Quantification, based on peak areas, was carried out by internal standard calibration. The 
calibration curves all showed a correlation coefficient (r2) of at least 0.999. The instrumental 
precision yielded less than 20% RSD except for trimethoprim. LOQ in sludge ranged from 6 ng/g, 
d.w. to 50 ng/g, d.w. for pharmaceuticals and from 14 ng/g, d.w. to 150 ng/g, d.w. for OPs, while 
LOQ for the PS-BFRhospital carriers was lower due to the greater sample mass used for analysis 
(Table 5-7, Table 5-6). The accuracy of the method was determined by estimating relative 
recoveries in pre-spiked native samples of sludge from both PS-BFRhospital and NF-MBRWWTP, as 
well as PS-BFRhospital carriers. Accuracy then was estimated by subtracting the analyte amount 
measured in native samples from the amount measured in the spiked ones (Table 5-5). Due to an 
irreplaceable loss of finished samples, the following results for the PS-BFRhospital stem from one 
set of spiked and native samples for sludge and carriers each. Accuracy for sulfamethoxazole, 
sulfamerazine, sulfadimidine, oxycodone, doxepin and TCEP ranged between 55 and 143% in all 
three matrices. Other compounds as sulfadimethoxine, tiamulin, trimethoprim, carbamazepine, 
codeine, nordiazepam, TDCPP, TPP, TnBP and TiBP showed acceptable accuracy in one or two 
matrices but less good results for the third. Generally, a tendency to too high recoveries is 
observed throughout, which could indicate an incomplete homogenisation of the sample 
material during pestling of the freeze-dried sludge. OPs in samples from the PS-BFRhospital show 
an especially poor accuracy. The reason for this can be found in the material of the polyurethane 
carriers which are assumed to emit OPs themselves (see Chapter 4.3), though the exact 
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composition of the carrier material is confidential. The carrier material was constantly moving 
and being rubbed, and the abraded matter was occasionally visible in the sludge samples as a 
fine dust, explaining insufficient accuracy results for OPs not only in carriers but in sludge as 
well. Severe inaccuracy was observed for TBEP and TCPP, which therefore are reported in Table 
5-7 with their analysed environmental concentrations, but excluded from further discussion 
regarding the PS-BFRhospital samples.  
 
To evaluate what influence the sample quantity used for PLE has on sensitivity (i.e., greater 
enrichment compared to the possibly higher matrix effect when using larger sample mass), 
sludge from the NF-MBRWWTP was extracted using sample masses of 0.5 g and 1 g (Table 5-6). 
The differences in compound concentrations observed for the different sample quantities 
ranged from 1.28 to 64.4%. Nine substances show higher concentrations in samples of 0.5 g 
(10,11-dihydrocarbamazepine, 10,11-dihydro-10,11-dihydroxycarbamazepine, primidone, 
temazepam, doxepin, TDCPP, TPP, TiBP, TCEP), while six were higher concentrated in samples of 
1 g (clarithromycin, sulfamethoxazole, carbamazepine, methadone, TBEP, TCPP). Since no 
definite tendency was found to prefer a sample mass of 0.5 g or 1 g, and in most cases the 
differences were small, a sample quantity for PLE of 1 g was chosen for further investigations.  
Table 5-5: Accuracy and instrumental precision of the analytical procedure 
 
Accuracy [%] 
 
Instrumental precision 
[RSD, %]3 
 
Sludge BFR1 Carrier BFR1   Sludge MBR2 
  
Antibiotics 
CLA a.r. a.r. 210 ; 228 
 
8.46 
SMI 145 470 132 ; 157 
 
7.63 
SDI 112 117 118 ; 119 
 
4.35 
SMA 122 127 117 ; 123 
 
3.86 
SMX 99.3 102 96.9 ; 102 
 
15.6 
N-Ac-SMX 90.9 155 101 ; 104 
 
7.52 
TAM 137 75.7 197 ; 204 
 
0.989 
TMP 243 a.r. 59.3 ; 72.3 
 
46.9 
Psycho-active compounds 
CBZ 197 213 188 ; 197 
 
1.34 
DH-CBZ 192 182 180 ; 180 
 
2.77 
DHH 344 531 331 ; 392 
 
1.39 
DXP 103 55.0 67.4 ; 101 
 
17.5 
PMD 396 527 302 ; 385 
 
5.29 
CDN 177 186 192 ; 195 
 
1.49 
DHC 309 219 291 ; 297 
 
4.03 
MTD 207 151 232 ; 237 
 
7.80 
OCN 110 95.0 128 ; 153 
 
10.6 
DZP 222 201 197 ; 208 
 
0.916 
NZP 193 182 195 ; 216 
 
1.63 
TZP 222 200 262 ; 306 
 
2.20 
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Table 5-5: continued. 
 
 
Accuracy [%] 
 
Instrumental precision 
[RSD, %]3 
 
Sludge BFR1 Carrier BFR1   Sludge MBR2 
  
OPs 
TBEP 1293 -1,900 155 ; 174 
 
6.21 
TnBP 190 158 102 ; 117 
 
5.97 
TiBP 150 164 50.0 ; 146 
 
10.4 
TPP 190 23.7 111 ; 115 
 
3.56 
TCEP 143 113 94.1 ; 114 
 
9.39 
TCPP 410 466 267 ; 287 
 
11.2 
TDCPP 194 13.0 121 ; 130 
 
4.47 
1n=1; 2n=2; 3n=2-4. 
      
Table 5-6: Comparison of compound amounts [ng/g, d.w.] found in aliquot samples of NF-MBRWWTP sludge 
with different extraction quantities during PLE. Print in bold: the greater average amount per compared 
pair. 
Sample 
weight [g]    
0.5 g 
 
1 g 
 
Difference1 
ng/g , d.w. 
 
LOQ 
 
Median Average SD 
 
Median Average SD 
 
[%] 
Antibiotics 
 CLA 
 
10 
 
35.9 35.9 1.84 
 
47.6 47.6 2.19 
 
24.5 
SMI 
 
10 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
SDI 
 
10 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
SMA 
 
10 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
SMX  
 
10 
 
46.0 46.0 1.13 
 
50.0 50.0 2.05 
 
7.91 
N-Ac-SMX  
 
40 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
TAM 
 
10 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
TMP 
 
10 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
Psycho-active compounds 
CBZ 
 
10 
 
101 101 6.79 
 
109 109 3.54 
 
6.73 
DH-CBZ 
 
6 
 
8.10 8.1 1.24 
 
6.88 6.88 0.042 
 
15.1 
DHH 
 
20 
 
187 187 7.78 
 
142 142 3.54 
 
31.8 
DXP 
 
10 
 
71.0 71.0 2.83 
 
62.1 62.1 1.27 
 
12.5 
PMD 
 
40 
 
71.0 71.0 0.000 
 
42.8 42.8 0.495 
 
39.8 
CDN 
 
50 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
DHC 
 
20 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
MTD 
 
20 
 
64.8 64.8 3.39 
 
70.0 70.0 9.83 
 
7.36 
OCN 
 
20 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
DZP 
 
20 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
NZP  
 
20 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
TZP 
 
10 
 
16.7 16.7 0.240 
 
12.3 12.3 0.283 
 
26.2 
OPs 
TBEP 
 
25 
 
484 484 56.57 
 
552 552 22.63 
 
12.3 
TnBP  
 
50 
 
< LOQ < LOQ  --- 
 
< LOQ < LOQ  --- 
 
 --- 
TiBP  
 
150 
 
652 652 45.25 
 
232 232 16.97 
 
64.4 
TPP  
 
25 
 
232 232 28.28 
 
187.4 187 13.29 
 
19.2 
TCEP  
 
14 
 
39.2 39.2 9.56 
 
17.2 17.2 1.12 
 
56.1 
TCPP  
 
110 
 
5,000 5,000 849 
 
5,330 5,330 891 
 
6.19 
TDCPP  
 
60 
 
98.2 98.2 0.849 
 
78.2 78.2 3.68 
 
20.4 
1 difference between the average amount in corresponding samples with 0.5 g and 1g sample mass for PLE   
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5.3.3 METHOD APPLICATION  
5.3.3.1 Sludge 
In sludge samples from the two pilot plants, the overall maximum concentrations found for 
single compounds of antibiotics, psycho-active drugs and OPs were 342 ng/g, d.w., 537 ng/g, 
d.w. and 5330 ng/g, d.w., respectively (Table 5-7). The antibiotics sulfadimethoxine, 
sulfamerazine, sulfadimidine and tiamulin as well as the antibiotic metabolite N4-
acetylsulfamethoxazole were not quantified in any of the samples. In contrast, eleven analytes 
(sulfamethoxazole, carbamazepine, 10,11-dihydrocarbamazepine, 10,11-dihydro-10,11-
dihydroxycarbamazepine, dihydrocodeine, temazepam, doxepin, TDCPP, TPP, TiBP, TCEP) were 
found in sludge from both pilot plants. Primidone could not be quantified in PS-BFRhospital sludge 
but was quantified in sludge from the NF-MBRWWTP. Trimethoprim, codeine, nordiazepam and 
dihydrocodeine were only quantified in samples from the PS-BFRhospital, while methadone was 
only found in sludge from the NF-MBRWWTP.  
 
UBIQUITOUS SUBSTANCES. In the group of compounds found in sludge both from the PS-BFRhospital 
and the NF-MBRWWTP, clarithromycin, sulfamethoxazole, 10,11-Dihydro-10,11-
dihydroxycarbamazepine and doxepin showed higher concentrations at the hospital sampling 
site. All other substances in this omnipresent group showed very similar concentrations in both 
sludge types, indicating that despite being different in terms of feed water and treatment 
method, the sludges from the PS-BFRhospital and NF-MBRWWTP are comparable regarding their 
overall load of pharmaceuticals and OPs. This basic similarity between the xenobiotic 
composition in the sludge samples from PS-BFRhospital and NF-MBRWWTP is also reflected in the 
sum of concentrations for each compound group (Figure 5-3). The overall amount of antibiotics 
was more than eight times higher in sludge at the hospital (PS-BFRhospital) than at the WWTP (NF-
MBRWWTP), which is probably caused by high usage of these pharmaceuticals in the hospital. Yet 
the total of psycho-active compounds was no more than roughly twice as high in the PS-
BFRhospital sludge, reflecting widespread use elsewhere than at the hospital site, and the amount 
of OPs was almost identical at both sampling sites, which reflects the ubiquitous character of this 
compound group.  
 
ANTIBIOTICS. When comparing the results for antibiotics in the presented study with data given 
in the literature, similar amounts for sulfamethoxazole and clarithromycin at the WWTP were 
reported previously, while the amount of clarithromycin in the sludge from the hospital is higher 
than reported in other studies. On the other hand, trimethoprim, which was not found in the 
sludge from the NF-MBRWWTP, was frequently detected in sludge from WWTPs by other 
researchers. In activated sludge from several WWTPs in Germany and Switzerland with 
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conventional activated sludge treatment (CAS), Göbel et al. (Göbel et al., 2005a; Göbel et al., 
2005b) found concentrations of sulfamethoxazole, trimethoprim and clarithromycin ranging 
from 34 – 100 ng/g d.w., 13 – 133 ng/g d.w. and 16 – 95 ng/g d.w., respectively. They also 
investigated sulfadimidine but detected none in any samples, which is in agreement with the 
results of my study. In secondary sludge from a CAS-WWTP in Spain, Radjenović et al., 2009a 
found concentrations of 21.0 + 7.2 ng/g d.w. and 42.6 + 7.2 ng/g d.w. for sulfamethoxazole and 
trimethoprim, respectively. In the same study, sludge from two different types of NF-MBRWWTP 
was investigated. One was equipped with hollow-fibre (HF) ultra-filtration membranes and the 
other with micro-filtration flat-sheet (FS) membranes. The sludge yielded concentrations of 
27.9 + 6.5 ng/g d.w. (HF) and 17.0 + 9.6 ng/g d.w. (FS) for sulfamethoxazole, and 34.2 + 13.1 
ng/g d.w. (HS) and 22.4 + 10.4 ng/g d.w. (FS) for trimethoprim. 
 
PSYCHO-ACTIVE COMPOUNDS. Not many studies are available regarding the occurrence of psycho-
active compounds in sewage sludge. Ternes et al., 2005 used ultrasonication and LC-MS/MS 
analysis to determine carbamazepine and diazepam in both activated and digested sludge from 
Swiss and German WWTPs. Neither substance was detected in any samples above the limit of 
quantification, which was 20 ng/g d.w., and it was assumed that sorption onto sludge was 
negligible for these substances, which in the case of carbamazepine is not in accordance with my 
data. In contrast, and essentially in agreement with the results presented here, Miao et al., 2005 
reported the amounts of carbamazepine and 10,11-Dihydro-10,11-dihydroxycarbamazepine in 
activated sludge from a Canadian CAS-WWTP to be 69.6 ng/g d.w. and 7.5 ng/g d.w., 
respectively. Radjenović et al., 2009a found carbamazepine concentrations in activated sludge 
from a CAS-WWTP, in sludge from a MBR equipped with hollow-fibre ultra-filtration membrane 
and from another MBR with micro-filtration flat-sheet membranes to be 34.1 + 6.3 ng/g d.w., 45.0 + 
11.9 ng/g d.w. and 41.6 + 20.3 ng/g d.w., respectively.  
 
OPS. To date, OPs in sludge have rarely been investigated. To my knowledge, no data regarding 
activated sludge have been published. Marklund et al., 2005 investigated digested sludge from 
11 Swedish WWTPs of different sizes and using different treatment technology for the 
occurrence of eight OPs, finding TBEP, TCPP and TiBP to be the most abundant ones (< 5.1–1900 
ng/g d.w., 61–1900 ng/g d.w. and 27–2700 ng/g d.w, respectively), while TnBP (39–850 ng/g 
d.w.), TPP (52–320 ng/g d.w.), TDCPP (3.0–260 ng/g d.w.) and TCEP (6.6–110 ng/g d.w.) were 
found at lower concentrations. In regard of TnBP, these results differ from the results presented 
here, where the substance is only found above the limit of quantification in the PS-BFRhospital 
carrier material, probably originating from the polyurethane foam itself.  
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Table 5-7: Concentrations of xenobiotics in sludge and carriers from PS-BFRhospital and in NF-MBRWWTP 
sludge. 
Sample weight [g] 
    
1.0231 3.5221 
 
1.015+0.0042 
         
  
  
LOQ 
 
BFR 
 
MBR 
Compound 
 
Sludge Carrier 
 
Sludge Carrier 
 
Sludge 
  
ng/g d.w. 
 
ng/g d.w. 
 
ng/g d.w. 
Antibiotics 
CLA 
 
10 2.86 
 
342 > 2,0003 
 
47.6 + 2.19 
SMI 
 
10 2.86 
 
< LOQ < LOQ 
 
< LOQ 
SDI 
 
10 2.86 
 
< LOQ < LOQ 
 
< LOQ 
SMA 
 
10 2.86 
 
< LOQ < LOQ 
 
< LOQ 
SMX 
 
10 2.86 
 
112 92.0 
 
50.0 + 2.05 
N-Ac-SMX 
 
40 11.4 
 
< LOQ < LOQ 
 
< LOQ 
TAM 
 
10 2.86 
 
< LOQ < LOQ 
 
< LOQ 
TMP 
 
10 2.86 
 
291 240 
 
< LOQ 
Psycho-active compounds 
CBZ 
 
10 2.86 
 
88.0 96.3 
 
109 + 3.54 
DH-CBZ 
 
6 1.71 
 
6.77 5.76 
 
6.88 + 0.042 
DHH 
 
20 5.71 
 
537 188 
 
142 + 3.54 
DXP 
 
10 2.86 
 
143 90.9 
 
62.1 + 1.27 
PMD 
 
40 11.4 
 
< LOQ 15.0 
 
43.0 + 0.495 
CDN 
 
50 14.3 
 
47.9 70.7 
 
< LOQ 
DHC 
 
20 5.71 
 
93.9 47.1 
 
n.d. 
MTD 
 
20 5.71 
 
< LOQ < LOQ 
 
70.0 + 9.83 
OCN 
 
20 5.71 
 
< LOQ 9.54 
 
< LOQ 
DZP 
 
20 5.71 
 
< LOQ 10.6 
 
< LOQ 
NZP 
 
20 5.71 
 
20.0 34.9 
 
< LOQ 
TZP 
 
10 2.86 
 
12.5 8.77 
 
12.3 + 0.283 
OPs 
TBEP 
 
25 7.14 
 
4,9204 11,0164 
 
552 + 22.6 
TnBP 
 
50 14.3 
 
< LOQ 69.8 
 
< LOQ 
TiBP 
 
150 42.9 
 
350 341 
 
232 + 17.0 
TPP 
 
25 7.14 
 
33.0 123 
 
188 + 13.3 
TCEP 
 
14 4.00 
 
21.6 14.7 
 
17.23 + 1.12 
TCPP 
 
110 31.4 
 
8302 1662 
 
5,330 + 891 
TDCPP 
 
60 17.1 
 
70.8 315 
 
78.2 + 3.68 
1 n=1; 2 n=2; 3 above concentration range; 4 semi-quantitative data due to poor quality assurance results 
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Figure 5-3: Sum of concentrations per investigated compound group in sludge and carrier material from 
the PS-BFRhospital and in the sludge from the NF-MBRWWTP. Concentrations below LOQ were taken into 
account with LOQ/2; concentrations above the calibration range were calculated with the amount of the 
highest calibration point; *for the sum of OPs, concentrations of TBEP and TCPP were not taken into 
account (see Chapter 5.3.2).  
 
5.3.3.2 CARRIERS 
When comparing the concentrations detected in sludge and carrier material from the PS-
BFRhospital, for most compounds very similar amounts were found (Table 5-7). This could be a 
result of co-extracted sludge particles which remained attached to the carrier material 
throughout drying and freeze-drying or, more likely, it could be caused by the sludge and the 
biofilm having similar surface characteristics. So the exceedingly large amounts of 
clarithromycin found in the carrier material are unexpected at first. However, the extracellular 
polymeric substances (EPS), which hold flocs of activated sludge together as well as being the 
backbone of the cell-surrounding gels of biofilms, are negatively charged at pH > 7 (Bryers, 2000 
cited in Wunder et al., 2011; Stewart and Costerton, 2001).  
 
IONIC INTERACTIONS. Since clarithromycin was, in contrast to the other xenobiotics investigated 
in this study, positively charged under the pH conditions present in the PS-BFRhospital pilot plant, 
higher sorption of clarithromycin can be expected. Wunder et al., 2011 found that ionic 
interactions are more essential for the sorption of antibiotics to biofilm polymers than 
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hydrophobic interactions. Accordingly, Abegglen et al., 2009 reported strong sorption processes 
for clarithromycin in the sludge from an MBR with approximately 40% of the originally spiked 
amount still being bound in the sludge after two weeks. As was shown elsewhere (see Chapter 
4.3), clarithromycin concentrations in the feed water of the PS-BFRhospital were high (1.2 + 0.7 
µg/L). The large surface provided by the porous polyurethane foam carriers and the constant 
movement of the carriers in the feed water allow the substances easy access to the biofilm 
surface. In this way, the problem of restricted mass transfer to and through the biofilm is 
circumvented, which was found to inhibit sorption of the comparably large macrolide molecules 
(molecular weight of clarithromycin: 747.95; see Chapter 2.1.1.1) reported from bench-scale 
laboratory studies using biofilms grown on compact media (Wunder et al., 2011). Taking the 
strong sorption tendency of the substance and the large surface area provided by the porous 
polyurethane foam carriers into account, the large amounts of clarithromycin found in the 
carrier material seem realistic.  
 
5.4 CONCLUSIONS 
A PLE method was developed which allowed the simultaneous extraction of 27 substances of 
different xenobiotic compound groups (antibiotics and metabolites, psycho-active substances 
and metabolites, OPs) from biosolids. LOQs ranged from 1.71 ng/g d.w. to 150 ng/g d.w. 
depending on the extracted biosolids and the compound. While matrix effects were an issue in 
case of several substances, no general differences were found when varying sample quantities 
were used for PLE. The PLE method was applied to sewage sludge from a nanofiltration 
membrane bioreactor pilot plant located at the influent of a WWTP, and to sludge and carrier 
material from a particle-supported biofilm reactor pilot plant situated at the effluent of a 
municipal hospital. The highest concentrations found in the sludge were 342 ng/g d.w., 537 ng/g 
d.w. and 5330 ng/g d.w., for antibiotics, psycho-active drugs and OPs, respectively. These results 
underline the presence of xenobiotics in sludge. In many countries sludge is later used as 
fertiliser in agriculture, and therefore provides a possible gateway for sludge-bound xenobiotics 
to enter the environment. Xenobiotic concentrations found in biofilm carriers suggested 
bleeding of the carrier material during PLE, which in some cases led to inaccuracies regarding 
OP concentrations. Furthermore, indications were found that particle-supported biofilms have 
advanced sorption capacities.  
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5-A ANNEX  
Table 5A-1: Amounts of water-originating xenobiotics in the biosolids investigated. 
 
PS-BFRhospital NF-MBRWWTP  
Compound Sludge Carrier  Sludge 
Antibiotics 
 CLA 1.45 
 
4.91 
SMX  10.3 12.6 10.2 
N-Ac-SMX   ---  ---  --- 
SMI  ---  ---  --- 
SMA  ---  ---  --- 
SDI  ---  ---  --- 
TAM  ---  ---  --- 
TMP  ---  ---  --- 
Psycho-active compounds 
CBZ 2.71 2.48 4.19 
DH-CBZ 1.74 2.04 2.66 
DHH 9.21 26.3 17.6 
PMD  --- 58.2 15.7 
CDN  ---  ---  --- 
DHC  ---  ---  --- 
MTD  ---  --- 0.331 
OCN  ---  ---  --- 
DZP  ---  ---  --- 
NZP  0.411 0.236  --- 
TZP 0.669 0.953 0.958 
DXP n.w. n.w. 1.65 
OPs 
TBEP 1.11 0.496 5.42 
TDCPP  n.w. n.w. 0.949 
TPP  n.w. n.w. 0.050 
TCPP  n.w. n.w. 0.079 
TnBP   --- 0.419  --- 
TiBP  n.w. n.w. 3.66 
TCEP  1.34 1.96 2.21 
 --- = not determinable due to sludge concentrations < LOQ; n.w. = not 
determinable due to water concentrations < LOQ. 
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Table 5A-2: Recoveries of OPs in spiked suspended matter (trial test schemes). 
Test 
scheme No. 
2   
  methanol   
  
Absolute recovery 
(n=2) 
  
Relative recovery 
(n=3) 
  
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  71.9 71.9 35.1 185 173 13.9 
TnBP  66.8 66.8 11.9 104 101 5.7 
TiBP  75.0 75.0 0.4 92.0 94.3 15.6 
TCEP  117 117 12.2 182 186 3.6 
TPP  64.5 64.5 15.1 125 133 12.9 
TCPP  266 266 124.9 348 451 85.8 
TDCPP  58.3 58.3 5.1 102 100 5.4 
min 58.3 58.3 0.356 92.0 94.3 3.56 
max 266 266 125 348 451 85.8 
       
      
  
Test 
scheme No. 
3   
  acetone (n=2)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  11.5 11.5 421.5 875 875 110.1 
TnBP  19.7 19.7 112.4 97.7 97.7 8.0 
TiBP  16.2 16.2 104.3 83.2 83.2 21.2 
TCEP  61.7 61.7 3.3 573 573 95.2 
TPP  12.1 12.1 221.8 62.0 62.0 117.5 
TCPP  -6.38 -6.38 -1431 711 711 85.5 
TDCPP  14.2 14.2 174.5 68.8 68.8 66.4 
min -6.38 -6.38 -1431 62.0 62.0 7.96 
max 61.7 61.7 421.5 875 875 117 
       
       
Test 
scheme No. 
4   
  methanol:acetone 20:80 (n=3)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  34.3 42.7 78.4 79.7 79.7 5.07 
TnBP  18.2 21.4 71.7 33.8 33.8 6.84 
TiBP  8.11 15.2 119 20.1 20.1 17.5 
TCEP  26.7 19.7 72.0 30.7 30.7 47.3 
TPP  22.7 24.7 81.1 53.3 53.3 19.0 
TCPP  -79.3 -54.5 -105 -38.7 -38.7 -28.4 
TDCPP  23.6 25.0 45.7 39.1 39.1 13.3 
min -79.3 -54.5 -105 -38.7 -38.7 -28.4 
max 34.3 42.7 119 79.7 79.7 47.3 
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Test 
scheme No. 
6   
  methanol:acetone 80:20 (n=3)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  65.1 65.5 9.73 187 186 6.98 
TnBP  71.1 67.2 11.0 104 106 7.71 
TiBP  81.4 76.1 13.8 101 100 9.57 
TCEP  85.2 86.5 6.85 140 139 9.36 
TPP  62.1 62.7 16.0 113 123 15.3 
TCPP  -15.8 -14.1 -116 98.0 100 27.5 
TDCPP  56.2 54.8 11.3 89.8 94.8 10.1 
min -15.8 -14.1 -116 89.8 94.8 6.98 
max 85.2 86.5 16.0 187 186 27.5 
       
       
Test 
scheme No. 
7a 
 
   ethyl acetate (n=2) 
 
  Absolute recovery   Relative recovery 
 
  %   % 
 
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  23.1 23.1 21.7 82.0 82.0 48.3 
TnBP  49.9 49.9 16.6 113 113 1.88 
TiBP  -190 -190 -5.09 -126 -126 -3.37 
TCEP  88.0 88.0 83.9 202 202 92.0 
TPP  39.3 39.3 26.8 106 106 8.64 
TCPP  -282 -282 -39.6 51.5 51.5 625 
TDCPP  47.2 47.2 18.2 108 108 1.96 
min -282 -282 -39.6 -126 -126 -3.37 
max 88.0 88.0 83.9 202 202 625 
      
  
      
  
Test 
scheme No. 
7b   
  ethylacetate b (n=3)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  -54.4 -54.8 -1.97 300 382 43.8 
TnBP  0.519 0.534 85.6 95.5 97.5 4.47 
TiBP  -224 -224 -0.702 -41.0 -44.0 -22.4 
TCEP  95.7 90.1 19.1 1335 1372 24.5 
TPP  -9.65 -9.93 -7.59 47.7 48.3 15.4 
TCPP  -213 -212 -2.76 1149 1106 15.3 
TDCPP  -6.45 -6.88 -10.8 61.6 61.5 7.16 
min -224 -224 -10.8 -41.0 -44.0 -22.4 
max 95.7 90.1 85.6 1335 1372 43.8 
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Test 
scheme No. 
8a   
  hexan:aceton:heptan a (n=2)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  -15.6 -15.6 -15.4 142 142 22.9 
TnBP  15.2 15.2 24.2 110 110 8.36 
TiBP  -60.0 -60.0 -26.2 57.5 57.5 67.6 
TCEP  1.51 1.51 46.4 12.7 12.7 2.23 
TPP  -1.58 -1.58 -201 102 102 58.6 
TCPP  -145 -145 -63.6 169 169 247 
TDCPP  13.2 13.2 10.3 121 121 36.7 
min -145 -145 -201 12.7 12.7 2.23 
max 15.2 15.2 46.4 169 169 247 
       
      
  
Test 
scheme No. 
8b   
  hexan:aceton:heptan b (n=2)   
  Absolute recovery   Relative recovery   
  %   %   
Sample 
Name 
Median  Average  RSD Median  Average  RSD 
TBEP  13.4 13.4 69.5 486 486 34.9 
TnBP  8.96 8.96 57.4 112 112 10.1 
TiBP  22.0 22.0 52.5 255 255 17.2 
TCEP  97.4 97.4 25.6 1331 1331 25.0 
TPP  2.38 2.38 47.0 32.9 32.9 15.5 
TCPP  52.7 52.7 133 375 375 13.2 
TDCPP  5.48 5.48 42.2 70.1 70.1 10.4 
min 2.38 2.38 25.6 32.9 32.9 10.1 
max 97.4 97.4 133 1331 1331 34.9 
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6. SUMMARISING DISCUSSION 
 
You have learnt something. That always feels at first as if you had lost something. 
– Georg Bernard Shaw (1856-1950), Major Barbara, Act III, 1905 – 
 
 
 
In this chapter, the results of the individual studies presented in Chapters 3 to 5 are contrasted 
and related to each other. Thus, the properties found for the investigated wastewater types are 
compared, the xenobiotic loads of different wastewater streams are investigated and the studied 
wastewater treatment methods are compared regarding their capacity for xenobiotic removal.  
 
6.1 CHARACTERISATION OF WASTEWATER FROM DIFFERENT SOURCES 
The cumulative concentrations of all investigated xenobiotic compound groups found for the 
hospital effluent and the influent of the municipal WWTP are shown in Figure 6-1. The total 
concentration is more than ten times higher in the hospital effluent (1,647 µg/L) than in raw 
municipal wastewater (135 µg/L). In both cases, ICMs are the xenobiotic compound group with 
the highest total concentration (WWTP influent: 91.9 µg/L, hospital effluent: 1,573 µg/L) and 
they are mainly responsible for the difference between the total concentrations in the two 
wastewater types: The concentration for ∑ NSAIDs at the hospital is only slightly higher than at 
the WWTP (35.7 µg/L vs. 11.6 µg/L), and all other compound groups show very similar 
cumulative concentrations at the hospital and at the WWTP (∑ antibiotics being 4.76 µg/L 
(WWTP) and 5.58 µg/L (hospital), ∑ psycho-active compounds being 13.3 µg/L (WWTP) and 
18.7 µg/L (hospital), ∑ OPs 13.4 µg/L (WWTP) and 13.0 µg/L (hospital)). These results reflect 
the extensive use of ICMs and, to a lesser degree, NSAIDs in the hospital, while the incidence of 
antibiotics and psycho-active compounds seems not to be primarily hospital-bound. The 
similarity of total concentrations of OPs in both wastewater types seems to mirror the 
ubiquitous use of these industrial chemicals. However, it is noteworthy that while the total 
concentration is similar, the number of OPs contributing to it is not: in the case of the WWTP, six 
out of the eight OPs studied were quantified and amounted to roughly the same cumulative 
concentration as only three OPs quantified in raw hospital wastewater (for details, see Chapters 
3.3.2 and 4.3.2).  
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Figure 6-1: Cumulative concentrations per compound group [ng/L] in raw municipal wastewater (WWTP 
influent) and in raw hospital wastewater (hospital effluent). 
 
For ICMs, too, distinct differences between the hospital and the municipal wastewater were 
found (Figure 6-2). In raw hospital wastewater, two substances, diatrizoic acid and iomeprol, are 
responsible for practically the whole concentration of ICMs. On the other hand, these two 
compounds are quite insignificant in the case of municipal wastewater, where iopromide is the 
most highly concentrated ICM. It can be assumed that diatrizoic acid and iomeprol reflect a very 
specific use at the hospital, with other sources (other hospitals and households) seemingly not 
contributing in major ways. The opposite seems to be true for iopromide, for which sources 
other than the investigated hospital seem to be important (see also Chapter 6.2).  
 
In summary, it can be said that there are basic differences between wastewater streams 
originating from the hospital and from mixed municipal sources regarding concentrations for 
ICMs, while other pharmaceuticals are more evenly distributed. For OPs, similar overall 
concentrations in the two wastewater types derived from a very different set of single 
substances. The results regarding ICMs are in contrast to the often postulated opinion that ICMs 
are applied at hospitals to outpatients but excreted mainly away from the hospital after return to 
home (e.g. Chèvre et al., 2013). Indeed, the rapid passage of the substances through the human 
body, with highest excretion rates occurring within an hour after application (Sprehe et al., 
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2000, see also Chapter 2.1.1.2), make it very plausible that ICMs are excreted in high 
concentrations at the hospital before outpatients leave the facilities, and thus reflect specialised 
use patterns.  
 
 
Figure 6-2: ICMs in raw hospital (left) and municipal (right) wastewater.  
 
6.2 CONTRIBUTION OF HOSPITAL WASTEWATER TO THE XENOBIOTIC LOAD IN MUNICIPAL 
WASTEWATER 
The annual loads of xenobiotics in hospital and municipal wastewater (normalised to the 
number of inpatients in the case of the hospital and expressed on a per capita basis for the 
WWTP) are given in Table 6-1 and Table 6-2. The hospital investigated is relatively small (see 
Chapter 4.2.2) and only 0.15% of the annual municipal WWTP water inflow originates from it. 
Subsequently, the hospital-derived load of most of the xenobiotics found in the WWTP is less 
than 1% (Figure 6-3), which concurs with results from other studies (Thomas et al., 2007; 
Langford and Thomas, 2009). Overall, for only four substances – all of them ICMs or ICM-TPs – 
was it found that the estimated load originating from the hospital exceeds 1% of the overall 
WWTP influent load. However, 21.5% of the annual load of diatrizoic acid reaching the WWTP is 
estimated to originate from the hospital. The high contribution of diatrizoic acid is surprising, 
especially when taking into account that a) ICMs are often assumed to be excreted away from 
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the hospital (Chèvre et al., 2013) and b) because of the presence of several further radiological 
facilities connected to a large university clinic within the service area of the WWTP. It could 
therefore be expected that these larger facilities exceed the smaller hospital in regard of 
administering ICMs. These results might point to a specific use pattern of ICMs between different 
medical facilities and underlines the assumption given above that wastewater streams from 
different sources can be dissimilar (see Chapter 6.1). Hospital effluent and municipal 
wastewater might have comparable patterns for some therapeutic groups and not for others, 
hospital wastewater thus having a different finger print from municipal wastewater.  
When calculating the contribution of hospital wastewater to municipal loads, it has to be kept in 
mind that for substances known to retransform from metabolites into parent compounds in 
wastewater, the results have to be assumed to contain increased uncertainties.  
 
 
 
 
Figure 6-3: Estimated contribution of the effluent of the investigated hospital to the input load of the 
municipal WWTP [%]. 
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Table 6-1: Estimated normalised annual mass loads of the investigated xenobiotics in raw municipal 
wastewater (influent WWTP). n.a.: not analysed; ---: < LOQ/not detected 
 
WWTP influent   WWTP influent 
 
[mg/year/person]   [mg/year/person] 
 
Antibiotics   NSAIDs and bezafibrate 
CLA 48.0  BZF 112 
ROX 10.9  DCF 117 
SMI 2.48  IBP 718 
SDI ---  NPX 79.2 
SSX ---   Psycho-active compounds 
SMA ---  CBZ 103 
SMX 114  DH-CBZ 4.66 
N-Ac-SMX 227  DHH 675 
TAM ---  DXP 25.7 
TMP 12.0  PMD 208 
 
ICM 
 
 
CDN 20.4 
DTZ 647  DHC 2.89 
IOP 1,247  MTD 5.22 
IPM 152  MPN 34.9 
IMI 5,933  OCN --- 
IMI-TP 805 A 10.8  DZP --- 
IMI-TP 805 B ---  NZP --- 
IMI-TP 819 69.8  OZP 90.3 
IMI-TP 817 A ---  TZP 3.25 
IMI-TP 787 A ---   OPs 
IMI-TP 731 A ---  TBEP 657 
IMI-TP 731 B ---  TnBP 10.9 
IMI-TP 729 A ---  TiBP 379 
IMI-TP 759 42.0  TEHP --- 
IMI-TP 701 A 10.2  TPP 2.45 
IMI-TP 701 B ---  TCEP 14.6 
IMI-TP 643 ---  TCPP 96.0 
  
 TDCPP 19.6 
a Loads were calculated and normalised using average concentrations (see Table 3-8) and the following data: WWTP: 
influent flow rate: 15,000,000 m3/year; persons connected to the sewage system: 170,000 (MWB, 2013).  
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Table 6-2: Estimated normalised* annual mass loads of the investigated xenobiotics in raw hospital 
wastewater (hospital effluent). n.a.: not analysed; ---: < LOQ/not detected 
 
Hospital effluent   Hospital effluent 
 
[mg/year/patient]   [mg/year/patient] 
 
Antibiotics   NSAIDs and bezafibrate 
CLA 2.61  BZF 12.4 
ROX 0.066  DCF 7.86 
SMI n.a.  IBP 59.4 
SDI n.a.  NPX 0.122 
SSX n.a.   Psycho-active compounds 
SMA n.a.  CBZ 1.25 
SMX 6.07  DH-CBZ 0.062 
N-Ac-SMX 2.82  DHH 26.0 
TAM n.a.  DXP 0.227 
TMP 0.899  PMD 4.61 
 
ICM# 
 
 CDN 0.260 
DTZ 2,366  DHC 0.306 
IOP 1,112  MTD --- 
IPM ---  MPN 0.174 
IMI 7.71  OCN 0.260 
IMI-TP 805 A 15.4  DZP --- 
IMI-TP 805 B ---  NZP 0.043 
IMI-TP 819 5.10  OZP 8.57 
IMI-TP 817 A 1.27  TZP 0.044 
IMI-TP 787 A ---   OPs 
IMI-TP 731 A 2.56  TBEP 28.7 
IMI-TP 731 B ---  TnBP 0.154 
IMI-TP 729 A ---  TiBP --- 
IMI-TP 759 2.93  TEHP --- 
IMI-TP 701 A 2.82  TPP --- 
IMI-TP 701 B ---  TCEP 0.152 
IMI-TP 643 0.441  TCPP --- 
  
 TDCPP --- 
* Loads were calculated and normalised using average concentrations (see Table 4-2) and the following data: hospital: 
effluent water flow per year estimated from measurements during sampling campaign: 22,350 m3; estimated number 
of inpatients per year: 10,000 (Agaplesion Evangelisches Krankenhaus, 2013) – outpatients are not taken into 
account); #for ICMs, a larger uncertainty for the normalisation has to be considered since ICMs are administered to 
outpatients on a large scale but it is assumed that due to rapid excretion rates large amounts are actually excreted at 
the hospital before the patients leave (see Chapter 4).  
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6.3 DISTRIBUTION PATTERNS OF METABOLITES AND TRANSFORMATION PRODUCTS IN RAW 
AND TREATED WASTEWATER  
Human metabolites of two pharmaceuticals – carbamazepine and sulfamethoxazole – and the 
transformation products (TPs) of the ICM iopromide were analysed in raw hospital and 
municipal wastewater as well as in the effluents from the NF-MBRWWTP and PS-BFRhospital.  
 
RAW WASTEWATER. The distribution patterns of the three pharmaceuticals and their metabolites 
and TPs, respectively in raw hospital and municipal wastewater are shown in Figure 6-4.  
In the case of iopromide, a profound difference between the two types of raw wastewater can be 
seen. Whilst in raw municipal wastewater, 98% of the substance was found in the form of the 
parent drug, it only accounts for 22% in raw hospital wastewater, whereas six of the twelve 
investigated transformation products amount to 78%. Since ICMs are designed to pass through 
the human body without being metabolised, it can be assumed that no degradation of the 
iopromide has taken place before the substance reaches the sewage system. Therefore, the 
transformation must have occurred in the wastewater almost instantaneously since only 
minutes elapsed between the water reaching the sewage system and its arrival at the sampling 
point. It can be assumed that highly reactive compounds in the undiluted hospital wastewater, 
such as disinfectants, or reactions between organic compounds and the chlorine present in the 
water (Orias and Perrodin, 2013) trigger immediate degradation processes of the ICM. For ICMs 
which are excreted away from the hospital by outpatients leaving the facility after treatment, 
these processes might take place with less intensity since the less concentrated (municipal) 
wastewater receiving the excreted substance is less reactive. The same might hold true for 
wastewater from larger clinic complexes where raw wastewater is considerably diluted on site 
by wastewater from e.g. laundry. The total load of iopromide and its investigated TPs 
(loadIMI+TPs) originating from the investigated hospital only accounts for less than 0.04% of the 
anual loadIMI+TPs reaching the WWTP (see Chapter 6.2). This could explain why in raw municipal 
wastewater, by far the main substance found is iopromide, while the TPs are practically absent.  
In contrast to iopromide, the distribution patterns of carbamazepine in the two types of raw 
wastewater were found to be largely similar. In both cases, the metabolite 10,11-dihydro-10,11- 
dihydroxycarbamazepine is, at about 90%, the most abundant form (95 and 86% in hospital 
effluent and WWTP influent samples, respectively) while the percentage of the parent drug is 
less than 15% and the second metabolite 10,11-Dihydrocarbamazepine does not exceed 1%.  
The distribution found for sulfamethoxazole and its metabolite N4-acetylsulfamethoxazole is 
practically inverted for hospital and municipal wastewater: in hospital wastewater, the 
percentages of parent drug and metabolite are 68 and 32%, while for municipal wastewater they 
are 34 and 66% (Figure 6-4). According to Göbel et al., 2005b, about 50% of administered 
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sulfamethoxazole is excreted in form of N4-acetylsulfamethoxazole. A reason for the lower 
amounts of the metabolite being detected in the raw hospital wastewater could be the highly 
reactive nature of the wastewater, as suggested above for iopromide. This might facilitate very 
rapid cleavage of the sulfamethoxazole metabolite and retransformation of the parent 
compound, leading to a higher percentage of sulfamethoxazole and a lower percentage of N4-
acetylsulfamethoxazole than would be expected from metabolism rates. For the lower 
percentage of the parent compound (34%) in raw municipal wastewater compared to the 
expected 50%, no explanation was found.  
 
TREATED WASTEWATER. When comparing the occurrence of the three compounds in the effluent 
of the PS-BFRhospital (Figure 6-5) with those in the untreated wastewater (Figure 6-4), almost 
identical patterns were found, making it evident that this form of treatment was not having 
much impact on these three substances and that no transformation processes seemed to take 
place. On the other hand, wastewater treated by the NF-MBRWWTP was very different from the 
corresponding raw wastewater (Figure 6-4 and Figure 6-5). While in raw municipal wastewater 
only about 2% of the iopromide was found in the form of (four different) TPs, in the effluent of 
the NF-MBRWWTP, 97% was found as TPs and only 3% as the parent compound. Furthermore, it 
should be pointed out that although all twelve investigated TPs were present in the effluent, 
many of them were detected exclusively in only this one matrix of all the four1 investigated, 
which points to dynamic biodegradation processes during the water treatment in the NF-
MBRWWTP. Biodegradation also explains why the percentage of carbamazepine in the water 
treated by the NF-MBRWWTP was higher (36%) than in the raw influent (13%), leading to the 
cleavage of the metabolites and the retransformation of the parent drug. The complete absence 
of the sulfamethoxazole metabolite N4-acetylsulfamethoxazole in the effluent of the NF-
MBRWWTP also can be related to the same reason. It can be assumed that under the influence of 
intense microbial activity as it occurs in the membrane reactor, the metabolite was entirely 
deconjugated back into the parent compound (Göbel et al., 2005b, see also Chapter 2.1.1).  
To determine whether removal in the NF-MBR was caused by biodegradation processes or by 
the NF-membrane, pure nanofiltration was investigated in comparison (see Chapter 3.3.5). The 
distribution patterns of carbamazepine and sulfamethoxazole along with their metabolites 
(Figure 6-6) revealed that the pure NF treatment does not alter the distribution of these 
substances in the wastewater in a profound way. Since the influent of the NF module was raw 
wastewater from the WWTP, the differences between the distribution patterns of 
sulfamethoxazole in the influent of the WWTP and the NF are unexpected, and no obvious 
                                                             
1 the four are raw hospital and municipal wastewater, PS-BFR effluent and NF-MBR effluent 
Chapter 6 
 
page | 175  
reason can be found. However, they might be explained by different sampling strategies and 
sampling times.  
 
 
 Hospital effluent                         WWTP influent 
a) 
  
 Hospital effluent                         WWTP influent 
b) 
  
 Hospital effluent                         WWTP influent 
C) 
  
Figure 6-4: Distribution patterns [%] of a) iopromide and its transformation products, b) carbamazepine 
and its metabolites and c) sulfamethoxazole and its metabolite in raw hospital wastewater (hospital 
effluent) and raw municipal wastewater (WWTP influent). Data are based on average concentrations (see 
Tables 3-8 and 4-2) and colour codes refer to figures in these same chapters.  
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 PS-BFR effluent                         NF-MBR effluent 
a) 
  
 PS-BFR effluent                         NF-MBR effluent 
b) 
  
   
 PS-BFR effluent                         NF-MBR effluent 
c) 
  
Figure 6-5: Distribution patterns [%] of a) iopromide and its transformation products, b) 
carbamazepine and its metabolites and c) sulfamethoxazole and its metabolite in the effluent 
from the BFR (left column) and the effluent from the NF-MBR. Data are based on average 
concentrations (see Tables 3-8 and 4-2) and colour codes refer to figures in these same chapters.  
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NF influent NF effluent NF influent NF effluent 
    
  
Figure 6-6: Distribution patterns [%] of carbamazepine and sulfamethoxazole and their 
metabolites in the influent and effluent of the lab-scale NF module  (see Chapter 3). Colour codes 
refer to figures in this chapter. 
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6.4 REMOVAL EFFICIENCY OF NF-MBR AND PS-BFR 
When comparing the removal efficiency found for the NF-MBR and the PS-BFR (see Chapters 3.3 
and 4.3), the former yields better results for the majority of the xenobiotics (Figure 6-7): For 
eight substances (circled in green), both treatment systems investigated yielded positive 
removal with the NF removal always exceeding that found for PS-BFR, while for a group twice as 
large (yellow circle), positive removal rates found for the NF-MBR contrasted with negative 
removal rates during BFR treatment. Only for two substances (orange circle) was negative 
removal in the NF found, while BFR treatment yielded zero or very slightly (< 10%) positive 
removal. Two substances were found to be removable by neither of the investigated systems 
(circled in red). On the whole, the NF-MBR treatment shows principally a much higher removal 
capacity for the very diverse group of investigated compound (sum of yellow- and green-circled 
compounds) than the PS-BFR treatment (sum of the green- and orange-circled compounds). This 
translated into a level of highly or very highly efficient treatment (meaning > 75% removal) for 
only four substances in the case of the PS-BFR, while this effectiveness was found for 18 
substances in NF-MBR treatment.  
 
 
 
 
Figure 6-7: Xenobiotic removal in the PS-BFR (y-axis) vs. the NF-MBR (x-axis) based on average 
concentrations (see Tables 3-8 and 4-2). Explanation for coloured markers: see text.  
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6.5 AQUATIC ENVIRONMENTAL ASSESSMENT  
To evaluate the risk posed by xenobiotics in the aquatic environment, environmental risk 
assessment (ERA) schemes are used. In the EU, ERA was implemented for, among other 
purposes, the evaluation of substances during the REACH registration (European Chemicals 
Bureau, 2003) and for medicinal products for human use (EMEA, 2006). This ERA approach 
consists of a multi-tiered process of which the exposure assessment is the first part. For 
exposure assessment, the ratio of PEC (predicted environmental concentration) to PNEC 
(predicted no effect concentration) is determined for the substance in question. A PEC/PNEC 
ratio of < 0.1 equals minimal risk to aquatic organisms, PEC/PNEC ratios between 0.1 and 1 
indicate medium risk, while substances with ratios > 1 are interpreted as posing high risk.   
The proper calculation of PEC according to European Chemicals Bureau, 2003 is often difficult 
since many required data are not commonly available, and highly diverse data may be reported 
for a single parameter (e.g. metabolism and excretion rates, production volume or market 
volume) (Letzel et al., 2009). Furthermore, PEC does not represent the situation at a certain 
sampling point but rather in generalised, hypothetic circumstances. Thus MEC (measured 
environmental concentration) is increasingly used instead of PEC to provide more realistic risk 
scenarios (e.g. Grung et al., 2008; Zhao et al., 2010; Santos et al., 2013). To be valid for ERA, 
PNECs must be derived from tests with organisms of three different trophic levels, of which the 
results of the most sensitive one are used in order to guarantee that the chosen PNEC is an 
appropriate indicator for the protection of the ecosystem.  
 
6.5.1 WORST CASE SCENARIO  
The ratio between the highest concentration measured (MECmax) and the PNEC represents a 
worst-case scenario for the exposure assessment at a specific sampling site, assuming that no 
wastewater treatment takes place. It describes the impact of raw wastewater at the infusion 
point before dilution, sorption or degradation in the receiving surface water can take place 
(European Chemicals Bureau, 2003). Such a scenario is also common during heavy rain events 
that overwhelm the capacity of the WWTP and lead to untreated water being discharged. From 
the data obtained in the presented study, the evaluation of risk posed by the municipal 
wastewater stream was evaluated, a site-specific assessment for the hospital was carried out 
and the effluents of the two pilot plants were considered. 
 
PHARMACEUTICALS. As shown in Table 6-3, in raw municipal wastewater, the MECmax/PNEC ratios 
revealed high environmental risk for eleven substances (four psycho-active substances, four 
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antibiotics, two NSAIDs and one lipid regulator) with oxazepam and diclofenac showing 
MECmax/PNEC ratios as high as over 500. For carbamazepine, iopromide, naproxen and 
sulfadimethoxine, medium risk is indicated, but it has to be pointed out that the MECmax/PNEC 
ratio of carbamazepine is bordering on factor 1 (0.9).  
In the effluent of the NF-MBR, generally reduced MECmax/PNEC ratios were found, pointing to 
effective reduction of these compounds during removal. However, the MECmax/PNEC ratio of 
oxazepam was still close to 200, and overall nine pharmaceuticals (four antibiotics, three 
psycho-active compounds and two NSAIDs including ibuprofen) exceeded factor 1. These results 
emphasise that environmental risk can be caused by a) substances that are not degraded in 
wastewater treatment (e.g. carbamazepine), of which the risk factor is slightly higher for the 
effluent of the NF-MBR than for untreated wastewater and by b) so called "pseudo-persistent" 
substances like ibuprofen, that are indeed degraded by wastewater treatment (see Chapters 2, 3 
and 4) but pose a risk nonetheless due to the sheer volume of application and subsequent 
permanent, high infusion into the environment, despite efficient removal (Dietrich et al., 2006).  
In raw hospital wastewater, the MECmax/PNEC ratio of oxazepam exceeded 2,000, and the ratios 
for diclofenac, ibuprofen, sulfamethoxazole and trimethoprim were over 100. Overall, a 
MECmax/PNEC ratio of more than 1 (high risk) was found for eleven substances (four antibiotics, 
four psycho-active compounds, two NSAIDs and one lipid-regulator).  
In hospital wastewater treated by a PS-BFR, for three substances a MECmax/PNEC ratio of more 
than 200 was still found, and overall ten substances showed high environmental risk (four 
antibiotics, three psycho-active substances, two NSAIDs and one lipid-regulator). Thus, while for 
some substances like ibuprofen and primidone, considerable reductions in the risk factor are 
found compared to in untreated wastewater, it is suggested that the BFR treatment does not 
greatly reduce the overall impact in the wastewater. In the case of the ICM iopromide, the 
MECmax/PNEC ratio is even higher after PS-BFR treatment than in raw hospital wastewater. This 
is due to complex transformation processes of the substances in raw hospital wastewater what 
seems to lead to retransformation of the parent compound during BFR treatment (see Chapters 
4.3.3 and 4.3.4).  
 
OPS. As industrial chemicals, OPs are subject to the REACH process in which risk assessment is 
mandatory. Thus, PNEC values for several aquatic media (for fresh water, meaning inland 
surface water, for marine waters and also for the microorganisms used in biological wastewater 
treatment) are to be found within the ECHA dossiers (ECHA). For TBEP, however, to date no 
PNECs have been given, rendering risk assessment unfeasible. When applying the PNECs from 
the REACH dossiers for the other OPs to the MECs of this study, medium risk is indicated for 
TiBP in raw municipal wastewater when compared with PNECfreshwater, suggesting a possible 
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minor threat when untreated wastewater reaches surface water. For all other OPs, the 
MEC/PNEC ratios do not imply any risk either for microorganisms during wastewater treatment 
or for receiving surface water.  
 
 
Table 6-3: PNECs and MECmax/PNECaquatic ratios for pharmaceuticals found in the PS-BFRhospital and the NF-
MBRWWTP. bold: RQ > 1; unterlined: 0.1 < RQ < 1; --- not listed in the literature or databases consulted.  
  
MECmax/PNECaquatic*  
  
PS-BFRhospital NF-MBRWWTP 
Compound PNEC [µg/L] Influent 
max 
Effluent max Influent 
max 
Effluent max 
Antibiotics 
CLA 0.04a,b,n 57 52 16 4 
ROX 0.01a, 0.15n; 4p 9 8 14 8 
SMI 0.248d,e, 3.5p 
  
0.5 0.0257 
SDI 12.77b,d,e n.d. n.d. n.d. n.d. 
SSX 0.62f,g n.d. n.d. n.d. n.d. 
SMA 0.68f,b,g, 116n n.d. n.d. n.d. n.d. 
SMX 0.027p, 0.59a,b,h, 20n 16 9 3 2 
TAM 23i n.d. n.d. n.d. n.d. 
TMP 0.0058a,b, 1n, 2.6p 170 202 27 15 
ICMs 
IPM 5363o 
  
0.001 0.0005 
IMI 256b, 370,000p 0.0206 0.2 1 0.0151 
NSAIDs and bezafibrate 
BZF 0.46a, 5.3p 28 6 4 0.1 
DCF 0.02a, 13.5j, 138.74k 772 506 552 1 
IBP 9.06l, 0.2a, 1.65r 434 42 9 5 
NPX 2.62r , 6.6a, 21.2j, 128m 0.038 0.0334 0.2 0.0045 
Psycho-active substances 
CBZ 2a,b, 6.36k 1 0.3 0.9 1.0 
PMD 0.069o 43 2 46 10 
CDN 0.06o, 16p 3 4 5 
 
MPN 0.09a 2 
 
5 
 
DZP 0.01a,b, 2p, 4.2l n.d. n.d. n.d. n.d. 
OZP 0.0019o 2,252 2,280 660 196 
*calculated with the most sensitive PNEC found in literature; n.d. = not determined due to measured 
environmental concentration was < LOQ or the substance was not detected; a Molander et al., 2009 cited 
in Orias and Perrodin, 2013; b EPA, 2012b; c Isidori et al., 2005b; d García-Galán et al., 2012 cited in Orias 
and Perrodin, 2013; e Park and Choi, 2008 cited in Orias and Perrodin, 2013; f Białk-Bielińska et al., 2011 
cited in Orias and Perrodin, 2013; g Park, 2005 cited in Orias and Perrodin, 2013; h Grung et al., 2008; i 
Boxall et al., 2000 – PNEC for soil pore water and groundwater; j Farré et al., 2001 cited in Santos et al., 
2007; k Jones et al., 2002; l Stuer-Lauridsen et al., 2000; m Webb, 2000 cited in Jones et al., 2002; n 
Kümmerer and Henninger, 2003; o Orias and Perrodin, 2013; p Sanderson et al., 2003; q Ferrari et al., 
2004; r Quinn et al., 2008 cited in Verlicchi et al., 2012b 
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Table 6-4: PNECs, MECmax/PNECfreshwater and MECmax/PNECWWTP ratios for pharmaceuticals found in the PS-BFRhospital and the NF-MBRWWTP. bold: RQ > 1; unterlined: 0.1 
< RQ < 1; *PNEC for soil pore water and groundwater; --- not listed in the literature or databases consulted.  
 PNEC [µg/L] MECmax/PNECfreshwater MECmax/PNECWWP 
   PS-BFRhospital NF-MBRWWTP PS-BFRhospital NF-MBRWWTP 
Compound Freshwater WWTP Influent Effluent Influent Effluent Influent Effluent Influent Effluent 
TBEP no PNEC 
availablea 
no PNEC 
availablea 
--- --- --- --- --- --- --- --- 
TnBP 35a no PNEC 
availablea 
0.003 0.002 0.006 n.d. n.d. n.d. n.d. n.d. 
TiBP 11a 3720a 0.017 0.015 0.806 0.012 4.91x10-5 4.45x10-5 0.0024 3.64x10-5 
TEHP "no hazard 
identified"a 
1000a --- --- --- --- n.d. n.d. n.d. n.d. 
TPP 3.7a 5000a n.d. n.d. 0.009 n.d. n.d. n.d. 6.55x10-6 n.d. 
TCEP 65b 32000b 0.001 0.002 0.003 0.003 2.68x10-6 4.92x10-06 6.77x10-6 5.62x10-6 
TCPP 420a no PNEC 
availablea 
0.001 0.000 0.004 0.002 n.d. n.d. n.d. n.d. 
TDCPP 10a,c 100000a,c n.d. 0.009 0.029 0.018 n.d. 8.79x10-7 2.92x10-6 1.76x10-6 
a ECHA; b European Chemicals Bureau, 2009; c European Chemicals Bureau, 2008 
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6.5.2 ENVIRONMENTAL RISK QUOTIENT (ERQ)  
When wastewater (treated or not) reaches the receiving surface water, dilution takes place, 
reducing the impact of the discharged xenobiotics. In exposure assessment, this can be 
accounted for by applying a suggested default factor of 10 (European Chemicals Bureau, 2003). 
Thus, Figure 6-8 and Figure 6-9 show the environmental risk quotient ((MECmax/10)/PNEC) for 
the four investigated media (raw municipal and hospital wastewater, effluent NF-MBR, effluent 
PS-BFR). 
 
 
 
Figure 6-8: ERQs of raw municipal wastewater (above) and the effluent of the NF-MBR (below). 
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MUNICIPAL WASTEWATER. In raw municipal wastewater, seven substances yielded ERQs > 1 (four 
antibiotics, two psycho-active compounds and one NSAID) with the maxima being oxazepam 
(ERQ: 66) and diclofenac (ERQ: 55). For four substances, ERQs indicated medium risk for the 
aquatic environment. In the effluent of the NF-MBR, four substances, the psycho-active 
compounds primidone and oxazepam as well as the antibiotics sulfamethoxazole and 
trimethoprim, still showed ERQs of > 1, the highest being oxazepam (ERQ: 19.6). Five more 
substances yielded ERQs suggesting medium risk.  
 
 
 
 
Figure 6-9: ERQs of raw hospital wastewater (above) and the effluent of the PS-BFR (below). 
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HOSPITAL WASTEWATER. The ERQs for raw hospital wastewater were > 1 for nine substances 
(three antibiotics, 2 NSAIDs, 2 psycho-active compounds and one lipid-regulator), with again, 
oxazepam yielding the highest risk quotient (ERQ: 225). For three more pharmaceuticals, the 
ERQs revealed medium risk (roxithromycin, codeine, morphine). In the effluent of the PS-BFR, 
five substances were ranked as high risk (the antibiotics trimethoprim, sulfamethoxazole and 
clarithromycin, the NSAIDs diclofenac and ibuprofen as well as the psycho-active compound 
oxazepam), while four more are of medium risk to the aquatic environment.  
 
COMPARISON WITH ERQS FROM LITERATURE. Because of the great diversities in wastewater 
streams, a comparison of MECmax/PNEC ratios or ERQs between different studies is difficult. This 
is even truer for a comparison between calculated PEC/PNEC ratios with studies using 
measured data (MECs). So, it is not surprising, that various studies describing ERAs for 
pharmaceuticals reported widely varying risk levels for certain substances. Based on data from 
Germany, Kümmerer and Henninger, 2003 determined PEC/PNEC ratios for several antibiotics 
in untreated wastewater, defining clarithromycin (PEC/PNEC: 13.6), sulfamethoxazole (11.13) 
and trimethoprim (1.53) as the highest risks, which is in general agreement with the results 
presented here, while for roxithromycin only minor risk was calculated (0.2), which is not 
supported by the result of this study. In a study describing the environmental risk posed by the 
top 25 prescription pharmaceuticals in the UK, Jones et al., 2002 found ibuprofen and 
carbamazepine posing minor risk to the environment, while no risk was identified for the 
environmental levels of naproxen and diclofenac (both 0.01). With the exception of naproxen, 
this is not congruent with the results of this study. Santos et al., 2007 described the MEC/PNEC 
for influent and effluent of a CAS-WWTP for carbamazepine as being 0.34 und 0.20, respectively, 
which is generally similar to the results presented here. For ibuprofen and naproxen, 
considerably higher MEC/PNEC ratios than in this study were found for the influent (41.00 and 
1.28, respectively), while the effluent ratios (5.30 and 0.20) were close to what we found.  
In a risk assessment for wastewater from a hospital in Brazil, Souza et al., 2009 calculated 
PEC/PNEC ratios according to consumption data and metabolisation rates, and found no risk in 
connection with sulfamethoxazole (PEC/PNEC: 0.0536) and high risk for trimethoprim 
(PEC/PNEC: 16.78). Thomas et al., 2007 determined ERQs for hospital wastewater in Norway 
and found diclofenac and sulfamethoxazole being of minor risk (ERQs 0.32 and 0.18 
respectively), while ibuprofen ERQ: 3.1 x 10-5) and trimethoprim (7.9 x 10-4) posed no risk, 
which does not concur with this study.  
 
IN CONCLUSION. The results of the presented study demonstrate that wastewater, both raw and 
treated, represents a risk when reaching receiving waters. High risk levels are being caused by 
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substances of not a single therapeutic group but several (psycho-active compounds, antibiotics, 
NSAIDs). However, in all wastewater types investigated, the highest risk was found for 
oxazepam.  
 
THE VALUE AND LIMITS OF RISK ASSESSMENTS. Comparison with literature data shows that 
exposure assessments are in essence only valid as a site-specific description, and generalising 
from the conclusions provided by a specific case seems highly problematic. Furthermore, it has 
to be kept in mind that this form of assessment only evaluates the risk of a single compound and 
does not account for any synergetic or cumulative effects of the random mixture of thousands of 
substances that are present in natural waters today. So the results of exposure assessment are 
inclined to underestimate the real risk pharmaceuticals pose to the aquatic environment. 
Exposure assessments revealing no or minor risk should therefore not be seen as a “card 
blanche” declaring a substance free of any notion of being environmentally relevant. More so, 
since for many substances toxicity data are profoundly incomplete or completely missing (which 
is, apparently, even true for substances regulated and supposedly assessed in depth under 
REACH). So, no PNEC values were available for 24 substances (23 pharmaceuticals and one OP) 
out of a total of 52, which equals 46% of the overall number of xenobiotics investigated in this 
study. Subsequently, for this 46% not even an attempt at a risk assessment, with whatever 
short-comings, can be made, which makes them “orphan” compounds in terms of ecotoxicity 
data (Orias and Perrodin, 2013). Another limitation of the current risk assessment process is 
that for both pharmaceutical metabolites and transformation products practically no 
ecotoxicological data exist (Orias and Perrodin, 2013).  
A basic flaw of the exposure assessment is the central role of PNEC values. The whole 
assessment is based on the determination of the PNEC, and therefore on the initial quality of the 
study data used to derive these values and the relevance of the endpoint used (Dietrich et al., 
2006). Since data regarding ecosystem effects for xenobiotics are to date generally very scarce, 
in the absence of more reliable data describing long-term, chronic toxicity, data about short term 
toxicity have in many cases been used to determine the PNEC and adequate assessment factors 
are applied (European Chemicals Bureau, 2003). Nonetheless, the somewhat questionable 
quality of many PNEC data is in stark contrast to the emphasis given to the PEC/PNEC 
calculations in recent (scientific) use of this quotient to arrive at a plausible risk estimate for 
pharmaceuticals in the aquatic environment. This becomes especially evident when observing 
the highly diverse PNECs reported in literature for estimating PEC/PNEC (see Table 6-3, e.g. 
PNEC for diclofenac ranging from 0.02 to 138 µg/L and varying between 256 µg/L and 370,000 
µg/L for iopromide). In the light of these considerations, exposure assessments can only be seen 
as a rough pointer to possible risks. 
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7. OVERALL CONCLUSIONS AND FURTHER PERSPECTIVES 
 
Till taught by pain, 
Men really know not what good water's worth. 
– Lord Byron (1788 –1824), Don Juan, Canto II, Stanza 84, 1818-1824 – 
 
 
If we were logical, the future would be bleak, indeed. But we are more than logical.  
We are human beings, and we have faith, and we have hope, and we can work.  
– Jacques-Yves Cousteau (1910-1997) –  
 
 
THERE IS REASON FOR CONCERN. The results of this study show that a wide range of xenobiotics is 
present in both municipal and hospital wastewater. While the fingerprints of the single point 
source and the accumulated mixture are for some compound groups different, the compositions 
of both wastewater streams give reason for environmental concern. This concern stems not only 
from the results of exposure assessments, which reveal high environmental risks in both raw 
and treated wastewater, but even more from the profound lack of knowledge due to missing, 
unreliable or questionable ecotoxicological data. For about 50% of the substances investigated 
in this study, the ecotoxicological data needed for attempting a risk assessment were unavailable 
in the literature, which, it could be argued, makes toxicological risk assessment a discipline of 
faith more than knowledge. This is bad enough in the case of the parent compounds, but is even 
worse for metabolites and environmental transformation products, the latter being for most 
pharmaceuticals completely unknown to date.  
A group of xenobiotics which serves to illustrate these problems is ICMs. In raw wastewater, 
they are found in concentrations up to mg/L which is 10 to 100 times higher than other 
micropollutants. As substances which are both highly polar and inert by design, they mostly 
bypass wastewater treatment, meaning they are constantly discharged into the aquatic 
environment in very considerable amounts, where they can be expected to be transported over 
long distances and timespans. As long ago as 2001, Kümmerer, 2001 pointed out that this is 
reconcilable with neither drinking water safety nor a precautionary principle approach. In the 
meantime, it was found that ICMs might be not as non-toxic to aquatic organisms as was 
postulated, with PNEC values for iopromide found in the literature dropping from 370,000 µg/L 
(Sanderson et al., 2003, estimated by Quantitative Structure Activity Relationship, QSAR) by a 
factor of about 1500 to 256 µg/L (EPA, 2012b). Subsequently, the MECmax/PNEC ratio for raw 
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municipal wastewater found in this study exceeded 1 (=high risk). Furthermore, my results 
revealed a highly dynamic transformation of the ICM iopromide in raw hospital wastewater (see 
Figure 4-11 and Figure 6-4), challenging the assumption of high stability. While this could be 
positive with regard to possible (bio)degradation in the environment, it makes clear that very 
large amounts of transformed ICMs are present in the environment. Moreover, while 
ecotoxicological information on the parent compounds is scarce (see Table 6-3), it can be 
considered to be completely absent for transformation products. Many of them have probably 
not even been identified yet. Thus, it must be assumed that the environmental behaviour of ICMs 
is currently unsatisfactorily described at best. 
 
PRECAUTIONARY PRINCIPLES. Taking all of the above mentioned into account, it is impossible to 
say with certainty that pharmaceuticals and other xenobiotics in (waste)water are not a threat 
to the aquatic environment. To compensate for the lack of knowledge, precautionary principles 
must be applied, and these xenobiotics should be kept from reaching the aquatic environment. 
Several international guidelines, such as the Convention for the Protection of the Marine 
Environment of the North-East Atlantic (OSPAR) and as a result the European Water Framework 
Directive (European Commission, 2000), too, set the ultimate target concentrations for man-
made synthetic pollutants “close to zero” (since the natural background is zero), rendering any 
amount of the substance in question found in the environment unfavourable. This should be the 
goal for “emerging compounds” such as pharmaceuticals and OPs as well.  
 
NON-APPLICATION. One possible way to achieve this would be the non-application of the 
substances, which in the case of pharmaceuticals is highly problematic. While attempts are being 
made to develop “green drugs” which pose less environmental threat (Daughton, 2002a; 
Daughton, 2002b; Zhang and Geißen, 2010), this approach to the problem seems to have limits. 
For example, the widely used painkiller ibuprofen, which is regularly named as one of the drugs 
posing risks to aquatic environment, is identified as a core drug for basic healthcare systems and 
part of the WHO’s List of Essential Medicines (WHO, 2011c) and therefore not likely to be 
substituted any time soon.  
 
SOURCE CONTROL. Another approach, recently discussed favourably, especially for 
pharmaceuticals, is source control by decentralised treatment of e.g. hospital wastewater 
streams. The treatment of high-strength, undiluted wastewater is described as being more 
efficient for biological removal and favourable for the elimination of persistent micropollutants 
(Joss et al., 2006). However, the results of the presented study suggest that highly concentrated 
wastewater, such as raw hospital wastewaters, favours the development of transformation 
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products and completely uncontrolled degradation processes. Treating such wastewaters on site 
instead of allowing them to enter the municipal wastewater system would increase the contact 
time of a seemingly highly reactive wastewater matrix with the pharmaceuticals (and other 
xenobiotics which might be affected in the same way), which could lead to the increased 
development of transformation products of unknown nature and toxicity (Orias and Perrodin, 
2013). With no hope of identifying all the individual TPs that could possibly develop under such 
conditions (which in themselves are highly variable both spatially and timewise), research into 
decentralised wastewater treatment should be closely connected to investigations of ecotoxicity 
effects.  
 
ADVANCED END-OF-PIPE-TREATMENT. Since organic micropollutants are not exclusively introduced 
into the wastewater stream by special point sources but by practically every sewage pipe 
entering the municipal sewers, decentralised source treatment is not the answer for overall 
reduction of xenobiotics in wastewater. Ultimately, advanced end-of-pipe-treatment is the only 
realisable way at present, since the currently used CAS treatment is mostly insufficient for 
micropollutant removal (see e.g. Joss et al., 2006). In the presented study, two advanced 
treatment systems were investigated for this purpose. While the NF-MBR reveals a much greater 
potential for micropollutant removal than the PS-BFR, even this system showed unsatisfactory 
results (< 75% removal) for 45% of the investigated substances. The results showed that the NF-
MBR was especially efficient in regard of biodegradation, while the removal of non-
biodegradable substances like carbamazepine was insufficient. The filtration capacity of the 
loose NF membrane did not yield better retention results than previously described for wider 
membrane types. The use of a tighter NF membrane would enhance removal, but such a system 
would not be suitable for the treatment of larger wastewater volumes and its use is therefore 
limited to small-scale applications (Fane, 2011).  
The PS-BFR demonstrated basic potential for biodegradation by removal rates of over 75% 
found for primidone, ibuprofen and morphine, but failed in regard to increased overall 
xenobiotic degradation. However, high concentrations (ranging up to over 2,000 ng/g d.w.) of 
clarithromycin found in the biosolids (sludge and biofilm of the carrier material) indicate that 
the system has a high sorption potential for ionic compounds such as macrolides that are 
positively charged under pH conditions found in hospital wastewater (pH 7.4 – 8.0). These 
sorption processes can be assigned to the extracellular polymeric substances (EPS), which hold 
flocs of activated sludge together as well as being the backbone of the cell-surrounding gels of 
biofilms, and which are described as being negatively charged at pH > 7 (Bryers, 2000 cited in 
Wunder et al., 2011; Stewart and Costerton, 2001). Recent studies indeed suggest the use of 
biofilms as adsorbents of pollutant ions in the treatment of water contamination (Kurniawan 
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and Yamamoto, 2013). Thus, it might be promising to implement this technology as a sorption 
step in decentralised hospital wastewater treatment to reduce the risk potential of 
micropollutants prone to sorption, such as macrolide antibiotics (Escher et al., 2011). This might 
be especially beneficial in the case of antibiotics since the biofilms attached to carrier material 
can be disposed of in a controlled fashion, thus permanently removing the antibiotics from the 
aquatic system. Furthermore, this would prevent the spreading of possibly changed genetic 
information ensuing from contact with antibiotics and contributing to bacterial antibiotic-
resistance.  
 
COMBINATION OF TREATMENT METHODS. None of the advanced treatment methods investigated in 
this study could remove the whole range of the studied xenobiotic micropollutants. Recent 
research shows that the same is true of virtually all realistic advanced treatment processes such 
as advanced oxidation or treatment with powdered activated carbon (PAC). Thus, a combination 
of treatment methods is increasingly becoming the centre of attention as the preferred strategy 
and is subsequently subject to intense research. For example, moving biofilm MBRs combine 
MBR treatment with the advantages of particle-supported biofilms (Fane, 2011). Other 
approaches are the combination of PAC with NF (Meier and Melin, 2005), with microorganisms 
(“biological [sic] activated carbon”, Reungoat et al., 2011) or as a follow-up to ozonisation 
(Hollender, 2013).  
 
OUTLOOK. Even after almost two decades of intensive research, numerous aspects of the fate of 
xenobiotic micropollutants in the water cycle are not even partly understood and in many cases 
the answers found just lead to more questions. However, newly developed high resolution mass 
spectrometry allows a much closer look at xenobiotics, their transformational pathways and 
their impact on the aquatic system, and holds the promise of more much-needed knowledge to 
be gained in this area. 
Nonetheless, the information that is already available today gives reason for concern. The 
transfer of scientific knowledge into legislative action is, however, only slowly evolving. To my 
knowledge, as the first country ever, Switzerland is currently implementing a fourth treatment 
step for large WWTPs (aiming at load reduction in surface waters), for WWTPs discharging into 
small receiving waters (where only low dilution of infused micropollutants is accomplished) or 
waters used for drinking water production (Hollender, 2013). These criteria apply to about one 
seventh of the country’s WWTPs. The goal is 80% removal of micropollutants in final effluents, 
which is to be achieved by a combination of treatment techniques (ozonisation followed by PAC 
treatment).  
In the EU, on the other hand, the application of precautionary principles was neglected when the 
water frame work directive (European Commission, 2013) was amended. In a commission 
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proposal (European Commission, 2012b), it was recommended that three pharmaceuticals 
(diclofenac and two estradiols) should be newly included in the list of priority substances. 
However, this was shelved and they were pushed down onto a so-called ‘watch list’ to be 
investigated and monitored further. At present no mandatory action is required to be taken by 
the member states with regard to these micropollutants. Since legislative regulation is often a 
necessary driver for both research and development, this is an unfortunate signal.  
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If there is magic on this planet, it is contained in water. 
- Loren Eiseley (1907–1977), The Immense Journey, 1957 – 
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